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Abstract 
 
Introduction: Differentiating irritable bowel syndrome (IBS) from organic disease 
is inherently challenging as symptoms can overlap. Symptom-based diagnostic 
criteria were developed to aid the clinician in making a positive diagnosis of IBS, 
and therefore avoid unnecessary invasive investigations. However, previous studies 
have shown these criteria perform only modestly in differentiating IBS from organic 
disease. 
 
Aim: The aim of this thesis is to assess the accuracy of the symptom-based 
diagnostic criteria, as well as address some of the limitations in their performance. 
 
Methods: A systematic review and meta-analysis was conducted in order to 
summarise the approaches that are currently available to aid in the diagnosis of IBS, 
including symptoms, biomarkers, psychological markers, and combinations thereof, 
as well as to understand the strengths and weaknesses of the available diagnostic 
tests for IBS. Using these findings, two diagnostic test studies were designed and 
undertaken with the intention of creating accurate, inexpensive, and easily 
administrable tests for clinicians consulting in routine clinical care. 
 
Results: A meta-analysis undertaken showed that symptom-based diagnostic 
criteria, biomarkers, and psychological markers perform only moderately well in 
diagnosing IBS. Combining symptoms with markers of organic disease or 
psychological affect seemed to represent the best way forward in improving the 
accuracy of diagnosing IBS. The first diagnostic test study undertaken confirmed 
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this finding, and showed that modifications to the symptom-based diagnostic criteria 
with the addition of symptoms, markers of affect, and simple laboratory tests 
resulted in improved diagnostic accuracy. The second diagnostic test study used 
latent class analysis to derive and validate a model that performs with similar 
accuracy to the symptom-based diagnostic criteria, but importantly this method has 
the potential for improvement in its accuracy through the addition of clinical 
markers, such as faecal calprotectin. 
 
Conclusions: This thesis has shown that combining symptoms with clinical 
markers, markers of affect, and/or novel biomarkers leads to greater accuracy in 
diagnosing IBS. The novel findings of two diagnostic test studies undertaken 
suggests that this approach may represent the best way forward in developing an 
accurate and non-invasive diagnostic test for IBS. 
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 This chapter will provide an overview of how the definition of irritable bowel 
syndrome (IBS) has developed over time, in particular the history and development 
of symptom-based diagnostic criteria, the current gold standard for diagnosing IBS, 
will be discussed. Our understanding of the likely pathophysiological mechanisms 
that underpin IBS, as well as possible treatment options, will also be reviewed. 
Finally, the current published literature on the available methods used to diagnose 
IBS will also be evaluated, in order to understand the rationale for conducting this 
body of work.  
 
1.1 History and Definition of the Irritable Bowel Syndrome 
It was in 1892 that Sir William Osler’s textbook “The Principals and 
Practice of Medicine” first made reference to a condition known as mucous colitis, 
which was described as “a tenacious mucus, which may be slimy and gelatinous, 
like frog spawn…” Patients with mucous colitis were also considered at the time to 
be hysterical, depressed, suffering from hypochondria, and likely to complain of 
colicky abdominal pain (Christensen, 1992). In the 1920’s, the term colonic spasm 
was coined, and it was thought to be a common feature of mucous colitis, in which 
patients complained of lower abdominal pain that was made worse by anxiety, 
smoking, menses, and defaecation. However, it was soon realised that colonic spasm 
and mucous colitis were the same condition, and it was felt that this was likely to 
occur as a consequence of autonomic nerve dysfunction related to a specific 
personality disorder (Christensen, 1992).  
It was not until the 1940’s that the term irritable bowel syndrome began to 
replace previous nomenclature in the literature (Peters and Bargen, 1944). This was 
defined as colonic dysfunction in the absence of either an organic colonic or extra-
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colonic disease causing the symptoms. Although “personality disorders” were 
thought to be associated with IBS, they were no longer considered as a primary 
cause, with autonomic disturbances, endocrinopathies, and allergies considered to 
have more important contributory roles (Christensen, 1992).    
In 1962, the first attempt at classifying IBS was undertaken (Chaudhary and 
Truelove, 1962). In this retrospective study of 130 patients, two main subtypes of 
IBS were recognised; the spastic colon group and the painless diarrhoea group. The 
predominant symptom in the spastic colon group was abdominal pain, which was 
considered to be colonic in origin. Bowel habit could vary between being normal, 
exclusively constipation, exclusively diarrhoea, or alternating between constipation 
and diarrhoea. The second group, the painless diarrhoea group, was considered to 
consist of individuals without abdominal pain, and whose predominant symptom 
was loose and frequent stools. Psychological comorbidity was thought to play a 
significant role in both the development and continuation of symptoms in both 
groups. 
 
1.1.1 The Manning Criteria 
A seminal paper published in 1978 by Manning and colleagues (Manning et 
al., 1978) was later to form the first symptom-based diagnostic criteria for IBS, now 
known as the “Manning criteria”. In this cross-sectional study, 65 patients referred 
to a gastrointestinal (GI) clinic for investigation of their symptoms were asked to 
complete a symptom questionnaire prior to their clinic appointment, and followed 
through until a final diagnosis was established. In total, 32 (49.2%) patients were 
finally diagnosed with IBS, and four individual symptom items were found to be 
markedly more common in these patients, compared with those found to have 
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organic GI disease after investigation. These were abdominal distension; abdominal 
pain relieved by defaecation; increased stool frequency associated with the onset of 
abdominal pain; and looser stools associated with the onset of abdominal pain. 
Combining these symptoms together led to a greater ability to discriminate between 
IBS and organic disease, with three or four of these symptoms present in 20 (63%) 
of the IBS patients, but in only five (15%) of the 33 patients with organic disease. 
Manning and colleagues concluded that the more of these symptoms that were 
present in combination, the more likely the diagnosis of IBS. The addition of two 
other symptoms, mucus per rectum and a feeling of incomplete stool evacuation, 
further increased the likelihood of IBS, with all six symptoms present in six (19%) 
of the patients with IBS, but in only one (3%) patient who had organic disease. The 
importance of this work is reflected by the fact that symptom-based diagnostic 
criteria still remain the gold standard for diagnosing IBS to this day. 
 
1.1.2 The Rome Criteria 
The Manning Criteria were superseded in the 1990’s, when a working 
committee for the Rome foundation produced the first comprehensive diagnostic 
criteria for all functional gastrointestinal disorders (FGIDs), including IBS, now 
known as the Rome I criteria (Drossman et al., 1990). The aim of these criteria were 
firstly to enable clinicians to make a positive diagnosis of IBS with the use of 
minimal investigations, secondly to help select homogeneous patients for clinical 
trials, and thirdly to ensure standardisation when investigating pathophysiological 
mechanisms of IBS.  The working committee chose to use a more restrictive criteria 
to define IBS than had been previously used, with the condition defined as “a 
functional gastrointestinal disorder attributable to the intestines and associated with 
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symptoms of abdominal pain, and/or altered defaecation, and/or bloatedness or 
distension” (Drossman et al., 1990). This differed from the Manning criteria, in that 
it was recognised that the change in stool consistency or frequency could be towards 
harder or less frequent stools, as well as looser or more frequent stools. Furthermore, 
the Rome criteria introduced, for the first time, a minimum frequency and duration 
of symptoms required to diagnose IBS.  Less emphasis was also placed on 
abdominal bloating or distension and mucus per rectum, which were now considered 
as supportive, rather than diagnostic, of IBS. 
Further modifications were made to the Rome criteria in 1999, published as 
the Rome II criteria (Thompson et al., 1999), and again in 2006, the Rome III 
criteria (Longstreth et al., 2006). In particular, changes were made to the minimum 
duration of symptoms required. The most recent criteria, Rome IV, published in 
2016 (Mearin et al., 2016), now define IBS as recurrent abdominal pain associated 
with a change in stool form and/or frequency, with the term “abdominal 
discomfort”, which was present in the Rome III criteria, removed as it was 
considered an ambiguous term for patients, and does not exist in certain languages. 
There was a change in the frequency of abdominal pain required to meet the 
threshold for IBS, from at least 3 days per month in the preceding 3 months in Rome 
III, to at least one episode per week in the preceding 3 months in Rome IV, as well 
as a change from “improvement of abdominal pain with defaecation” to “abdominal 
pain related to defaecation”, in an attempt to acknowledge that some patients with 
IBS report a worsening of abdominal pain following defaecation (Sood and Ford, 
2016). The original Manning criteria and the four iterations of the Rome criteria are 
shown in Table 1. 
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Table 1. Symptom-based Diagnostic Criteria for Irritable Bowel Syndrome. 
Criteria Symptom items included Minimum 
symptom duration 
Manning 1. Abdominal pain relieved by defaecation 
 
2. More frequent stools with onset of pain 
 
3. Looser stools with onset of pain 
 
4. Mucus per rectum 
 
5. Feeling of incomplete emptying 
 
6. Patient-reported visible abdominal distension 
None 
Rome I Abdominal pain or discomfort relieved with 
defaecation, or associated with a change in stool 
frequency or consistency, plus two or more of the 
following on at least 25% of occasions or days: 
1. Altered stool frequency 
 
2. Altered stool form 
 
3. Altered stool passage 
 
4. Passage of mucus 
 
5. Bloating or distension 
≥3 months 
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Rome II Abdominal discomfort or pain that has two of three 
features: 
1. Relieved with defaecation 
 
2. Onset associated with a change in frequency 
of stool 
 
3. Onset associated with a change in form of 
stool 
≥12 weeks (need 
not be consecutive) 
in last 12 months 
Rome III Recurrent abdominal pain or discomfort ≥3 days per 
month in the last 3 months associated with 2 or more of 
the following: 
1. Improvement with defaecation 
 
2. Onset associated with a change in frequency 
of stool 
 
3. Onset associated with a change in form of 
stool 
Symptom onset ≥6 
months prior to 
diagnosis 
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Rome IV Recurrent abdominal pain, occurring on average, at 
least 1 day per week in the last 3 months, and 
associated with 2 or more of the following: 
1. Related to defaecation  
 
2. Associated with a change in frequency of 
stool. 
 
3. Associated with a change in form 
(appearance) of stool. 
Symptom onset ≥6 
months prior to 
diagnosis 
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1.1.3 Subtypes of IBS 
The Rome II criteria, for the first time, also allowed classification of patients 
according to the dominant stool consistency. The IBS subtype definitions have also 
been updated with each iteration of the Rome criteria, and the Rome IV criteria 
classify IBS in to four subtypes consisting of: constipation predominant IBS (IBS-
C), whereby Bristol stool form types 1 and 2 (Lewis and Heaton, 1997) are 
experienced in >25% of bowel movements, and Bristol stool form types 6 and 7 are 
experienced in <25% of bowel movements; diarrhoea predominant IBS (IBS-D), 
whereby stool form types 6 and 7 are experienced in >25% of bowel movements and 
stool form types 1 and 2 are experienced <25% of the time; mixed constipation and 
diarrhoea IBS (IBS-M), whereby stool form types 1 and 2 and stool form types 6 
and 7 are experienced >25% of the time; and unsubtyped IBS (IBS-U), where there 
is insufficient abnormality of stool consistency to meet the three previously 
described subtypes (Mearin et al., 2016).  
However, a patient’s subtype is not necessarily stable, and it is possible to 
move between these subtypes over time. In a study that evaluated the stability of 
Rome III IBS subtypes over a 10-week period (Engsbro et al., 2012), 126 patients 
who were recruited to two placebo-controlled treatment trials of probiotics 
conducted in Denmark and Sweden, were also asked to complete a daily diary in 
which they scored all defaecations according to the Bristol stool form scale (Lewis 
and Heaton, 1997). IBS subtypes were calculated according to the information 
provided in the diary at 1- and 2-weekly intervals. Irrespective of the interval used, 
the distribution of IBS subtypes remained stable, with approximately one-third of 
the study population meeting the criteria for IBS-C, IBS-D and IBS-U respectively. 
IBS-M was the least prevalent subtype. However, only 18% to 35% of patients were 
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considered as having a stable subtype. There was a tendency for IBS-C and IBS-D 
patients to have the most stable subtype, and between 65% and 82% of patients 
changed subtype at least once during the 10-week period. Patients changing subtype 
most often changed between IBS-C or IBS-D and IBS-U. 
 
1.2 The Incidence and Prevalence of IBS 
In a systematic review and meta-analysis published in 2012 (Lovell and 
Ford, 2012), the pooled prevalence of IBS in 80 study populations, containing 
260,960 subjects, was found to be 11.2% (95% confidence interval (CI) 9.8% to 
12.8%). In this same study, the prevalence of IBS was also shown to differ 
according to geographical location, with the highest pooled prevalence of IBS in 
Northern Europe of 12.0% (95% CI 9.0% to 15.0%), compared with the lowest IBS 
prevalence in South-East Asia of 7.0% (95% CI 5.0% to 9.0%). The prevalence of 
IBS also depended on the criteria used to define it. Prevalence was highest when 
three or more of the Manning criteria (Manning et al., 1978) were used to define it 
(14.0% (95% CI 10.0% to 17.0%)), and lowest when the Rome I criteria (Drossman 
et al., 1990) were used to define IBS (8.8% (95% CI 6.8% to 11.2%)). In this same 
meta-analysis, the prevalence of IBS was found to be higher in women (14.0% (95% 
CI 11.0% to 16.0%)) compared with men (8.9% (95% CI 7.3% to 10.5%)), with an 
odds ratio (OR) of 1.67 (95% CI 1.53 to 1.82) favouring women. 
Furthermore, IBS is more prevalent in individuals with other FGIDs, 
including dyspepsia, gastro-oesophageal reflux disease, and chronic idiopathic 
constipation (CIC) (Ford et al., 2010; Lovell and Ford, 2012; Suares and Ford, 
2011). In a systematic review and meta-analysis of 19 papers, incorporating 18,173 
patients, the prevalence of IBS in individuals with dyspepsia was 27% (95% CI 23% 
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to 31%) compared with 7% (95% CI 5% to 10%) in those without dyspepsia (Ford 
et al., 2010). Similarly, in a systematic review and meta-analysis conducted by the 
same group, the prevalence of CIC was higher in those patients who also reported 
IBS (OR 7.98; 95% CI 4.58 to 13.92) (Suares and Ford, 2011).  IBS is also more 
common in those with non-FGIDs, such as fibromyalgia and chronic fatigue 
syndrome (Riedl et al., 2008), and these patients are also more likely to experience 
extra-intestinal and somatic symptoms when compared with healthy controls (HCs), 
as well as undergo a worse course of disease (Riedl et al., 2008). Symptoms such as 
chronic headache or migraine (Azpiroz et al., 2000; Cole et al., 2006), 
temporomandibular joint dysfunction (Aaron et al., 2000), urogenital syndromes 
including dysmenorrhoea and dyspareunia (Prior et al., 1989), back pain (Longstreth 
and Yao, 2004), palpitations (Vandvik et al., 2004), sleep disturbance (Patel et al., 
2016),  and bronchial hyper-reactivity (Kennedy et al., 1998), are also more 
common in IBS patients when compared with healthy individuals. 
The incidence of IBS is estimated to be 1% to 2% per year in the West in 
representative community samples (Ford et al., 2008), meaning that many people 
will report symptoms compatible with IBS at some point in their lives, and up to 
60% of those who experience symptoms will consult a primary care physician as a 
result (Koloski et al., 2002; Koloski et al., 2003). 
 
1.3 The Cost of IBS 
Partly as a consequence of the high incidence of IBS, as well as its chronic 
relapsing course, there are substantial costs to health-care services globally. A 
comprehensive burden-of-illness study in the USA estimated that IBS cost almost 
US $1 billion in direct costs such as hospital and physician services, endoscopy, 
 
 
34 
 
prescription and over-the-counter medications, and another $50 million in indirect 
costs such as loss of earnings (Everhart and Ruhl, 2009). IBS patients are also more 
likely to undergo surgery when compared with non-IBS patients, with rates of 
cholecystectomy, appendicectomy, and hysterectomy two to three times higher than 
non-IBS patients, further exacerbating direct and indirect costs (Longstreth and Yao, 
2004; Agreus, 1993). The effect of IBS on society as a whole is substantial, due to 
factors such as absenteeism from work and reduced quality of life (Drossman et al., 
1993). In a comprehensive search of the literature of six databases, a more recent 
narrative review looked at the costs incurred by the patient, such as the intangible 
cost of reduced quality of life (Canavan et al., 2014). This review reported on a 
survey conducted in the USA, in which 68% of IBS patients who responded missed 
the equivalent of one social activity per week over a 3-month period, directly as a 
result of their symptoms (Hulisz, 2004). In other studies conducted in Europe and 
North America, patients with IBS were more likely to report anxiety, depression, 
and lower perceptions of their own health, when compared with non-IBS patients 
(Bushnell et al., 2006; El-Serag et al., 2002). There are also direct out-of-pocket 
costs and loss of earnings to consider, predominantly through the cost of over-the-
counter medications with 15% to 43% of IBS patients buying medications such as 
analgesia and laxatives, as well as paying privately for medical consultations and 
alternative therapies (Pare et al., 2006; Silk, 2001).  
 
1.4 Aetiology of IBS 
To date, no structural or physiological cause of IBS has been established, and 
it is unlikely that there is a single unifying explanation. Several potential 
mechanisms have been implicated in the pathogenesis of the condition, which are 
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discussed below. These can be broadly defined as host factors contributing to IBS, 
such as altered brain-gut reaction, increased visceral hypersensitivity, and gut 
dysbiosis, and environmental factors, such as psychological stressors and food 
intolerances (Figure 1). 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
36 
 
Figure 1. Possible Pathophysiological Mechanisms of IBS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Host Factors 
 Altered brain-gut reaction 
 Visceral hypersensitivity and altered pain perception 
 Gut dysbiosis 
 Increased gut mucosal immune activation 
 Increased intestinal permeability 
 Increased genetic susceptibility 
 Disordered bile salt metabolism 
Environmental Factors 
 Psychological stressors 
 Food intolerances 
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1.4.1 Host Factors 
 
1.4.1.1 Altered Brain-Gut Reaction 
 The importance of brain-gut interactions in IBS and other FGIDs are 
increasingly being recognised. These interactions in health play an important role in 
regulating digestive processes such as appetite and the gut-associated immune 
system, and alterations in central and peripheral brain-gut interactions are likely to 
be part of the explanation underpinning the symptoms of IBS (Mayer and Tillisch, 
2011).  
 Findings from studies conducted in primary and secondary care show anxiety, 
depression, and somatisation are more prevalent in patients with IBS when 
compared with non-IBS patients. These associations have led some to hypothesise 
that the brain drives the gut manifestations of IBS (Tanaka et al., 2011). Studies that 
give credence to this theory include one large study of patients referred to secondary 
care for investigation of their GI symptoms (Patel et al., 2015). Of 4224 patients 
recruited, 840 met the Rome III criteria for IBS. The number of individual somatic 
symptoms and the mean somatisation score were found to be higher in IBS patients 
when compared with non-IBS patients (P < 0.001). In addition, high levels of 
somatisation were associated with a greater frequency of bloating and abdominal 
distension.  
 In one prospective population-based questionnaire study (Koloski et al., 2012), 
1775 of 4500 patients who had responded to and completed a survey were contacted 
again 12 years later. Of these 1775 patients, 1002 completed the follow-up survey. 
In patients who did not have a diagnosis of IBS at the time of initial recruitment, a 
clinically elevated level of anxiety (OR 1.11; 95% CI 1.03 to 1.18) or depression 
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(OR 1.10; 95% CI 1.03 to 1.18) were found to be predictors of a new diagnosis of 
IBS in the follow-up survey.  
 Further evidence to support a brain-gut pathophysiological mechanism is 
supported by a meta-analysis that looked at the association between medically 
unexplained symptoms and anxiety and depression in 244 observational studies. In 
this meta-analysis, IBS was significantly associated with both anxiety and 
depression, when compared with HCs, and controls with known organic disorders 
that cause GI symptoms (Henningsen et al., 2003). 
 Although an association between IBS and mood disorders is supported by 
findings from studies such as those described above, what is not always certain is if 
the relationship is exclusively unidirectional, or whether in some cases, IBS 
symptoms may arise prior to the manifestation of mood disorders. In one 
prospective cross-sectional study, 1900 patients were recruited and asked to 
complete a survey at baseline and at 1 year. Of those with a diagnosis of IBS at 
baseline, and normal anxiety and depression levels, significantly higher levels of 
anxiety (P = 0.002) and depression (P < 0.001) were found 1 year later, suggesting a 
primary gut-brain axis pathway in this subset of IBS patients (Koloski et al., 2016). 
 A bi-directional brain-gut theory is further supported by the findings of a 
matched cohort study conducted across 123 primary care practices in the UK (Jones 
et al., 2006), in which 13% of patients with IBS had consulted a primary care 
physician with depression, or had been prescribed antidepressants in the 2 years 
prior to the diagnosis of IBS, compared with 5% of controls. Consultation rates for 
anxiety and depression were found to be higher in the IBS group, in the 6 years after 
the diagnosis was made. 
 
 
39 
 
The sizable psychosocial component of IBS has resulted in considerable 
interest in patient reported outcomes (PROs). These PROs, such as the IBS quality 
of life scale, are usually questionnaire-based, and are used to encourage clinicians to 
examine the mental, social, and physical impact of symptoms, with the aim of 
improving patient outcomes and satisfaction through targeted therapy (Marshall et 
al., 2006; Spiegel et al., 2011). PROMIS, a US National Institute of Health 
programme, was launched in 2004, with the aim of developing and validating a 
standardised databank of PROs for health-related illness, and a GI version is being 
developed currently (Spiegel, 2013). Although there is certainly an unmet need in 
terms of identifying and addressing the psychological and social needs of patients 
with IBS, it is unclear how PROs could be utilised in primary care and general 
gastroenterology clinics, where the majority of these patients are managed (Sood et 
al., 2014). One possible avenue of interest could be to use PROs to enhance a 
clinician’s ability in making a positive diagnosis of IBS, and therefore avoid the 
need for expensive and invasive investigations. 
 
1.4.1.2 Visceral Hypersensitivity and Altered Pain Perception  
 Visceral hypersensitivity is defined as altered sensation in response to a 
physiological stimuli (Farzaei et al., 2016), and a subset of IBS patients have been 
found to have increased visceral sensitivity following colonic distension, exhibited 
as a reduced threshold for pain and/or increased intensity of sensation (Mayer and 
Gebhart, 1994; Bouin et al., 2002). There are thought to be two major components 
of visceral hypersensitivity; allodynia and hyperalgesia. Allodynia is enhanced 
nociceptive sensation in response to normal stimuli, and hyperalgesia is intensified 
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pain sensation in response to a stimuli that would normally be expected to cause 
some pain (Farzaei et al., 2016).  
 Visceral afferent nerve response is thought to be provoked by chemical, 
mechanical, and luminal stimuli and normally silent nociceptors can be activated 
when tissue injury occurs, such as when bile salts are instilled in to the colon (Zhou 
and Verne, 2011). There is evidence to suggest that pro-inflammatory cytokines, 
such as interleukin-one beta (IL-1ß) and tumour necrosis factor-alpha (TNF-α), are 
involved in the sensitisation of the nociceptive system following an inflammatory 
stimuli, which in turn leads to hyperalgesia (Eijkelkamp et al., 2012). There is also 
increasing evidence to suggest that chronic hyperalgesia may be a result of persistent 
tissue injury (Zhou and Verne, 2011). In a model of chronic visceral 
hypersensitivity, neonatal male rats were exposed to either mechanical stimuli in the 
form of balloon distension of the colon, or chemical stimuli through the intracolonic 
injection of mustard oil. The control group consisted of rats that received neither of 
these stimuli. Colonic irritation with chemical or mechanical stimuli resulted in 
chronic visceral hypersensitivity, as determined by abdominal withdrawal reflex, 
with characteristics of both allodynia and hyperalgesia, when compared with 
controls (Al-Chaer, 2000). 
 Other researchers have suggested that visceral hypersensitivity may occur as a 
result of disturbances of the central nervous system, an observation supported by 
functional magnetic resonance imaging (fMRI) studies. Several studies have 
addressed the role of placebo analgesia in IBS using oesophageal and rectal 
distension as pain models. In one study, 17 IBS patients and HCs, matched for age 
and sex, underwent rectal distension. Brain activity was measured using fMRI 
during the placebo and control phases. IBS patients showed a lower visceral 
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perception threshold following rectal distension when compared with HCs. fMRI of 
the IBS patients during the placebo analgesia phase showed increased activity of the 
cingulate cortex and other areas of the brain involved in pain modulation, as well as 
increased activity in the areas of the brain involved in anticipatory mechanisms (Lee 
et al., 2012).   
 A second study aimed to determine whether changes in central pain modulation 
following administration of visceral placebo analgesia were specific to IBS, and 
secondly to observe the relationship between negative affect and central pain 
modulation during visceral placebo analgesia (Schmid et al., 2015). Seventeen 
patients with IBS who were diagnosed using the Rome III criteria, 15 patients with 
quiescent ulcerative colitis (UC), and 36 HCs were recruited. On the study day, 
rectal distension was performed using a pressure-controlled barostat system to 
determine rectal perceptual and pain thresholds. This was followed by a structural 
magnetic resonance imaging (MRI). There were then three 7-minute sessions, during 
which eight rectal distensions of 16.8 seconds each were delivered. The first session 
served as an adaptation period and in the following two sessions, an intravenous 
catheter was inserted, and the patients were administered an intravenous saline 
solution. In order to induce the placebo condition or the control condition, patients 
were informed that they had either received an anti-spasmodic (placebo) or saline 
solution (control) intravenously, although in both instances they received saline. 
Brain imaging was performed using fMRI, and data were collected during each of 
the three sessions. Salivary cortisol samples were collected from each patient upon 
arrival on the day of the study, prior to the rectal threshold assessment session, and 
prior to each of the three fMRI sessions.  
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There were no differences in rectal pain thresholds between the groups, 
measured using an online visual analogue scale (VAS), nor were there any 
differences during the adaptation phase in anxiety, tension, cortisol concentration, or 
expected and perceived pain. There was a significant reduction in expected and 
perceived pain on the expectation of receiving an analgesic (placebo), when 
compared with the expected administering of saline (control). Following analysis of 
variance (ANOVA), a significant placebo response for expected pain was found in 
IBS patients when compared with UC patients (P < 0.001) and HCs (P = 0.003). 
There was a significant reduction in perceived pain intensity following 
administration of placebo in both UC patients and HCs, when compared with IBS 
patients (IBS vs UC, P < 0.001; IBS vs HCs, P < 0.001). fMRI of the IBS patients 
revealed significantly less downregulation of pain-induced neural activation during 
pain anticipation and following placebo analgesia, when compared with UC patients 
and HCs. In particular, there was less effective downregulation of neural activity in 
the midcingulate cortex (MCC) of IBS patients, when compared with HCs, and in 
the posterior cingulate cortex of IBS patients, when compared with UC patients. 
These areas of the brain are involved in pain modulation and orientation in response 
to nociceptive stimuli respectively. Additionally, IBS patients showed enhanced 
neural activation in the parietal cortex, when compared with HCs, and dorsolateral 
prefrontal cortex, when compared with UC patients, suggesting that anticipatory 
mechanisms may play a role in central pain processing in IBS patients. 
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1.4.1.3 Intestinal Dysbiosis 
 The microbiota of the human GI tract comprises a complex ecosystem that is 
important for the health and physiological functions of the individual. It has a role in 
immune regulation, including development of the immune system, and as part of the 
host defence against pathogens and toxins, as well as emerging roles in metabolic 
regulation, by means of support of digestion through the provision of enzymes (Tap 
et al., 2016). Healthy individuals harbour approximately 100 different species of 
bacteria in faecal microbiota, with dominant species including Actinobacteria, 
Bacteroidetes, Firmicutes, and Proteobacteria (Collins, 2014). Alterations in the 
constituents and diversity of the microbiota have been observed following use of 
antibiotics, prebiotics, and in obesity, and there is continuing interest in the gut 
microbiome for the cause, prevention, and treatment of conditions such as 
inflammatory bowel disease (IBD) (Prosberg et al., 2016), colorectal cancer 
(Brennan and Garrett, 2016), and diseases of the liver (Bluemel et al., 2016). 
 Variances in the intestinal microbiota between patients with IBS and HCs have 
mainly been studied using faecal material. The emergence of culture-independent 
methods, primarily through analysis of ribosome ribonucleic acid for bacteria and 
single-celled microorganisms (Suau et al., 1999), complementary methods such as 
fluorescent in-situ hybridisation (FISH), and quantitative polymerase chain reaction 
(PCR) testing, have also improved our understanding of the gut microbiome. Studies 
have suggested an increase in some bacteria such as Firmicutes, Enterobacteriaceae, 
and Clostridium species, and a decrease in other bacteria such as Bacteroidetes, 
Bifidobacteria, and Eubacterium species, as well as an overall decrease in 
heterogeneity, in faecal samples of IBS patients when compared with HCs. 
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Furthermore, the microbiota of IBS-D patients appear to deviate the most from HCs, 
whilst the microbiota of IBS-C patients deviate the least (Salonen et al., 2010).   
 In one study that examined the faecal microbiota of 14 IBS-C patients and 12 
matched HCs, using FISH to quantify main groups of bacteria, statistically 
significant lower numbers of lactate-producing, lactate-utilising, and hydrogen-
consuming bacteria were found in IBS patients (Chassard et al., 2012). Other studies 
have shown a predominance for methane-producing bacteria in IBS patients (Kim et 
al., 2012). In a larger study containing 114 IBS patients and 33 HCs, intestinal 
fermentation was measured using intestinal intraluminal pH and short-chain fatty 
acids (Ringel-Kulka et al., 2015). Colonic intraluminal pH was decreased, 
suggesting higher colonic fermentation in IBS patients when compared with HCs.  
 Although these studies suggest possible dysbiosis in IBS patients, with an 
overall decrease in heterogeneity of the intestinal microbiome and a predominance 
of bacteria that can result in increased intestinal fermentation, it should be 
acknowledged that there is currently a lack of clear consensus, and at present a 
specific microbiota profile for IBS patients has not been identified. One study has 
found a possible intestinal microbiota signature in patients with severe IBS 
symptoms (Tap et al., 2017). However, the investigators were unable to show any 
difference in the faecal microbiota of IBS patients, when compared with healthy 
patients. The lack of a specific microbiota profile for IBS is probably due to external 
factors including methodological differences, variances in diet, use of supplements 
and medications, such as antibiotics and proton pump inhibitors, and genetic 
variation (Zhuang et al., 2017). It is also likely that external influences, such as 
industrialisation, can alter the gut microbiota, as shown in a study that compared the 
microbiota of healthy children living in an Italian city, with a diet rich in fat and 
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protein, to those of healthy children living in a village in Burkina Faso, where the 
diet is predominantly fibre-based. The Burkina Faso cohort was found to have 
significantly higher levels of Bacteroidetes and significantly lower levels of 
Firmicutes (De Filippo et al., 2010).  
 In a more recent study undertaken in four Italian cities, heathy volunteers 
consisting of 51 vegetarians, 51 vegans, and 51 omnivores were recruited and asked 
to complete daily dietary information, as well as provide faecal samples on which 
metabolomic analysis was undertaken, using a technique known as gas-
chromatography mass spectrometry-solid phase microextraction (De Filippis et al., 
2015). The vegetarian and vegan volunteers were found to adhere to a mainly 
Mediterranean diet. Volunteers consuming more plant-based foods had higher faecal 
levels of Bacteroidetes, but also high levels of Firmicutes, which were also noted in 
those consuming mainly animal-based foods, which of course is not in keeping with 
the previously discussed study by De Filippo et al. 
 Studies in mice models, as well as in humans, have shown that antibiotics can 
lead to a disruption in gut microbiota (Anitha et al., 2012). In a small study of three 
patients, the gut microbiota was examined following two courses of ciprofloxacin. 
The effect of ciprofloxacin was profound, with an immediate decrease in the 
diversity of the microbiota (Dethlefsen and Relman, 2011). Evidence of an 
association between antibiotics and the development of IBS was seen in a large 
population based study of 26,107 patients (Villarreal et al., 2012). After controlling 
for gender and comorbidity, patients were more likely to develop IBS in the 
following 12 months after receiving a tetracycline (OR 1.48; P = 0.046). This 
finding has also been supported in another study of 421 patients who attended a 
health screening clinic and completed a symptom questionnaire. Forty-eight patients 
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had symptoms compatible with IBS, and antibiotic use was found to be strongly 
associated with IBS (OR 3.70; 95% CI 1.80 to 7.60) (Mendall and Kumar, 1998). 
 
1.4.1.4 Increased Gut Mucosal Immune Activation  
 Low-grade gut mucosal inflammation as a cause of IBS was first proposed in 
the 1960’s in a study in which the quantity of mast cells in the muscle layers of 
surgically resected colonic specimens were examined. Specimens included patients 
with a diagnosis of IBS, and these patients were found to have a similar number of 
mast cells to those with a diagnosis of UC (Hiatt and Katz, 1962). Following this 
landmark study, others have used endoscopic samples of colonic mucosa to compare 
the quantity of cells involved in inflammation such as eosinophils, lymphocytes, 
plasma cells, and neutrophils. Some of these studies have reported significantly 
higher levels of inflammatory cells in IBS patients, in particular IBS-D patients, 
when compared with HCs (Salzmann et al., 1989; Lee et al., 1988).  
 A previous systematic review has examined the role of surrogate markers of 
low-grade mucosal inflammation in IBS patients (Ford and Talley, 2011). Of 16 
studies, 13 obtained colonic mucosa samples, one study obtained mucosa biopsy 
samples from the proximal jejunum, one study obtained full thickness samples from 
the proximal jejunum at laparoscopy, and one study took biopsies from the first and 
second part of the duodenum at upper GI endoscopy. Eligible studies were required 
to compare IBS patients with HCs, or asymptomatic individuals undergoing 
investigation for reasons other than GI symptoms. Surrogate markers of low-grade 
inflammation examined included mast cells, T-lymphocytes, B-lymphocytes, 
eosinophils, neutrophils, plasma cells, and mucosal cytokines. Of these markers, 
mast cells, B-lymphocytes, T-lymphocytes, and mucosal cytokines were shown to 
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be altered in IBS patients when compared with HCs. However, a number of the 
studies reported conflicting results. The strongest evidence appeared to exist for 
mast cells, which are involved in the immune system and, when activated, degrade 
and release inflammatory and immune mediators, such as histamine and tryptase 
(Holtmann et al., 2016). This in turn leads to abnormal GI sensitivity and mucosal 
secretions. Activation of mast cells can be through an array of stimuli including 
immunoglobulin E (IgE)-mediated pathways, neuro-hormonal pathways induced by 
psychological stress, and bacteria. However, even with mast cells, there is 
inconsistency in reported outcomes with variances according to gender, bowel 
segment sampled, and IBS subgroup, with IBS-D patients showing higher levels of 
mast cells when compared with IBS-C patients, and some studies suggesting no 
difference in mast cell quantity when comparing IBS patients with HCs (Zhang et 
al., 2016).  
 A more recent systematic review has examined the relationship between 
systemic and mucosal cytokines, immune cells, and IBS (Martin-Viñas and Quigley, 
2016). This review showed that levels of the cytokine IL-10 were decreased in the 
systemic circulation of IBS patients, whereas levels of IL-6, IL-8, IL-1ß, and TNF-α 
were increased. Levels of mucosal IL-10 were decreased, and levels of IL-8, mast 
cells, enterochromaffin cells, and CD3+ and CD8+ T-lymphocytes cells were 
increased. However, once again, the results were not consistent across all studies, 
and the results of this systematic review were at odds with the results from a meta-
analysis by Bashashati et al. that suggested there was no difference in circulating 
levels of IL-10 in IBS patients, when compared with HCs, therefore highlighting the 
inconsistency in available evidence (Bashashati et al., 2014). Therefore, although 
there is good evidence to support the hypothesis of increased gut mucosal immune 
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activation as a cause of IBS, there is not the irrefutable evidence required to classify 
IBS as an inflammatory bowel disorder. 
 One hypothesis that has been explored for persistent low-grade inflammation in 
IBS patients is exposure to inflammatory stimuli in genetically susceptible 
individuals. Multiple community studies have shown an increase in post-infectious 
IBS (PI-IBS) following outbreaks of enteric infection (Borgaonkar et al., 2006; 
Marshall et al., 2006), and up to 17% of patients believe their IBS symptoms 
commenced following an episode of gastroenteritis (Longstreth et al., 2001). In one 
large cohort study, the incidence of PI-IBS was calculated following an outbreak of 
Escherichia coli 0157:H7 and Campylobacter jejuni gastroenteritis in a small rural 
town in Ontario, Canada (Marshall et al., 2006). Two years following the outbreak, 
residents who had clinically suspected gastroenteritis, residents who had self-
reported gastroenteritis, and non-affected residents (acting as controls) were asked to 
complete a modified questionnaire based on the Rome I criteria, allowing the 
incidence of PI-IBS to be calculated and its epidemiology characterised. Of 2069 
eligible participants, 71 (10.1%) of 701 controls, 249 (27.5%) of 904 with self-
reported gastroenteritis, and 168 (36.2%) of 464 with clinically suspected 
gastroenteritis, met the Rome I criteria (P < 0.001). Risk factors for PI-IBS were 
female gender, younger age, and features of systemic illness during the acute enteric 
infection, including weight loss, prolonged diarrhoea, and bloody stools.  
 In a recent systematic review and meta-analysis of 45 cohort studies reporting 
on the prevalence of IBS following infectious enteritis, the pooled prevalence of IBS 
at 12 months after infectious enteritis was 10.1% (95% CI 7.2% to 14.1%), and the 
prevalence of IBS more than 12 months after the index episode of infectious 
enteritis was 14.5% (95% CI 7.7% to 25.5%) (Klem et al., 2017).   
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 A retrospective study has shown that the risk of PI-IBS is independent of the 
pathogen that causes the initial gastroenteritis, giving credence to the theory that 
there is a common pathway triggered by infection, which in turn leads to persistent 
low-grade inflammation (Neal et al., 1997). However, whether an enteric infection 
induces a mast cell response, which then triggers a sustained immune response, 
persistent low-grade gut mucosal inflammation and symptoms of PI-IBS remains to 
be established (Zhang et al., 2016). 
 The role of allergens precipitating mast cell activation is well established, and 
is one other hypothesis of persistent low-grade gut inflammation that has been 
investigated. Allergens are known to precipitate an immune-mediated response 
which in turn leads to mast cell activation, leading to the allergic response (Zhang et 
al., 2016). Some studies have suggested elimination diets based on immunoglobulin 
G (IgG) antibodies have resulted in a significant decrease in symptoms experienced 
by IBS patients, compared with those who undergo dietary restrictions not guided by 
IgG antibody levels (Kalliomaki, 2005). The role of diet and food tolerances in the 
pathophysiology of IBS is explored later in this chapter. 
 
1.4.1.5 Increased Intestinal Permeability 
 The small intestine is lined with epithelial cells, with tight junctions between 
these cells. The tight junctions are composed of complex protein systems that allow 
absorption of nutrients by regulating transportation through the extra-cellular matrix. 
As tight junctions encircle epithelial cells, attaching them tightly to each other, this 
helps prevent antigens and unwanted solutes and microbes from entering the 
systemic circulation. Therefore, disruption to the tight junctions can result in 
increased intestinal permeability (Piche, 2014). Diseases such Crohn’s and UC are 
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characterised by intestinal inflammation, and it is known that inflammation can 
compromise the integrity of the intestinal barrier, through epithelial damage and 
increased gaps between tight junctions (gap density), resulting in increased intestinal 
permeability (Landy et al., 2016).  
 There is increasing evidence that a similar process may be the cause of 
symptoms experienced in a subset of patients with IBS. Studies using a technique 
known as confocal laser endomicroscopy (CLE), a non-invasive imaging modality, 
have shown that the gap density is increased in IBS patients, when compared with 
HCs. A case-control study was performed, in which 16 patients with IBS (12 IBS-D, 
4 IBS-C) and 18 HCs underwent CLE of the terminal ileum following colonoscopy 
and ileoscopy (Turcotte et al., 2013). The HCs consisted of patients undergoing 
colonoscopy for other reasons, including colorectal cancer screening and positive 
faecal occult blood testing. The study showed that IBS patients had a significantly 
increased gap density when compared with HCs (32 gaps/1000 cells in IBS patients 
vs. 6 gaps/1000 cells for HCs (P < 0.001)), thereby providing evidence for a 
hypothesis of low-grade gut mucosal inflammation causing IBS symptoms.  
Interestingly, no significant difference in gap density was found between the two 
IBS subtypes, although as the authors acknowledge, the study was not sufficiently 
powered to examine this.  
However, other studies using alternate techniques, have found differences in 
intestinal permeability amongst IBS subtypes. In one study that recruited 15 patients 
with PI-IBS, 15 patients with IBS-C and 15 HCs, participants ingested 1.8MBq of 
chromium labelled ethylene-diamine-tetra-acetate (51Cr-EDTA) (Dunlop et al., 
2006). Following this, urine was collected over 24 hours and small bowel 
permeability was expressed as a percentage of the total dose of 51Cr-EDTA 
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excreted.  Small intestinal permeability was increased in PI-IBS, when compared 
with IBS-C (P = 0.004) and HCs (P = 0.037).  
 Another study has examined the differential expression of tight junction 
proteins (Bertiaux-Vandaële et al., 2011). In 50 IBS patients (19 IBS-D, 14 IBS-C, 
15 IBS-M and 2 IBS-U) and 31 HCs, tight junction proteins were quantified in 
colonic mucosal biopsies using quantitative reverse transcriptase PCR, while 
localisation was determined by immunofluorescence. Expression of tight junction 
proteins was lower in IBS patients, when compared with HCs (P < 0.05). However, 
following sub-group analysis, tight junction protein expression was decreased in the 
IBS-D patients, when compared with HCs, but not in IBS-C or IBS-M, when 
compared with HCs, suggesting that increased intestinal permeability as a cause of 
IBS symptoms may be relevant only in IBS-D patients.  
  
1.4.1.6 Increased Genetic Susceptibility 
 Evidence suggests that IBS aggregates strongly in families. In a case-control 
study, 50 patients with IBS and 53 controls randomly selected from a medical 
outpatient clinic completed a symptom questionnaire, and provided contact details 
for first degree relatives, who were also asked to complete the same symptom 
questionnaire (Saito et al., 2008). Relatives were considered to have IBS if they met 
the Rome I or II criteria and there was no alternative GI diagnosis as a cause of their 
symptoms. The IBS patients reported that 21% of family members had IBS, whilst 
37% of family members of IBS patients met the Rome criteria for IBS. Controls 
reported that 4% of family members had IBS, whilst 16% of family members met 
the Rome criteria for IBS. Relatives of IBS patients were three times more likely 
than the relatives of the controls to have IBS (P < 0.05). In another case-control 
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study, 477 patients with IBS, 297 matched controls, 1492 relatives of IBS patients 
and 936 relatives of the matched controls were asked to complete a GI symptom 
questionnaire (Saito et al., 2010). At least one relative with IBS was observed in 
50% of IBS patients and 27% of controls, with an OR of 2.75 (95 % CI 2.01 to 3.76, 
P < 0.0001). 
 Evidence from studies such as those described above, has led some to 
hypothesise that genetics may play a significant part in the pathophysiology of IBS, 
an assertion supported by twin studies. In one study, same-sex twins completed a 
structured interview on symptoms consistent with FGIDs (Morris-Yates et al., 
1998). Of the 686 individuals, 33 (4.8%) had a diagnosis of a FGID. Genetic models 
were constructed, in which 56.9% (95% CI 40.6% to 75.9%) of the variance was 
accredited to genetic variance, with the remaining 43.1% attributed to environment. 
In another study, the contribution of genetic and environmental factors was assessed 
by comparing concordance for IBS in monozygotic and dizygotic twins with 
concordance between mothers and their children (Levy et al., 2001). Of 6060 twin 
pairs, concordance for IBS was significantly greater in monozygotic twins, when 
compared with dizygotic twins (17.2% vs. 8.4%, P = 0.03). Interestingly, the 
proportion of dizygotic twins with IBS, whose mother had IBS, was higher than the 
proportion of dizygotic twins who had co-twins with IBS (15.2% vs. 6.7%, P < 
0.001). Following logistic regression, having a mother or father with IBS was a 
stronger predictor than having a twin with IBS (P < 0.001). 
 This possible genetic link has encouraged investigators to look for mutations 
that may result in susceptible individuals developing IBS. SCN5A and KCNH2 
encode for sodium and potassium channels found on GI smooth muscle and 
interstitial cells of Cajal. However, these genes are also known to be associated with 
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congenital prolonged QT syndrome. In one study, patients who were referred to a 
clinic for prolonged QT syndrome genetic testing, and their family members who 
acted as controls, were contacted and asked to complete a GI symptom questionnaire 
(Locke et al., 2006). The association between ion channel genes and GI symptoms 
was assessed by logistic regression. Of 219 patients, 50% patients with the SCN5A 
mutation reported abdominal pain compared with 13% of controls (OR 5.7; 95% CI 
1.3 to 24.4). More than 65% of those with the SCN5A mutation reported at least one 
GI symptom, compared with 28% of controls (OR 5.2; 95% CI 1.5 to 18.3). No 
association was found between the KCNH2 mutation and GI symptoms.  
 Other investigators have examined the role of single nucleotide polymorphisms 
(SNPs), which are deoxyribonucleic acid (DNA) sequence variations in nucleotides, 
in the pathophysiology of IBS (Swan et al., 2013). The authors hypothesised that 
IBS-D is characterised by a genetic susceptibility to over-react to an inflammatory 
insult. Twenty-one patients with Campylobacter jejuni infection in the previous 6 
months, 37 patients with IBS-D, 19 patients with IBS-C and 25 HCs underwent 
flexible sigmoidoscopy and rectal biopsy. Following gene expression analysis, SNPs 
of the gene TNFSF15 were associated with IBS-D, whilst SNPs of TNF-α were 
associated with PI-IBS.  A further study consisting of 1992 patients supports this 
association between SNPs of the TNFSF15 gene and the risk of developing IBS (OR 
1.37; 95% CI 1.19 to 1.58) (Zucchelli et al., 2011). This study also showed that this 
association was greatest in IBS-C patients, when compared with other IBS subtypes 
(OR 1.79; 95% CI 1.41 to 2.26). A probable role for TNFSF15 in the development 
of IBS is supported by a meta-analysis that has looked at the association between 16 
separate SNPs and the risk of developing IBS in 2894 patients (1073 IBS-D, 839 
IBS-C and 502 IBS-M patients) and 3138 HCs (Czogalla et al., 2015). Only one 
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SNP linked to the TNFSF15 gene was found to increase the risk of IBS (OR 1.19; 
95% CI 1.08 to 1.31), and in particular for the IBS-C subtype (OR 1.24; 95% CI 
1.08 to 1.42).  
 Environmental factors are thought to have a significant effect on the function of 
genes. In a pilot study, 27 IBS patients and 23 age-matched and sex-matched HCs 
provided blood samples from peripheral blood mononuclear cells for measurement 
of DNA methylation (the change in activity of a DNA segment) (Mahurkar et al., 
2016). Gene expression was measured using PCR, and the participants were also 
asked to complete a symptom questionnaire. The investigators identified 133 
differentially methylated positions that were potentially related to oxidative stress 
and neuropeptide hormone activity. Furthermore, epigenetic changes in one of the 
genes, subcommissural organ-Spondin, were associated with elevated hospital 
anxiety and depression scale (HADS) scores in IBS patients, suggesting a role for 
DNA methylation in the pathogenesis of IBS. However, these findings have yet to 
be confirmed in larger independent studies. 
 
1.4.1.7 Disordered Bile Salt Metabolism 
 Bile acids are synthesised in the liver before being released in the duodenum, 
where they are responsible for solubilisation of fatty acids and monoglycerides. 
Reabsorption occurs in the terminal ileum via the apical ileal bile acid transporter. 
Approximately 95% of bile acid is reabsorbed, with the remainder being recycled by 
hepatocytes via the portal vein (Holtmann et al., 2016). The mechanism of action 
underpinning bile acid malabsorption (BAM) is thought to be as a result of defective 
feedback in the inhibition of bile acid synthesis by fibroblast growth factor (FGF-
19). FGF-19 normally works by feeding back negatively on hepatocytes, reducing 
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the production of new bile acid when recycled bile acids are returned to the 
hepatocytes.  
 Abnormalities in bile acid metabolism have been recognised for many years in 
Crohn’s disease (Beigel et al., 2014), or following surgery such as cholecystectomy 
(Sauter et al., 2002) and ileal resection (Walters, 2010), although a significant 
proportion of patients presenting with lower GI symptoms may have idiopathic 
BAM. In a systematic review of 18 studies, reporting on 1223 patients presenting 
with symptoms consistent with IBS-D, 10% (95% CI 7% to 13%) had confirmed 
severe idiopathic BAM on tauroselcholic [75 selenium] acid (SeHCAT) scan, 32% 
(95% CI 29% to 35%) had moderate BAM, whilst 26% (95% CI 23% to 30%) had 
mild BAM (Wedlake et al., 2009). These findings were confirmed in a large 
retrospective study of 373 patients that showed of those patients with IBS-D, 27.3% 
had evidence of BAM (Gracie et al., 2012).  
 Although there is sufficient evidence to confirm a link between BAM and IBS-
D, what is less clear is whether BAM is a cause or a consequence of IBS. Studies 
have shown that faecal levels of primary bile acids are higher in IBS-D patients 
when compared with HCs (Duboc et al., 2012; Shin et al., 2013). Another study 
examined the interplay between faecal microbiota composition, serum and faecal 
bile acid compositions, 7α-4-Cholesten-3-one (7α-C4) (a metabolite that reflects 
hepatic bile acid synthesis and whose increase closely correlates with BAM), and 
FGF19 (Dior et al., 2016). In this study of 15 HCs, 16 IBS-D patients and 15 IBS-C 
patients, an increase in Escherichia coli was found in IBS-D patients, and an 
increase in Bacteroides and Bifidobacterium found in IBS-C patients, which are 
bacteria known to metabolise bile acid. Faecal bile acids were significantly higher in 
the IBS-D patients when compared with HCs, whilst serum bile acids were 
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significantly increased in both IBS-D and IBS-C patients when compared with HCs, 
with no significant difference in 7α-C4 or FGF19 levels between the three groups. 
This study therefore showed that serum and faecal bile acid profiles differ between 
IBS patients and health, which may be secondary to dysbiosis, and gives credibility 
to the hypothesis that BAM is a consequence of, rather than a cause of IBS. 
 
1.4.2 Environmental Factors 
 
1.4.2.1 Psychological Stressors 
 The associations between psychological life stressors such as abuse and 
trauma, and medical illness, such as IBS, have been well established for several 
decades (Drossman, 2011). In one of the first studies to report on the link between 
sexual and physical abuse in women and FGIDs, a self-administered questionnaire 
was completed by 206 consecutive patients referred to a university based 
gastroenterology clinic for investigation of GI symptoms (Drossman et al., 1990). Of 
these patients, 89 (44%) reported a history of physical or sexual abuse. Patients with 
a FGID diagnosis were more likely to report physical abuse (OR 11.39; 95% CI 2.22 
to 58.48), sexual abuse (OR 2.08; 95% CI 1.03 to 4.21), chronic abdominal pain 
(OR 2.06; 95% CI 1.03 to 4.12), and an increased number of surgical procedures 
(2.7 procedures vs. 2.0 procedures, P < 0.03). The increased prevalence of physical 
and sexual abuse in IBS and other FGIDs has been confirmed in subsequent studies, 
in both community and tertiary referral populations (Longstreth and Wolde-Tsadik, 
1993; Delvaux et al., 1997).  
 An increased prevalence of FGIDs has also been reported in patients who 
experience other forms of trauma, such as psychological trauma (Ablin et al., 2010). 
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Although the mechanisms of why patients who experience trauma report an 
increased prevalence of IBS is not completely understood, some experts have 
hypothesised that this may be due to enhanced activity of the MCC (Drossman, 
2011), as previously discussed. 
   
1.4.2.2 Food Intolerances  
 There is limited evidence for a true immune-mediated allergy to certain food 
groups that may precipitate IBS symptoms. It is estimated that between 20% and 
65% of IBS patients believe that their symptoms can be attributed to adverse food 
reactions (Nanda et al., 1989; Dainese et al., 1999), and one study has previously 
observed a high prevalence of functional dyspepsia and IBS in patients with food 
reactions (Ciprandi and Canonica, 1988). A systematic review examined this issue 
and found that, in a subset of IBS patients, a true food allergy may exist mediated by 
IgE and IgG, with elevated levels of IgE and IgG4 reported in IBS patients when 
exposed to known food intolerances (Park and Camilleri, 2006). 
 A study that examined food intolerances in IBS patients using the CLE 
technique provides further evidence for food acting as an allergen. Thirty-six 
patients with suspected food intolerances, and 10 patients with Barrett’s metaplasia, 
who acted as controls, underwent CLE (Fritscher-Ravens et al., 2014). An increase 
in intraepithelial lymphocytes (IELs) and epithelial breaks were seen in 14 of the 36 
IBS patients when exposed to an allergen (CLE+ patients). Baseline IELs were 
higher in these patients when compared with CLE- patients, and IELs and epithelial 
gaps increased significantly, when compared with baseline, following exposure to 
antigens (P = 0.0008 and P < 0.001 respectively). Following a 4-week exclusion 
diet, GI symptom scores improved by >50% in these patients.   
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1.5 Treatment of IBS 
 
1.5.1 Physical Activity 
Treatments are generally targeted towards the symptoms of IBS including 
abdominal pain, bloating, diarrhoea, and constipation. However, there may be some 
general measures that patients can take, which include increasing physical activity. 
In a RCT, 102 IBS patients were randomised to a physical activity group, which 
involved a physiotherapist instructing them to increase their physical activity, or the 
control group, whereby the patients were asked to maintain their current lifestyle 
(Johannesson et al., 2011). The study found a significant improvement in the IBS 
severity scoring system in the physical activity group, when compared with the 
control group (P = 0.003). Furthermore, the proportion of patients with an increase 
in IBS symptom severity during the study was significantly larger in the control 
group. 
 
1.5.2 Diet 
 
1.5.2.1 Dietary Fibre 
 Although true food allergies are uncommon in IBS, food intolerances are 
frequently reported (Chey et al., 2015; Eswaran et al., 2013). Historically, increasing 
dietary fibre was one of the recommended treatments for IBS. However, two diverse 
opinions currently exist. The first that believes a low-fibre western diet is a cause of 
IBS, and the second, that fibre may exacerbate the symptoms of IBS (Burkitt et al., 
1972; Painter, 1972). Some early RCTs found a significant improvement in IBS 
symptoms, such as abdominal pain and stool form and frequency, with high fibre 
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diets consisting of wheat bran or isphagula husk (Manning et al., 1977; Prior and 
Whorwell, 1987; Lambert et al., 1991). However, patients with IBS often believe 
that fibre worsens symptoms, as highlighted in a survey of 100 patients which found 
that 55% of patients’ symptoms were made worse by wheat bran, whereas only 10% 
thought fibre improved symptoms (Francis and Whorwell, 1994). This discrepancy 
between patient beliefs and evidence cited by clinicians was highlighted in a survey 
of IBS patients and their general practitioners (GPs), which found that patients often 
considered fibre as a food intolerance that exacerbated their symptoms, whilst GPs 
regarded a lack of fibre as an aetiological cause of symptoms (Bijkerk et al., 2003).  
A systematic review and meta-analysis sought to clarify the role of fibre in IBS 
(Ford et al., 2008). In 12 RCTs, 155 of 300 (52%) patients who were assigned to a 
high fibre diet had no improvement, or persistent symptoms, compared with 168 of 
291 (57%) patients assigned to placebo or a low fibre diet (RR 0.87; 95% CI 0.76 to 
1.00, P = 0.05). The number needed to treat (NNT) with fibre to prevent persistent 
symptoms was 11.  When wheat bran and isphagula husk were considered 
separately, this statistically significance benefit persisted only for isphagula husk 
(RR 0.78; 95% CI 0.63 to 0.96). The NNT was 6 to prevent one patient having 
persistent symptoms.  
 
1.5.2.2 Short-Chain Carbohydrates 
 Other investigators have looked at the role of short-chain carbohydrates in the 
role of IBS. These are small and osmotically active molecules in the intestinal 
lumen, which can cause increased intestinal luminal water volume if absorbed 
slowly. These molecules also rapidly ferment which leads to the production of 
carbon dioxide, hydrogen, and methane. It is these two mechanisms that are thought 
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to cause symptoms in IBS patients when exposed to these molecules (Shepherd et 
al., 2013). The discovery of these mechanisms has led to the development of the 
fermentable oligosaccharide, disaccharide, monosaccharide and polyol (FODMAP)-
restricted diet, which essentially eliminates all classes of poorly absorbed short-
chain carbohydrates from the diet.  
In a single-blind, cross-over interventional trial, 15 IBS patients and 15 HCs 
were asked to consume diets that were either high or low in FODMAP content for 2 
days, following which, breath samples for hydrogen and methane tests were 
collected (Ong et al., 2010). Higher levels of hydrogen were produced by patients 
consuming a high FODMAP diet, with statistically higher levels found in IBS 
patients when compared with HCs. Levels of methane were reduced in the HCs with 
a high FODMAP diet, but unchanged in the IBS patients. IBS patients reported 
higher levels of all GI symptoms (P < 0.01), worsening heartburn (P = 0.025), and 
tiredness (P = 0.012) with a high FODMAP diet. A recent systematic review has 
looked at the efficacy of a low FODMAP diet in clinical trials, and the investigators 
found that a restricted FODMAP diet improved symptoms in IBS patients in the four 
studies included (Rao et al., 2015). However, because of the significant 
heterogeneity between the studies, and poor methodological quality, further high 
quality studies are required before a definitive conclusion can be made. 
 
1.5.2.3 Gluten 
 Uptake of gluten-free diets (GFD) amongst the general population has 
increased, and in one study, 13% of 1002 patients surveyed in the UK reported a 
sensitivity to gluten (Aziz et al., 2014). More recently the term non-coeliac gluten 
sensitivity (NCGS) has been coined to encompass individuals who do not have 
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coeliac disease, but who report GI symptoms that improve following withdrawal of 
gluten from their diet (Lebwohl et al., 2015). IBS patients who have tested negative 
for coeliac disease have also reported GI symptoms on a gluten-containing diet 
(GCD) that improve on a GFD. In a double-blinded RCT in which IBS patients 
received either gluten-containing food or placebo for 6 weeks, patients who received 
the gluten-containing food were more likely to report poorly controlled symptoms 
(68% vs 40%, P = 0.0001) (Biesiekierski et al., 2011).  
The pathophysiology of NCGS in IBS patients is unclear, although studies have 
reported an increase in small bowel intestinal permeability in those who report 
symptoms whilst on a GCD. In one RCT of 45 patients with IBS-D, of which 23 
were placed on a GFD and 22 placed on a GCD, the GCD patients had a greater 
number of bowel movements per day and higher small bowel permeability. Of note, 
those who tested positive for the genes HLA-DQ2 and HLA-DQ8, had statistically 
greater number of bowel movements and increased small bowel permeability, 
compared with those who did not (Vazquez-Roque et al., 2013). In a second RCT 
that recruited 34 patients with IBS, although a significant worsening of GI 
symptoms were reported in those on a GCD, there was no significant change in 
small bowel permeability (Biesiekierski et al., 2011). 
 
1.5.3 Pharmacological Treatments for IBS-D 
 
1.5.3.1 Medications Acting on Opioid Receptors 
Loperamide is the only anti-diarrhoeal that has been evaluated in RCTs for 
the treatment of IBS. Two studies have shown an improvement in stool frequency 
and consistency, but with no overall improvement in global IBS symptoms. 
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Therefore, in the recently published American College of Gastroenterology 
guidelines (Ford et al., 2014), loperamide was not recommended for this indication.  
Eluxadoline is a mixed mu-opioid receptor agonist and delta-opioid receptor 
antagonist that is orally administered and acts locally in the GI tract (Keating, 2017). 
In two phase 3 trials, 2427 patients with IBS-D were randomised to eluxadoline 
(75mg or 100mg) or placebo, for 26 weeks in the first trial (IBS-3001), and 52 
weeks in the second trial (IBS-3002). The primary end point was the proportion of 
patients who had a composite response of a decrease in abdominal pain and an 
improvement in stool consistency on the same day for at least 50% of the days. In 
the IBS-3001 trial, efficacy was sustained from 1 to 26 weeks in patients who 
received eluxadoline 100mg when compared with placebo (29.3% vs. 19.0%, P < 
0.001), and in the IBS-3002 trial, for eluxadoline 75mg and 100mg when compared 
with placebo (30.4% and 32.7% vs. 20.2%, P = 0.001 and P < 0.001 respectively) 
(Lembo et al., 2016). 
 
1.5.3.2 Antispasmodics 
Antispasmodics work by relaxing gut smooth muscle through anticholinergic 
mechanisms, or through the blocking of calcium channels. A Cochrane review in 
2011 of 29 RCTs (2333 patients) showed a beneficial effect for antispasmodics over 
placebo for improvement in abdominal pain (RR 1.32; 95% CI 1.12 to 1.55, P < 
0.001, NNT = 7), global assessment (RR 1.49; 95% CI 1.25 to 1.77, P < 0.0001, 
NNT = 5), and symptom score (RR 1.86; 95% CI 1.26 to 2.76, P < 0.01, NNT = 3) 
(Ruepert et al., 2011). This finding was subsequently confirmed in a systematic 
review in 2014, which also showed there was a class effect (Ford et al., 2014). 
Hyoscine bromide, dicyclomine hydrochloride, pinaverium bromide, and 
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cimetropium bromide were all shown to be beneficial. Mebeverine, alverine, 
trimebutine, pirenzipine, rociverine, propinox, and prifinium did not have a 
significant effect on IBS symptoms, although many of the trials were hampered by 
the small number of patients recruited.  
 
1.5.3.3 Serotonin Receptor Antagonists 
Serotonin, a hormone produced in the gut, is known to influence gut motility 
and sensitivity (Mawe and Hoffman, 2013). Alosetron was shown to be effective in 
improving global IBS symptoms, when compared with placebo in a meta-analysis 
containing 8 RCTs (RR = 0.79, 95% CI 0.69 to 0.90, NNT = 8 ) (Ford et al., 2014). 
The drug was licensed for the treatment of IBS-D in the USA, but during post-
marketing surveillance, there were several reports of ischaemic colitis, and it was 
therefore withdrawn. It is now available again for women with severe IBS-D, under 
a restricted access programme. (Camilleri and Boeckxstaens, 2017) 
More recently, ondansetron has recently been evaluated in a RCT for the 
treatment of IBS-D, and was found to improve stool consistency, frequency, 
urgency, and abdominal bloating when compared with placebo, although abdominal 
pain did not improve significantly. Sixty-five percent of patients reported adequate 
relief of symptoms with ondansetron, compared with 14% in the placebo arm of the 
trial (RR 4.7; 95% CI 2.6 to 8.5, P < 0.001) (Garsed et al., 2014). 
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1.5.4 Pharmacological Treatments for IBS-C 
 
1.5.4.1 Laxatives 
 Only two studies have compared the osmotic laxative polyethylene glycol 
(PEG) with placebo, with no evidence that PEG improves overall symptoms and 
pain in IBS (Ford et al., 2014). There are no trials involving IBS-C patients for the 
osmotic laxative, lactulose, or stimulant laxatives such as bisacodyl, sodium 
picosulfate, or senna. 
 
1.5.4.2 Pro-Secretory Agents  
 
1.5.4.2.1 Lubiprostone 
Lubiprostone is a chloride channel activator that works by stimulating 
intestinal fluid secretion (Chey et al., 2015). Three studies, reporting on 1366 
patients, have shown that lubiprostone is effective in the treatment of IBS-C when 
compared with placebo (NNT 12.5, 95% CI 8 to 25) (Ford et al., 2014). 
 
1.5.4.2.2 Linaclotide 
Linaclotide is a 14-amino-acid peptide guanylate cyclase-C (GC-C) agonist. 
It binds to, and activates, GC-C receptors, resulting in release of chloride and 
bicarbonate in to the intestinal lumen, and subsequently increased intestinal fluid 
secretion (Sood and Ford, 2013). A systematic review and meta-analysis of three 
RCTs (1773 patients), comparing linaclotide with placebo for IBS-C, has shown that 
linaclotide is moderately effective in improving symptoms in patients with IBS-C 
(Atluri et al., 2014). Using the Food and Drug Administration endpoint of an 
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improvement of >30% from baseline in the average of the worst abdominal pain 
scores, and an increase of >1 complete spontaneous bowel movements from 
baseline, 66% of patients receiving linaclotide failed to achieve this endpoint, 
compared with 82.6% of patients receiving placebo (RR of failure to respond 0.80; 
95% CI 0.76 to 0.85).  
 
1.5.5 Other Treatments  
 
1.5.5.1 Probiotics and Antibiotics  
Probiotics are live microorganisms that when administered may result in a 
benefit for the host. In a recent systematic review and meta-analysis of 21 RCTs,  
when compared with placebo, probiotics were associated with an overall 
improvement in symptom response (RR 1.82; 95 % CI 1.27 to 2.60), and quality of 
life (standardised mean difference 0.29; 95 % CI 0.08 to 0.50), but not in individual 
symptoms (Zhang et al., 2016). 
Rifaximin is a poorly systemically absorbed antibiotic, that is derived from 
rifamycin, and is effective against both aerobic and anaerobic bacteria (Pimentel, 
2016). A systematic review and meta-analysis of five RCTs, comparing rifaximin 
with placebo, showed an improvement in global IBS symptoms (OR=1.57; 95% CI 
1.22 to 2.01, NNT = 10.2) and bloating (OR=1.55; 95% CI 1.23 to 1.96 NNT = 
10.1) (Menees et al., 2012). The side effect profile of rifaximin has been shown to be 
similar to placebo, probably as a result of its poor systemic absorption (Schoenfeld 
et al., 2014). 
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1.5.5.2 Antidepressants 
The efficacy of tricyclic antidepressants (TCAs) in IBS have been evaluated 
in 11 RCTs (744 patients). Of those patients receiving TCAs, 43.3% showed no 
improvement in IBS symptoms, compared with 63.7% receiving placebo. The RR of 
IBS symptoms not improving on TCAs was 0.66 (95 % CI 0.56 to 0.79), with a 
NNT of 4 (95% CI 3 to 6) (Ford et al., 2014). Seven RCT have compared selective 
serotonin reuptake inhibitors (SSRIs) with placebo, with a RR of IBS symptoms not 
improving on SSRIs of 0.68 (95% CI 0.51 to 0.91), and a NNT of 4 (95% CI 2.5 to 
20) (Ford et al., 2014). 
 
1.5.5.3 Psychological Therapies 
Psychological therapies include gut-directed hypnotherapy, relaxation 
therapy, and cognitive behavioural therapy (CBT) (Eriksson et al., 2015). In a meta-
analysis that included 41 RCTs (2290 IBS patients), which predominantly used CBT 
as the intervention, psychological therapy resulted in a significant improvement in 
GI symptoms in both the short-term (1 month to 6 months) and long-term (6 months 
to 12 months), when compared with a control group, which included sham 
treatment, online discussion forums, and symptom monitoring (Laird et al., 2016). 
 
1.6 Diagnosing IBS 
Diagnosing IBS can be challenging, not only because of the complex and 
overlapping pathophysiological mechanisms previously discussed, but also because 
the presenting symptoms of IBS can overlap with those of organic disease, such as 
colorectal cancer (Chang et al., 2015), IBD (Halpin and Ford, 2012), BAM (Gracie 
et al., 2012; Wedlake et al., 2009), and coeliac disease (Sainsbury et al., 2013; 
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Sanders et al., 2001), resulting in uncertainty for both the patient and doctor if a 
diagnosis is based on symptoms alone (Sood et al., 2014). Most people who report 
lower abdominal discomfort associated with a change in stool form or frequency 
will have IBS, which can, for the most part, be managed in a primary care setting 
(Yawn et al., 2001). However, as there is the potential for a missed diagnosis of 
organic GI disease, the difficulty arises for clinicians in distinguishing between IBS 
and organic causes of these types of symptoms, and in deciding on who will require 
investigation. 
Part of the rationale for the development of the symptom-based diagnostic 
criteria was to encourage physicians to make a positive diagnosis of IBS, and 
minimise unnecessary investigations. Current guidelines for the management of IBS 
in both the UK and USA still advocate this approach (Brandt et al., 2009; National 
Institute for Health and Care Excellence, 2008; Ford et al., 2014), and state clearly 
that IBS is not a diagnosis of exclusion. However, it has been suggested that such 
criteria, although useful for recruiting homogeneous groups of patients into clinical 
trials of therapies for IBS, are less relevant to routine clinical practice (Shivaji and 
Ford, 2015). Studies that have developed and validated these types of criteria have 
also been hampered by the lack of an accepted reference standard for the diagnosis 
of IBS.  Most investigators have used a normal colonoscopy as confirmation of a 
diagnosis of IBS, that is, physicians still regard IBS as a diagnosis of exclusion, 
which is perhaps justified by the modest performance of the different symptom-
based criteria, as shown below (Dogan and Unal, 1996; Ford et al., 2013; Tibble et 
al., 2002). 
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1.6.1 Diagnostic Accuracy of Symptoms and Symptom-based Diagnostic 
Criteria 
 
1.6.1.1 Symptoms  
 Patients with IBS report symptoms such as lower abdominal pain, change in 
stool form or frequency, passage of mucus per rectum, abdominal pain relieved by 
defaecation and visible abdominal distension, or a sensation of bloating. Several 
studies have assessed the accuracy of individual symptoms in terms of their 
accuracy in the diagnosis of IBS (Frigerio et al., 1992; Hammer et al., 2004; Jeong 
et al., 1993; Kruis et al., 1984; Manning et al., 1978; Rao et al., 1993). A systematic 
review and meta-analysis (Ford et al., 2008), which pooled the results of these six 
studies, containing between 188 and 915 patients for the analysis of each symptom 
item, demonstrated that individual symptoms performed poorly in predicting IBS, 
with pooled sensitivities in the range of 39% to 90% and specificities in the range of 
32% to 77%, respectively (Table 2). 
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Table 2. Pooled Sensitivity and Specificity for Individual Symptoms in Diagnosing 
Irritable Bowel Syndrome (Ford et al., 2008). 
 
Symptom item Number of 
studies 
Number of 
patients 
Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
Lower abdominal 
pain 
4 915 90 (79-97) 32 (21-44) 
Mucus per rectum 4 507 45 (22-69) 65 (47-81) 
Incomplete 
evacuation 
4 507 74 (66-82) 45 (31-60) 
Looser stools at 
onset of pain 
4 507 58 (46-69) 73 (64-81) 
More frequent 
stools at onset of 
pain 
4 188 53 (41-66) 72 (58-84) 
Pain relieved by 
defaecation 
4 507 60 (54-67) 66 (57-73) 
Patient-reported 
visible abdominal 
distension 
3 227 39 (20-60) 77 (64-88) 
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1.6.1.2 Symptom-based Diagnostic Criteria 
 The poor performance of individual symptoms in differentiating between IBS 
and organic disease is, perhaps, not unexpected. In a real-life setting, physicians 
rarely use a single item from the clinical history to formulate a diagnosis, and are 
more likely to combine various items. The groups of symptoms that constitute the 
Manning or Rome criteria cluster together, and demonstrate statistically significant 
associations with each other in community-based factor analysis studies (Talley et 
al., 1998; Drossman et al., 1990). These observations were taken as evidence to 
support the biological plausibility of IBS as a distinct clinical entity, and led to the 
development of some of the available symptom-based diagnostic criteria described 
earlier. 
 
1.6.1.2.1 The Manning Criteria 
A systematic review and meta-analysis (Ford et al., 2008) identified three 
studies that validated the Manning criteria (Dogan and Unal, 1996; Jeong et al., 
1993; Rao et al., 1993).  When data from these three studies were pooled with the 
original validation study, the Manning criteria demonstrated a sensitivity and 
specificity of 78% and 72%, respectively. A further study has been published since 
this meta-analysis (Ford et al., 2013), which showed that when three or more 
symptoms were used, sensitivity and specificity were 62% and 82%, respectively. 
Perhaps not unexpectedly, the Manning criteria performed well in the original 
validation study (Manning et al., 1978), but also demonstrated reasonable accuracy 
in a study from Turkey (Dogan and Unal, 1996).  
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1.6.1.2.2 The Rome Criteria 
A systematic review and meta-analysis, published in 2008 (Ford et al., 
2008), found only one eligible study containing 602 patients that reported on the 
accuracy of the Rome I criteria (Tibble et al., 2002) with sensitivity and specificity 
of 71% and 85%, respectively. A further study has been published in the intervening 
years (Ford et al., 2013), recruiting 1,848 individuals referred to secondary care for 
consideration of investigation of GI symptoms, with good sensitivity (96%), but a 
specificity of only 71%. 
The accuracy of the Rome II and III criteria remained unknown, due to a lack 
of prospective validation studies until 2013, when a study of 1,848 individuals 
referred to secondary care in Canada was published, which validated all iterations of 
the Rome criteria and the Manning criteria simultaneously within the same dataset 
(Ford et al., 2013). The sensitivity and specificity of the Rome II criteria were 90% 
and 72%, respectively, whereas Rome III demonstrated a sensitivity of 69% and 
specificity of 79.5%. Importantly, the Rome III criteria did not perform better than 
any of the previous symptom-based criteria within this dataset (Ford et al., 2013). 
The Rome IV criteria have yet to be externally validated in an unselected 
population, although they have been internally validated by the Rome committee in 
differentiating IBS from other FGIDs such as functional dyspepsia and CIC and 
were found to have a sensitivity of 62.7% and a specificity of 97.1% (Palsson et al., 
2016). 
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1.6.2 Biomarkers  
Perhaps because of the modest performance of symptom-based diagnostic 
criteria, interest has focused on various biomarkers as a means of diagnosing IBS. 
Biomarkers are measurable biological characteristics including physiological 
responses, genes, metabolites, or proteins that can serve as an indicator of a disease 
state or condition. Some of the potentially available biomarkers that have been 
developed are based on our understanding of the pathophysiology of IBS. 
 
1.6.2.1 Visceral Hypersensitivity as a Biomarker 
Altered visceral perception in IBS patients, expressed as reduced sensory 
thresholds, has been demonstrated in a number of studies (Mertz et al., 1995; 
Naliboff et al., 1997). There has been one retrospective study that has evaluated the 
sensitivity and specificity of rectal sensitivity to distension in patients with IBS 
(Bouin et al., 2002). 86 patients with IBS, 25 HCs, and 78 controls with other FGIDs 
were recruited. All patients underwent rectal distension testing, which involved 
placement of a rectal probe, inflated with a barostat bag to a maximum pressure limit 
of 48mmHg. Discomfort and pain levels were scored. IBS patients were found to 
have a significantly lower threshold for pain, when compared with the other groups. 
The optimal level of distension to identify IBS was 40mmHg, which yielded a 
sensitivity of 95.5% and a specificity of 72% in differentiating IBS from health or 
other FGIDs (Table 3). In a similar study recruiting patients with IBS and HCs, a 
threshold pressure of 26mmHg was able to distinguish between IBS and health with 
63% sensitivity and 90% specificity (Ludidi et al., 2012). As a potential biomarker, 
it would be more desirable if this test was able to differentiate accurately between 
IBS and organic disease, thus reassuring both patient and clinician, and avoiding 
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unnecessary investigation. However, this test fails to fulfil these criteria, particularly 
as visceral hypersensitivity has also been described in patients with UC (Delvaux, 
2002). Additionally, the invasive nature of the test, and its lack of availability 
outside of a research setting, probably limit its role in clinical practice. 
 
 
 
 
 
 
74 
 
Table 3. Sensitivity and Specificity of Symptom-based Diagnostic Criteria, Biomarkers, Psychological Markers, or Combinations 
Thereof in Diagnosing Irritable Bowel Syndrome. 
 
 Study and Year Sensitivity 
(95% confidence interval) 
 
Specificity  
(95% confidence interval) 
Manning criteria 
 
Ford et al. 2008 
Ford et al. 2013 
78 (62-90) 
62 (57-67) 
72 (55-87) 
82 (80-91) 
Rome I Tibble et al.  
Ford et al. 2013 
71 (66-76) 
96 (93-97) 
85 (80-89) 
71 (68-73) 
Rome II Ford et al. 2013 
 
90 (87–93) 72 (69-74) 
Rome III Ford et al. 2013 
 
69 (64-73) 79.5 (77-81.5) 
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Visceral  
hypersensitivity as a 
biomarker 
≥48mmHg 
 
 
 
≥26mmHg 
 
 
 
Bouin et al.  
IBS from health and 
other FGIDs 
 
Ludidi et al.  
IBS from health 
 
 
 
 
 
95.5 (not reported) 
 
 
 
63 (not reported) 
 
 
 
 
72 (not reported) 
 
 
 
90 (not reported) 
Altered pain 
perception as a 
biomarker 
Kim et al.  
IBS from health and 
other FGIDs 
 
86 (not reported) 
 
 
76 (not reported) 
 
 
 
76 
 
Serum biomarkers 
10-biomarker panel 
 
34-biomarker panel 
 
 
Anti CdtB Ab 
 
 
 
 
Anti-vinculin Ab 
 
Lembo et al.  
IBS from non-IBS 
Jones et al.  
IBS from health 
 
Pimentel et al. 
IBS-D from IBD 
IBS-D from coeliac 
IBS-D from health 
  
Pimentel et al.  
IBS-D from IBD 
IBS-D from coeliac 
IBS-D from health 
 
 
50 (not reported) 
 
81 (75-87) 
 
 
44 (not reported) 
33 (not reported) 
29 (not reported) 
 
 
33 (not reported) 
44 (not reported) 
44 (not reported) 
 
 
88 (not reported) 
 
64 (54-75) 
 
 
92 (not reported) 
81 (not reported) 
95 (not reported) 
 
 
84 (not reported) 
79 (not reported) 
91 (not reported) 
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Faecal biomarkers 
Volatile organic 
metabolites 
 
 
 
Volatile organic 
compounds 
 
 
 
 
Secretogranin II 
(>0.16nmol/g) 
 
Ahmed et al.  
IBS-D from Crohn’s 
IBS-D from UC 
IBS-D from health 
 
Aggio et al. 
IBS from active IBD 
IBS from inactive IBD 
IBS from all IBD 
IBS from health  
 
Öhman et al.  
IBS from health 
 
 
 
 
94 (not reported) 
96 (not reported) 
82 (not reported) 
 
 
93 (not reported) 
89 (not reported) 
92 (not reported) 
74 (not reported) 
 
 
80 (not reported) 
 
 
 
82 (not reported) 
80 (not reported) 
78 (not reported) 
 
 
90 (not reported) 
80 (not reported) 
78 (not reported) 
81 (not reported) 
 
 
79 (not reported) 
 
 
78 
 
Secretogranin III 
(>0.53nmol/g) 
 
Chromogranin b 
(<0.48nmol/g) 
Öhman et al.  
IBS from health 
Öhman et al.  
 
IBS from health 
 
80 (not reported) 
 
 
78 (not reported) 
 
68 (not reported) 
 
 
69 (not reported) 
Colonic mucosal 
immune biomarkers 
 
 
Cremon et al.  
IBS from health 
 
 
IBS from UC 
 
80 to 94  
(not reported) 
 
86 to 100  
(not reported) 
 
73.5 to 90  
(not reported) 
 
90 to 95  
(not reported) 
Tight junction 
disruption as a 
biomarker 
Turcotte et al.  
IBS from health 
 
 
62 (not reported) 
 
89 (not reported) 
 
 
79 
 
Psychological 
markers 
Jones et al.  
IBS from health 
 
74 (not reported) 
 
75 (not reported) 
Biomarkers and 
psychological 
markers 
Jones et al.  
IBS from health 
 
85 (not reported) 
 
88 (not reported) 
Kruis scoring system Ford et al.  77 (68-85) 89 (76-97) 
Faecal calprotectin 
and small intestinal 
permeability ratio 
Tibble et al. 
 
69 (64-74) 
 
92 (88-95) 
 
Faecal calprotectin, 
small intestinal 
permeability ratio, 
and Rome I criteria 
Tibble et al. 50 (45-56) 98 (96-99) 
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1.6.2.2 Altered Pain Perception as a Biomarker 
 As discussed earlier, visceral hypersensitivity is an important 
pathophysiological mechanism in the aetiology of IBS. Kim et al. investigated 
whether there were any differences in pain perception during colonoscopy between 
IBS and non-IBS patients (Kim et al., 2010). 217 patients, 101 with IBS, 37 with 
other FGIDs, and 79 HCs underwent colonoscopy for either investigation of GI 
symptoms, or screening purposes in the case of HCs. Those found to have organic 
pathology, including IBD, or who underwent procedures such as polypectomy, were 
excluded from the final analysis. Pain perception immediately post-procedure was 
evaluated by patients using a 100-mm VAS. Generally, IBS patients experienced 
more pain during colonoscopy. The optimal VAS pain score in differentiating 
between IBS and HCs, or other non-IBS FGIDs, was 31mm, with a sensitivity of 
86% and 76% respectively (Table 3). Again, this study used an invasive test to make 
a positive diagnosis of IBS, perhaps defeating the purpose of a clinically useful 
biomarker. This study is also limited by its exclusion of patients with organic 
pathology. 
 
1.6.2.3 Serum Biomarkers 
In 2009, Lembo et al. validated a panel of biomarkers for differentiating IBS 
patients from non-IBS patients (Lembo et al., 2009). Following a review of the 
medical literature, 60,000 biomarkers were identified that were related to potential 
pathophysiological processes in IBS, or other organic GI diseases. Each represented 
a relationship between a gene, protein, cellular process, or physiological condition in 
the GI tract. When only those that were serum-based and had a viable commercial 
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assay were considered, this number fell to 140. Of these, 10 were chosen finally, 
among them IL-1β, anti-tissue transglutaminase, and anti-neutrophil cytoplasmic 
antibody (ANCA), based on their performance in differentiating IBS from non-IBS. 
These were then combined to form an algorithm. Serum samples collected from 
1721 individuals with IBS, organic GI diseases, other FGIDs, non-GI functional 
disorders, and healthy people were then split into a derivation cohort of 1205 
subjects, used to train the algorithm, and a validation cohort of 516 individuals. 
However, sensitivity and specificity in differentiating IBS from non-IBS were 50% 
and 88% respectively (Table 3), which is no better than existing available symptom-
based criteria, and potentially far more expensive.   
Jones and colleagues added another 24 biomarkers to the original panel, 14 
of which were identified by analysing genes that were expressed differentially in 
IBS patients compared with healthy people, with the other 10 selected from 
pathways involved in pain, inflammation, serotonin metabolism, or mast cell 
activation (Jones et al., 2014). These included histamine, tryptase, serotonin, IL-12, 
IL-10, Il-6, IL-8, low density lipoprotein receptor, and vasoactive intestinal peptide 
receptor-1. However, performance of the 34 biomarker panel in 204 patients who 
met the Rome III criteria for IBS and 90 age and gender-matched healthy volunteers 
was again modest, with sensitivity and specificity of 81% and 64% respectively 
(Table 3). A subset of four biomarkers accounted for the majority of the 
performance. The major limitation of this study was that the serum biomarker 
algorithm was used to differentiate between IBS and health, whereas a biomarker 
that could differentiate between functional and organic GI disease would be far more 
relevant to clinical practice. 
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Recently, Pimentel et al. (Pimentel et al., 2015) validated two serum 
biomarkers, antibodies (Abs) to cytolethal distending toxin B (CdtB) and vinculin, 
primarily focusing on differentiating IBS-D from IBD. CdtB is a bacterial toxin 
commonly produced by Campylobacter jejuni, as well as E.coli, Salmonella, and 
Shigella. Infection of rats with C.jejuni can lead to PI-IBS, similar to humans, and 
the presence of CdtB appears to be positively associated with the likelihood of 
developing a PI-IBS phenotype. In addition, rats infected with a strain of C.jejuni 
that lacks CdtB exhibit a lower likelihood of developing this phenotype (Jee et al., 
2010; Pokkunuri et al., 2012). Vinculin is a host cell adhesion protein, with which 
anti-CdtB Abs are known to cross react. The study recruited 2681 participants aged 
18 to 65 years old from 180 centres. Of these, 2375 were Rome III IBS-D subjects 
recruited into a large RCT of rifaximin in IBS, 142 had IBD (73 with Crohn’s 
disease and 69 with UC), 121 had coeliac disease, and 43 were healthy volunteers. 
Participants in the IBS-D group were approximately 4 years older, when compared 
with the non-IBS participants, but there was no difference in sex distribution 
between IBS-D and non-IBS participants. ELISA testing was performed on plasma 
samples collected from all participants, using recombinant Campylobacter CdtB 
protein, and full length human vinculin protein, as antigens. Levels of anti-CdtB and 
anti-vinculin Abs were then calculated and compared from optical densities, and the 
sensitivity, specificity, and likelihood ratios (LRs) of these were assessed, and 
receiver operating characteristics (ROC) curves constructed. 
Levels of anti-CdtB Ab titres were found to be significantly higher in 
participants with IBS-D (2.53 + 0.69) when compared with Crohn’s disease (1.72 + 
0.81), UC (1.54 + 0.68), coeliac disease (2.23 + 0.70), or healthy subjects (1.81 + 
0.73) (P < 0.001). Furthermore, levels of anti-vinculin Abs were significantly higher 
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in IBS-D subjects (1.34 + 0.85) when compared with Crohn’s disease (1.05 + 0.91), 
UC (0.96 + 0.77), coeliac disease (1.07 + 0.98), or healthy subjects (0.81 + 0.59) (P 
< 0.0001).  
When determining optimum cut-off points on ROC curves using anti-CdtB 
and anti-vinculin Ab levels to distinguish between IBS-D and non-IBS subjects, the 
authors elected to maximise specificity over sensitivity, reducing the number of false 
positive results, and therefore improving the positive LR. When distinguishing IBS-
D from IBD, the area under the curve (AUC) was higher for anti-CdtB Abs when 
compared with anti-vinculin Abs (0.81 vs. 0.62). Using a cut-off point of levels 
>2.80 for anti-CdtB Abs, sensitivity was 43.7%, specificity 91.6%, and positive and 
negative LRs were 5.2 and 0.6 respectively. Using a cut-off point of levels >1.68 for 
anti-vinculin Abs, sensitivity and specificity were 32.6% and 83.8%, with a positive 
and negative LR of 2.0 and 0.8 respectively.   
ROC curves constructed for anti-CdtB Abs were also able to differentiate 
IBS-D from coeliac disease and healthy volunteers, with an AUC of 0.63 and 0.76 
respectively. At levels >1.68 of anti-CdtB Abs, IBS-D was differentiated from 
coeliac disease with a sensitivity of 32.6% and a specificity of 81.0%. Positive and 
negative LRs were 1.7 and 0.8 respectively. At levels >1.80 of anti-CdtB Abs, IBS-
D was differentiated from healthy volunteers with a sensitivity of 28.9% and 
specificity of 95.4%, with positive and negative LRs of 6.2 and 0.7 respectively.  
The AUCs for anti-vinculin Abs in differentiating IBS-D from coeliac 
disease, and IBS-D from healthy volunteers, were 0.61 (sensitivity 43.7%; 
specificity 79.3%; positive LR 2.1; negative LR 0.7, at levels >2.80) and 0.68 
(sensitivity 43.7%; specificity 90.7%; positive LR 4.7; negative LR 0.6, at levels 
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>2.80) respectively. Sensitivity and specificity were not reported for either marker in 
differentiating IBS subjects from all non-IBS subjects. 
This study is important for two reasons. Firstly, the fact that these two 
antibodies were able to differentiate IBS-D from IBD and HCs, with a reasonable 
degree of accuracy, suggests that a substantial proportion of individuals with IBS 
may have an overt or sub-clinical post-infectious trigger, resulting in intestinal 
microbial disturbances, and the development of IBS-D. Secondly, the ability of these 
tests, if positive, to rule in IBS-D and rule out IBD is encouraging, especially when 
compared with the accuracy of previously validated serum-based biomarkers. Their 
ability to make a positive diagnosis is in direct contrast to other available biomarkers 
such as faecal calprotectin, in which a negative test rules out IBD, and therefore only 
reaches a “diagnosis” of IBS-D via the exclusion of an organic disease. However, a 
major limitation of this study, as well as previous studies assessing the accuracy of 
serum-based biomarkers, is that they have all been conducted in secondary or 
tertiary care with an enriched sample of cases, resulting in an artificially high 
prevalence of IBS, meaning that the diagnostic accuracy reported may not be 
reproducible in an unselected primary care population, where the prevalence of IBS 
is likely to be lower. This is also the setting in which an accurate diagnostic test is 
probably required the most. 
 
1.6.2.4 Faecal Biomarkers 
Other biomarkers have also been assessed as a potential diagnostic tool in 
IBS. A recent study examined the accuracy of volatile organic metabolites (VOMs) 
in differentiating 30 patients with IBS-D from 110 patients with active IBD (Ahmed 
et al., 2013). VOMs are chemicals that are released in faeces, and which then 
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undergo changes as a result of organic disease or alterations in the intestinal 
microbiota, and these were extracted from faeces using solid-phase microextraction 
fibres, after faecal samples had been heated in a water bath at 60°C for 1 hour. 
Following univariate analysis, 44 VOMs were found to be able to differentiate IBS-
D from active IBD, of which 35 were more abundant in IBS-D. Sensitivity and 
specificity of the model in differentiating IBS-D from Crohn’s disease was 94% and 
82% respectively, and sensitivity and specificity of differentiating between IBS-D 
and UC was 96% and 80% respectively. Finally, the model was able to differentiate 
between IBS-D and HCs with a sensitivity of 82% and specificity of 78% (Table 3).  
Aggio et al. (Aggio et al., 2016) conducted a study that used a prototype 
device based on gas chromatography to separate volatile organic compounds 
(VOCs) (products from digestion and fermentation by the intestinal microbiota),  
from faecal gas, in order to identify patterns that could be used to differentiate 
between IBS, IBD, and health. Patients were recruited prospectively between 
October 2010 and October 2011, and faecal samples were obtained from 28 patients 
with IBS, as defined by the Rome II criteria (26 patients with IBS-D), 33 patients 
with active IBD, 50 patients with inactive IBD, and 41 HCs. A simple clinical 
activity index score >3 or a Harvey Bradshaw index >4 were used to define active 
UC and active Crohn’s disease, respectively.  
Faecal samples were stored at -20оC, and samples were analysed by gas 
chromatography, which works by characterising the VOCs contained in the faecal 
samples. Patterns in the VOCs were then detected for each of the individual medical 
disorders. This prototype device had a runtime of only 40 minutes, therefore 
potentially providing a means for a point-of-care test. The device was able to 
distinguish between IBS and active IBD with a maximum sensitivity and specificity 
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of 93% and 90% respectively; between IBS and inactive IBD with a maximum 
sensitivity and specificity of 89% and 80% respectively; between IBS and all IBD 
patients with a maximum sensitivity of 92% and specificity of 78%; and between 
IBS and HCs with a maximum sensitivity and specificity of 74% and 81% 
respectively. Following construction of a ROC curve, the AUC for all comparisons 
ranged between 83.2% for differentiating between IBS and HCs and 96.5% for 
differentiating between IBS and active IBD.  
Granins, such as chromogranins (Cg) and secretogranins (Sg), are proteins 
found in the secretory cells of the enteric, endocrine, and immune system, which are 
thought to reflect activity of these systems. In one study of 82 IBS patients and 29 
HCs, higher levels of faecal CgA, SgII, and SgIII were found in IBS patients relative 
to healthy individuals, and levels of CgB were found to be lower in IBS patients 
(Ohman et al., 2012). However, these faecal biomarkers performed only modestly in 
differentiating IBS from HCs, with SgII performing the best (sensitivity 80%, 
specificity 79%) (Table 3). Again, this study was limited by the small sample size 
and the biomarker being used to differentiate between IBS and health, rather than 
IBS and organic disease. Granins are also unlikely to be specific markers of IBS, as 
increased levels are also associated with organic GI diseases, such as lymphocytic 
colitis and coeliac disease (Camilleri, 2012).  
 
1.6.2.5 Colonic Mucosal Biomarkers 
As previously discussed, studies have reported increased mast cells and T-
lymphocytes within the colonic mucosa of patients diagnosed with IBS (Cremon et 
al., 2009; Akbar et al., 2008). In one study, Cremon et al. (Cremon et al., 2013) 
examined whether colonic mucosal immune biomarkers, including mast cells, 
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immune cells, or immune gene expression, could be used to diagnose IBS. In total, 
144 patients with IBS, 32 with UC, and 68 HCs underwent colonoscopy and colonic 
mucosa sampling for histological examination. Using quantitative real time reverse 
transcriptase PCR the expression of nerve growth factor, interferon-ɣ, toll-like 
receptor-4, and pre-haptoglobin-2 were measured. These were all significantly 
increased in IBS patients, compared with HCs, but were significantly lower than 
among UC patients. Sensitivity and specificity of the biomarkers in distinguishing 
between IBS and HCs were 80% to 94% and 73.5% to 90% respectively (Table 3). 
Sensitivity and specificity, when distinguishing between IBS and UC, were 86% to 
100% and 90% to 95%, respectively. However, there have been no other studies 
replicating these findings and, at the time of writing, the results of this study have 
not been fully published. 
 
1.6.2.6 Exhaled Organic Compounds as a Biomarker 
Hundreds of VOCs are present in human exhaled breath, some of which can 
be associated with pathophysiological processes such as lung cancer and asthma 
(Tang et al., 2017; Oguma et al., 2017). In one study, the researchers collected 
breath samples and symptom data from 170 IBS patients, as well as 153 age- and 
gender-matched HCs in whom GI symptoms and disorders were excluded following 
medical consultation (Baranska et al., 2016). A further 1307 participants were 
enrolled from a large general population cohort, and provided exhaled breath 
samples and a 7-day GI symptom diary. Analysis of breath was by thermal 
desorption-gas chromatography, combined with mass spectrometry, in order to 
determine a combination of VOCs that best discriminated IBS patients from HCs, 
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following which a ROC curve was constructed to determine the sensitivity and 
specificity of this biomarker panel.  
The investigators identified 16 VOCs that best discriminated between 123 
IBS patients and 123 HCs. The accuracy of this panel was then validated in the 
remaining 47 IBS patients and 30 HCs, and was able to differentiate between the 
two with a sensitivity of 89% and specificity of 73%. Positive and negative 
predictive values (PPV and NPV) were 84% and 82% respectively, and the AUC 
was 0.83. Analysis of breath-o-grams from the IBS patients and HCs demonstrated 
visible separation between the two in both the derivation and validation cohorts. 
However, some IBS patients had VOC profiles that overlapped with the HCs, which 
could not be explained either by medical history or baseline characteristics. 
In the IBS cohort, a significant correlation was found between the panel of 
VOCs and abdominal pain, discomfort, belching, and flatulence (r = 0.55, P = 
0.0003). In the general population cohort, only participants with 7-day mean scores 
for abdominal pain or discomfort >1.5 on a 1 to 5-point scale were used in the 
correlation analysis, and a moderate but significant correlation was found between 
the panel of VOCs and abdominal pain, belching, bloating, flatulence, nausea, and 
diarrhoea (r = 0.54, P = 0.0004). The authors concluded that breath analysis may be 
useful in both the diagnosis and monitoring of IBS, but could also be used as a 
screening tool to detect the condition in the general population. The study is 
important for two reasons. Firstly, this is the only study that has attempted to 
identify and then validate a panel of exhaled VOCs that can differentiate IBS from 
health, and which can potentially be applied as a simple and non-invasive clinical 
test. Secondly, in utilising multiple VOCs, this is more likely to encompass the 
multifactorial aetiology of IBS, compared with individual markers. Finally, in 
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showing that a panel of VOCs appears to correlate with GI symptoms, an issue that 
has not been explored in previous studies, there is the potential for developing a 
means to monitor IBS symptoms following instigation of medical therapy. However, 
the major limitation of this study is that once again the VOC panel was validated 
only in terms of its ability to differentiate IBS from health. 
 
1.6.2.7 Tight Junction Disruption as a Biomarker 
As previously discussed, disruption to the tight junctions resulting in 
increased intestinal permeability may be an important pathophysiological 
mechanism in IBS. In one small study, 17 IBS patients and 18 HCs underwent 
colonoscopy and ileoscopy, with the aim to identify presence of epithelial gaps 
using CLE (Turcotte et al., 2013). IBS patients were found to have significantly 
higher epithelial gap densities in the terminal ileum compared with controls. Using a 
cut-off of 30 gaps per 1000 cells as the threshold to define abnormal gap density, 
sensitivity and specificity were 62% and 89% respectively (Table 3). However, the 
usefulness of this test is probably limited, as increased epithelial gap density has also 
been demonstrated in IBD patients (Liu et al., 2011). In addition, the performance of 
the test is likely to be highly dependent on the operator, and the required skills may 
not be available in other centres. 
 
1.6.2.8 Faecal Bile Acid, Colonic Transit, and Intestinal Permeability as a 
Biomarker 
 In one study, the ability of three quantitative traits, total faecal bile acids, 
colonic transit, and intestinal permeability, were assessed in order to identify 
treatable processes that may discriminate between IBS-D, IBS-C, and HCs 
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(Camilleri et al., 2014). The study recruited 64 patients with IBS-D, 30 patients with 
IBS-C, and 30 HCs, and all study participants completed a validated bowel disease 
questionnaire, the somatic symptom checklist (SSC), HADS questionnaire, and 
underwent measurement of colonic transit, testing for faecal BAM, evaluation of 
bile acid synthesis, and also assessment of intestinal permeability. Colonic transit 
was evaluated by scintigraphy, using methods validated previously. Evidence of 
BAM was assessed using serum 7α-C4, and a combination of liquid chromatography 
and mass spectrometry was used to measure faecal bile acid excretion. Daily faecal 
fat excretion was estimated by nuclear magnetic resonance spectrometry. Bile acid 
synthesis was quantified by measuring serum FGF19, and intestinal permeability, 
via urinary excretion of lactulose and mannitol, after oral ingestion.  
 Psychosomatic and depression scores, according to the SSC and HADS, were 
statistically higher among IBS patients when compared with HCs. Faecal fat, serum 
C4 levels, and total faecal bile acid levels were higher in the IBS-D patients, 
compared with both IBS-C patients and HCs. Colonic transit studies at 48 hours 
showed a higher geometric centre in the IBS-D patients (P < 0.001). Urine mannitol 
levels at 2 hours were also higher in the IBS-D group, when compared with IBS-C 
patients and HCs (P = 0.039). Significant correlations were demonstrated between 
total faecal bile acids and colonic transit (at both 24 hours and 48 hours), and 
between total faecal bile acids and intestinal permeability.  
 Following logistic regression analysis and using ROC curves, with estimation 
of AUC, total faecal bile acids were found to be a predictor for IBS-D vs. HCs (P = 
0.025, ROCAUC = 0.70), and for IBS-D vs. IBS-C (P = 0.024, ROCAUC = 0.81). The 
addition of C4 and FGF19 measurements did not improve the accuracy of total 
faecal bile acids in discriminating between the three study groups. Colonic transit at 
 
 
91 
 
48 hours was also able to discriminate IBS-C from HCs (P = 0.03, ROCAUC 0.70), 
and IBS-C from IBS-D (P < 0.001, ROCAUC = 0.78). Small intestinal permeability 
on its own was not a significant predictor. However, combining total faecal bile 
acids, colonic transit, and small intestinal permeability led to greater accuracy in 
differentiating IBS-C from HCs when compared with each of these variables 
independently (ROCAUC = 0.73).   
 A two-item model, consisting of colonic transit measurement at 48 hours, and 
total faecal bile acids, was assessed in terms of its accuracy to discriminate IBS from 
health. Using a fixed threshold of 80% sensitivity on the ROC curve, the specificity 
of the model in differentiating IBS-D from HCs was 43%, in differentiating IBS-C 
from HCs it was 57%, and in distinguishing between IBS-D and IBS-C it was 81%. 
When using a reduced sensitivity threshold of 60%, these specificities increased to 
75%, 85%, and 90% respectively.  
 Limitations of the study include the fact that 10 of the 64 IBS-D patients 
(15.6%) had undergone cholecystectomy, a slightly higher proportion than in both 
the IBS-C group (10%) and HCs (6.7%). In a study which has previously been 
discussed, 190 (50.9%) of 373 patients with chronic diarrhoea who underwent 
SeHCAT scan were found to have BAM, with cholecystectomy associated with an 
increased risk for an abnormal SeHCAT scan (OR 2.51; 99% CI 1.10 to 5.77) 
(Gracie et al., 2012). Therefore, in the current study, the higher cholecystectomy rate 
in the IBS-D group could have contributed to the higher level of total faecal bile 
acids observed in this group. In addition, once again the biomarker combination was 
used to differentiate IBS from health but, as previously stated, a test that 
differentiates IBS from organic GI disease presenting with similar symptoms, would 
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be more clinically useful. Finally, the study was conducted in a tertiary centre with a 
relatively small, and potentially highly selected, patient group. 
 
1.6.3 Diagnosing IBS Using Psychological Markers 
 The link between psychological life stressors and IBS has previously been 
discussed. In one study that assessed the accuracy of psychological markers in 
diagnosing IBS (Jones et al., 2014), 244 individuals were recruited, 168 of whom 
had IBS and 76 were HCs. All participants were asked to complete three validated 
measures of psychological wellbeing, the HADS scale, the patient health 
questionnaire-15 (PHQ-15), and the perceived stress scale. Mean scores across all 
three measures were significantly higher among those with IBS, compared with 
HCs. Psychological measures alone had a sensitivity and specificity of 74% and 
75% in differentiating IBS from health (Table 3).  
 
1.6.4 Diagnosing IBS Using Combinations of Symptoms, Biomarkers, and 
Psychological Markers 
None of the methods described above, with the exception of faecal 
VOMs/VOCs in two relatively small studies and anti-CdtB Abs in a case-control 
study with a high IBS prevalence, seem to be able to predict the presence of IBS 
with any particular accuracy, or are hampered by their applicability in a clinical 
setting. Combining clinical items, biomarkers, and psychological markers together 
may lead to a greater ability to discriminate between IBS and organic disease. As 
early as 1984, Kruis and colleagues developed a statistical model to aid in the 
diagnosis of IBS (Kruis et al., 1984), based on a scoring system which incorporated 
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the clinical history, physical examination, and the results of some simple blood tests, 
including a full blood count and an erythrocyte sedimentation rate (ESR) (Table 4).  
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Table 4. The Kruis Statistical Model. 
 
Symptom items included Minimum symptom duration 
Symptoms (reported by the patient using a 
form): 
Abdominal pain, flatulence, or bowel 
irregularity 
Description of abdominal pain as “burning, 
cutting, very strong, terrible, feeling of 
pressure, dull, boring, or ‘not so bad’” 
Alternating constipation and diarrhoea 
Signs (each determined by the physician): 
Abnormal physical findings and / or history 
pathognomonic for any diagnosis other than 
IBS 
ESR >20mm/2h 
Leucocytosis >10,000/μL 
Anaemia (Haemoglobin <12 g/dL for females 
or <14 g/dL for males) 
Impression by the physician that the patient’s 
history suggests blood in the stools 
 
 
 
 
 
>2 years 
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This was assessed in 479 patients in the original study, with the items described above 
combined to produce a scoring system, and a score of ≥44 used as the threshold to define 
IBS. The Kruis statistical model has been validated subsequently in three studies (Dogan 
and Unal, 1996; Frigerio et al., 1992; Bellentani et al., 1990), meaning that its accuracy 
has been assessed in 1171 patients in total. A meta-analysis pooled the results of these 
four studies (Ford et al., 2008), and reported sensitivity and specificity of 77% and 89% 
respectively (Table 3). However, there have been few other investigators who have used 
this type of approach, until recently.  
In the study conducted by Jones et al. (Jones et al., 2014), the authors 
combined the markers of psychological effect described in the previous section 
above, with the 34-biomarker panel they had validated. This led to a greater ability 
to distinguish between patients with IBS and healthy volunteers, with improvement 
in sensitivity and specificity of 85% from 81% and 88% from 64% respectively, 
when compared with biomarkers alone (Table 3). 
In the previously discussed study from Tibble et al. (Tibble et al., 2002), 
patients provided a stool sample for measurement of faecal calprotectin levels, in 
addition to undergoing a lactulose/L-rhamnose small intestinal permeability test. 
Using a faecal calprotectin level of <10 mg/L and a permeability ratio of <0.05, this 
biomarker combination was able to identify IBS patients with a sensitivity of 69% 
(95% CI 64% to 74%) and specificity of 92% (95% CI 88% to 95%). 
In the same study, a positive result for the Rome I criteria was incorporated 
with faecal calprotectin levels of <10mg/L and permeability ratio of <0.05, resulting 
in a sensitivity of 50% (95% CI 45% to 56%) and a specificity of 98% (95% CI 96% 
to 99%) (Tibble et al., 2002). 
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1.7 Possible Future Directions 
Gastroenterologists and primary care physicians consulting in clinic need 
diagnostic tests that distinguish between IBS and other organic disorders that may 
produce similar symptoms, and which could be confused with IBS, such as coeliac 
disease or IBD, rather than between IBS and health. Limitations of the methods of 
diagnosing IBS studied above include their conduct in referral populations, meaning 
that the results may not be generalisable to primary care where the prevalence of 
IBS is lower. The studies have had relatively small sample sizes in some instances, 
with a lack of other studies validating the more novel approaches prospectively, 
such as faecal VOMs/VOCs, and several of the techniques described have been used 
to discriminate between people with IBS and healthy individuals. One of the striking 
observations is the relatively modest performance of all the available symptom-
based diagnostic criteria. This is probably not surprising, given that they are, for the 
most part, derived from each other, meaning that the same strengths and weaknesses 
have been passed on from one set of criteria to another.  
The performance of biomarkers is also disappointing, particularly given their 
potentially expensive nature. However, faecal VOMs/VOCs appear promising, 
although the results reported by Ahmed et al. (Ahmed et al., 2013) and Aggio et al. 
(Aggio et al., 2016)  need to be replicated by other investigators before their 
accuracy is confirmed. Perhaps combining demographic data such as age, gender, 
upper, as well as lower, GI symptoms, biomarkers, and psychological markers, using 
methodology, akin to the Kruis statistical model, as a means of improving IBS 
diagnostics is one future direction to consider. However, one drawback to this 
approach is increasing complexity, and a diagnostic test that may become too 
cumbersome to use in routine clinical practice. This is probably one of the reasons 
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why the Kruis scoring system has never been adopted widely, despite its reasonable 
performance in predicting IBS.  
The diagnostic ability of any of these methods (symptom-based, 
demographic information, and biomarkers) could be improved through the use of 
more complex statistical methods. Latent class analysis (LCA) is one such method. 
LCA uses patterns in measured variables, such as symptoms, to develop an estimate 
of an unmeasured attribute, such as IBS, which has no specific biomarker. These 
methods are widely applied in other fields, such as psychiatry, and have been shown 
to be particularly valuable when, as is the case for IBS, an accurate and accepted 
gold standard test is lacking (Rindskopf and Rindskopf, 1986; Kato et al., 2010; 
Schur et al., 2007). LCA methods are designed to use the sets of measurements that 
we do have access to, in order to construct an appropriate pattern of measurements 
that most closely represents the latent construct IBS. They are a type of categorical 
data analysis, which define groups known as classes, and could be used to improve 
the predictive power of methods used to diagnose IBS, and therefore to discriminate 
between IBS and non-IBS symptom profiles.  
For example, in a group of diseases that share some of the same symptoms, 
LCA can be used to detect patterns of association in the disease entities, and 
therefore determine the likelihood of belonging to a particular group. There are few 
instances of this type of modelling being used in FGIDs. Two such examples in the 
literature have examined the association between the most common functional 
somatic symptoms and syndromes, including IBS, which often show considerable 
overlap, and are thought to share similar aetiologies (Kato et al., 2010; Schur et al., 
2007). Given the limitations of current approaches, better methods to diagnose IBS 
are required.    
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CHAPTER 2 
Aims and Objectives 
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 The aim of this thesis is to explore diagnostic approaches to IBS, to try to 
enhance the limited ability of symptom-based diagnostic criteria to correctly identify 
patients with IBS, and to assess the performance of novel methods to differentiate 
IBS from organic diseases that may present with similar symptoms, such as 
colorectal cancer, IBD, and coeliac disease. The following pieces of work have been 
conducted: 
 
2.1 The Accuracy of Diagnosing Irritable Bowel Syndrome with Symptoms,  
Biomarkers, and Psychological Markers 
 As described previously, symptom-based diagnostic criteria appear to perform 
only moderately well in in differentiating IBS from organic pathology. Given their 
modest performance, more accurate ways of diagnosing IBS are required, and as 
discussed, interest has increased in developing biomarkers as a diagnostic tool to aid 
in this. A previous systematic review has already examined the accuracy of 
symptom-based diagnostic criteria in differentiating IBS from organic disease (Ford 
et al., 2008), but since this systematic review further individual studies have been 
published examining the accuracy of these criteria, as well as studies describing 
more novel methods to diagnose IBS, including biomarkers and psychological 
markers.  A systematic review and meta-analysis was therefore conducted in order to 
summarise all available approaches in diagnosing IBS, including symptoms, 
biomarkers, psychological markers, and combinations thereof (Chapter 3). The aim 
was to understand the strengths and weaknesses of the available diagnostic tests for 
IBS. Using these findings, two diagnostic test studies were designed and undertaken 
with the intention of creating accurate, inexpensive, and easily administrable tests 
for clinicians consulting in routine clinical care. 
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2.2 Validating the Rome III Criteria in Secondary Care and Enhancing their 
Performance 
 There has been only one study to date, published in 2013 and undertaken in 
Canada (Ford et al., 2013), that has validated the Rome III criteria, despite these 
criteria being first described in 2006. A further validation of the gold standard in 
diagnosing IBS is therefore required in a demographically different study 
population. 
 As previously discussed, combining symptoms with clinical biomarkers and/or 
markers of psychological effect may lead to an increased ability to discriminate 
between IBS and organic disease. To date, no study has assessed the effect of 
combining the Rome III criteria with one or more relevant biomarkers or 
psychological markers, such as haemoglobin, C-reactive protein (CRP), anxiety and 
depression scores, somatisation scores, and other symptoms such as nocturnal 
passage of stools, to assess if this improves accuracy in differentiating IBS from 
organic disease. A diagnostic accuracy study was therefore conducted among 
consecutive new patient referrals with lower GI symptoms in Leeds, UK, in order to 
assess the performance of the Rome III criteria, as well as the effect of modifications 
to them. The aim was to develop an accurate, inexpensive, and potentially easily 
administrable test in routine clinical care.  
 
2.3 A Novel Approach to Diagnosing IBS Using Latent Class Analysis 
 There are few examples in the literature of LCA being used to aid in the 
diagnosis and management of  FGIDs (Kato et al., 2010; Schur et al., 2007), and 
only one study that has used this approach in IBS patients. In this study by Koloski 
et al. LCA was used to differentiate between IBS-C and CIC (Koloski et al., 2015). 
No studies, to date, have used LCA as a diagnostic test to aid in distinguishing 
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between IBS and organic disease. Using the database from the only study that has 
validated the Rome III criteria (Ford et al., 2013), we aimed to use LCA to derive a 
model that identified predictors of IBS, which could then be used as a diagnostic test 
for the disorder. This model was then validated in the database of consecutive 
patients referred with lower GI symptoms in Leeds recruited in the previous study. 
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CHAPTER 3 
Systematic Review and Meta-Analysis: 
Accuracy of Diagnosing Irritable Bowel 
Syndrome with Symptoms, Biomarkers and 
Psychological Markers 
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3.1 Introduction 
 As discussed, symptom-based diagnostic criteria perform only modestly in 
differentiating IBS from organic disease. Furthermore, these criteria have been 
criticised for being overly complex and impractical in a clinical setting, particularly 
in primary care where the majority of IBS patients are diagnosed and managed 
(Shivaji and Ford, 2015; Thompson et al., 1997). Partly as a consequence of this, 
interest has grown in developing novel biomarkers, some of which have been 
reviewed in chapter one. However, a comprehensive systematic review and meta-
analysis of novel biomarkers for IBS, incorporating several literature databases, has 
not previously been undertaken. 
 Additionally, although the accuracy of symptom-based diagnostic criteria in 
predicting IBS has previously been examined (Ford et al., 2008), since this meta-
analysis was performed, there have been more studies published relating in 
particular to the Rome II and Rome III criteria that were not included in this meta-
analysis. 
 Patients with IBS are more likely to have higher levels of anxiety, neuroticism, 
or mood instability when compared with healthy individuals and those with other 
lower GI disorders (Creed et al., 2001; Henningsen et al., 2003; Koloski et al., 2006; 
Lee et al., 2008). As a result, studies have also been conducted to assess whether 
measures of psychological wellbeing can aid in the diagnosis of IBS. However, no 
systematic review has assessed the accuracy of markers of psychological affect in 
predicting a diagnosis of IBS. 
 A systematic review and meta-analysis was therefore conducted to examine all 
the available methods that use symptoms, biomarkers, markers of psychological 
affect, or combinations thereof, to aid in the diagnosis of IBS. 
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3.2 Methods 
 
3.2.1 Search Strategy and Study Selection 
The systematic review was performed according to the Cochrane Methods 
Group on screening and diagnostic tests guidelines. A search of the medical 
literature was conducted using MEDLINE (January 1946 to February 2015), 
EMBASE, and EMBASE classic (1947 to February 2015). Eligible studies were 
required to report prospectively on  adult (≥16 years of age) patients with lower GI 
symptoms, and had to assess the accuracy of one or more of the available accepted 
symptom-based diagnostic criteria for IBS, biomarkers, psychological markers, or 
combinations thereof, in diagnosing IBS against an accepted reference standard, 
taken as being a physician’s diagnosis of IBS, another set of accepted diagnostic 
criteria, or the absence of an organic explanation for these symptoms, such as IBD, 
microscopic colitis, or colorectal cancer, following lower GI endoscopy (Box 1).  
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Box 1. Eligibility Criteria. 
 Adult patients (aged >16 years) with lower GI symptoms 
 Cross-sectional design or case-control 
 Applied a diagnostic test for IBS to all patients, including one or more of: 
symptom-based diagnostic criteria†, biomarkers, psychological markers, or 
combinations thereof 
 Confirmed presence of IBS using an accepted reference standard‡ 
 Results of diagnostic test for IBS compared with the reference standard  
 ≥50 patients included 
 
†Manning, Rome I, Rome, II, or Rome III criteria 
‡Normal colonoscopy, barium enema, CT colonography, physician’s opinion that 
this was IBS, or accepted symptom-based diagnostic criteria for IBS 
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When assessing the accuracy of symptom-based diagnostic criteria, the 
reference standard was mandated as negative lower GI investigations, but when 
assessing the accuracy of novel biomarkers this could either be accepted symptom-
based diagnostic criteria or a physician’s diagnosis of IBS. Studies that applied an 
accepted test for organic disease, such as faecal calprotectin, and therefore 
effectively reached a diagnosis of IBS by exclusion of the specific organic disease 
that the test was designed to detect, were not considered as eligible for inclusion in 
this meta-analysis.  
Search terms used to identify potentially relevant publications were: irritable 
bowel syndrome, IBS, functional diseases, colon, or functional adj5 bowel. These 
were combined, using the set operator AND, with the following search terms: Kruis, 
Manning, Rome 1, Rome I, Rome 2, Rome II, Rome3, Rome III, biomarker, f$ecal 
biomarker, psychological marker, metabolite, transit time, colonic motility, small 
intestinal motility, visceral hypersensitivity, pain, bile acid, cytokine, mast cell, 
intestinal permeability, chromogranin, or secretogranin. These were again 
combined using the set operator AND with the search terms sensitivity or specificity. 
There were no language restrictions and abstracts of the papers identified by the 
initial search were evaluated by the lead author for appropriateness to the study 
question. All potentially relevant papers were obtained and evaluated in detail. 
Foreign language papers were translated. Abstract books of conference proceedings 
between 2007 and 2014 were hand-searched to identify potentially eligible studies 
published only in abstract form. The bibliographies of all identified relevant studies 
were used to perform a recursive search of the literature. Articles were assessed 
independently by two reviewers using pre-designed eligibility forms, according to 
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the prospectively defined eligibility criteria. Any disagreement between 
investigators was resolved by consensus. 
 
3.2.2 Data Extraction 
 All data were extracted independently by two reviewers on to a Microsoft 
Excel spreadsheet (XP professional edition; Microsoft Corp, Redmond, WA, USA) 
as total number of patients with IBS, total number of IBS patients testing positive 
for IBS using the diagnostic criteria, biomarker, psychological marker, or 
combination thereof under study, total number of non-IBS patients, and the total 
number of non-IBS patients testing positive for IBS using the same diagnostic test. 
In addition, the following clinical data were extracted for each study: setting 
(primary or secondary care), number of centres, country of origin, and diagnostic 
test applied. 
 
3.2.3 Data Synthesis and Statistical Analysis 
The degree of agreement between investigators, in judging study eligibility, 
was measured using the Kappa statistic. The accuracy of diagnostic tests is often 
summarised using sensitivity and specificity. Although these are useful measures of 
a test’s performance, they provide the probability of the test being positive if the 
disease of interest is present, or the probability of the test being negative if the 
disease is absent. However, for a physician consulting with a patient it is more 
useful to know the probability of the patient truly having the disease if the test is 
positive, or truly not having the disease if the test is negative. These are the PPV and 
NPV of the test.  
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One of the limitations of predictive values is that their magnitude varies 
according to the prevalence of the disease under study. For this reason, more useful 
summary measures of the diagnostic accuracy of a test are the positive and negative 
LRs. These are derived from the sensitivity and specificity of a test, which are fixed, 
and therefore do not vary according to the prevalence of the disease of interest 
(Moayyedi and Axon, 1999). The positive LR is derived from the formula:  
𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦
1−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦
 while the negative LR is derived from the formula:  
1−𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦
𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦
  As a 
rule of thumb, positive LRs above 10 are very useful in ruling in a disease, and 
negative LRs below 0.1 are very useful in ruling out a disease.  
For each study identified in the literature search, the raw data from the paper 
was extracted, as described above, into a Microsoft Excel spreadsheet (XP 
professional edition; Microsoft Corp, Redmond, WA, USA), in order to calculate the 
sensitivity, specificity, PPV and NPV of each of the diagnostic tests for IBS under 
study. The positive and negative LRs, and their 95% CIs, were also calculated 
within the same spreadsheet, using the aforementioned formulas. These calculations 
were checked using Meta-DiSc® version 1.4 (Universidad Complutense, Madrid, 
Spain). Where data were not extractable, the authors of the original paper were 
contacted, if possible, in order to obtain further information.  
Where the accuracy of  identical symptom-based criteria, biomarkers, 
psychological markers, or combinations thereof, were reported by more than one 
study, LRs were combined from each study using StatsDirect version 2.7.7 
(StatsDirect Ltd, Sale, Cheshire, England), in order to generate pooled positive and 
negative LRs with 95% CIs. Results were also pooled from all studies in order to 
obtain pooled positive and negative LRs with 95% CIs for each approach used to 
diagnose IBS, including symptom-based criteria alone, biomarkers alone, 
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psychological markers alone, and combinations of these.  A random effects model 
was used to provide a more conservative estimate of the accuracy of the various 
methods, allowing for heterogeneity between studies. Heterogeneity was assessed 
using the χ2 and I2 statistic, with a value >50% indicating significant heterogeneity. 
QUADAS-2, a quality assessment tool for primary diagnostic accuracy studies, was 
used to assess the risk of bias and any applicability concerns in the eligible studies 
(Whiting et al., 2003). All eligible studies were judged against four key domains 
covering patient selection, the diagnostic test applied, the reference standard, and the 
flow of patients through the study. 
 
3.3 Results 
 The search strategy identified 4348 citations, of which 33 studies appeared to 
be eligible and were retrieved for evaluation. Twenty-two of these met all eligibility 
criteria (Ahmed et al., 2013; Bellentani et al., 1990; Bouin et al., 2002; Camilleri et 
al., 2014; Crade and Pham, 2006; Dogan and Unal, 1996; El-Salhy et al., 2014; El-
Salhy et al., 2014; Ford et al., 2013; Frigerio et al., 1992; Hammer and Talley, 2008; 
Jeong et al., 1993; Jones et al., 2014; Kang et al., 1994; Kim et al., 2010; Kruis et 
al., 1984; Lembo et al., 2009; Manning et al., 1978; Ohman et al., 2012; Rao et al., 
1993; Spiller et al., 2010; Tibble et al., 2002) (Figure 2). 
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Figure 2. Flow Diagram of Studies Identified in the Systematic Review. 
 
 
 
  
4348 citations identified in 
literature search
33 studies retrieved for 
evaluation
22 studies eligible for inclusion
11 excluded 
- Diagnostic test or reference 
standard did not meet eligiblity 
criteria = 5
- <50 patients = 3
- No diagnostic test applied = 2
- Children included = 1 
4315 excluded based on title 
and abstract
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 Agreement between investigators when assessing eligibility was excellent 
(94% agreement, К = 0.86). The 22 included studies evaluated a total of 7106 
patients with a pooled IBS prevalence of 53.5% (95% CI 47.4% to 59.6%). Eleven 
of the studies were conducted in Europe, six in North America, four in Asia, and one 
in Australasia. Thirteen of the studies were of cross-sectional design, and nine were 
case-control. Twenty-one were conducted in secondary care, with one in both 
primary and secondary care. Individual study characteristics are summarised in 
Table 5. The diagnostic tests utilised in the eligible studies are shown in Table 6, 
along with the number of studies assessing the accuracy of each test, total number of 
patients included, and the positive and negative LRs with 95% CIs (pooled where 
appropriate). Study bias and applicability outcomes assessed, according to the 
QUADAS-2 tool, are shown in Table 7. Fourteen of the 22 studies were judged as 
high risk in one or more of the four key domains.
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  Table 5. Characteristics of all Eligible Studies. 
 
Study Country Study design Setting (no. of 
centres) 
No. of 
patients 
No. with 
IBS (%) 
Diagnostic test applied Reference 
standard used 
Overall risk of bias 
according to 
QUADAS-2 tool 
Manning 1978 
 
England 
 
Cross-
sectional 
 
Secondary  care 
(1) 
 
65 
 
32 (49.2) 
 
>2 Manning criteria 
>3 Manning criteria 
>4 Manning criteria 
 
Normal 
colonoscopy or 
barium enema 
 
High 
Kruis 1984 
 
Germany 
 
Cross-
sectional 
 
Secondary  care 
(1) 
 
317 
 
108 (34.1) 
 
Kruis statistical model 
score > 44 to diagnose 
IBS 
Normal 
colonoscopy or 
barium enema 
Low 
Bellentani 1990 
 
Italy 
 
Cross-
sectional 
 
Primary and 
secondary care 
(15) 
 
254 
 
152 (59.8) 
 
Kruis statistical model 
Own statistical model 
 
Normal 
colonoscopy or 
barium enema 
Low 
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Frigerio 1992 Italy 
 
Cross-
sectional 
 
Secondary  care 
(1) 
 
253 
 
52 (20.6) 
 
Kruis statistical model 
Modified Kruis model 
with lowering of the 
predetermined cut-off 
point of haemoglobin 
level 
Normal 
colonoscopy 
Low 
Jeong 1993 
 
South 
Korea 
 
Cross-
sectional 
 
Secondary  care 
(1) 
74 
 
86 (77.5) 
 
>2 Manning criteria 
>3 Manning criteria 
>4 Manning criteria 
Normal 
colonoscopy or 
barium enema 
Low 
Rao 1993 
 
India 
 
Cross-
sectional 
 
Secondary  care 
(1) 
 
88 
 
65 (73.9) 
 
>2 Manning criteria 
>3 Manning criteria 
>4 Manning criteria 
Normal 
colonoscopy or 
barium enema 
Low 
Kang 1994 
 
Singapore 
 
Case-control 
 
Secondary  care 
(1) 
 
138 
 
128 (92.8) 
 
Pain perception during 
rectal insufflation at 
diagnostic 
sigmoidoscopy or 
colonoscopy 
Manning criteria High 
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Dogan 1996 
 
Turkey 
 
Cross-
sectional 
 
Secondary  care 
(2) 
 
347 
 
165 (47.6) 
 
>2 Manning criteria 
>3 Manning criteria 
>4 Manning criteria 
Kruis statistical model 
Normal 
colonoscopy or 
barium enema 
High 
Bouin 2002 
 
Canada Case-control 
 
Secondary  care 
(1) 
 
189 
 
86 (77.5) 
 
Visceral 
hypersensitivity: rectal 
distension using a 
barostat bag with 
optimum performance 
determined using a  cut-
off of 40mmHg 
Rome II 
criteria 
High 
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Tibble 2002 
 
England 
 
Cross-
sectional 
 
Secondary care 
(1) 
 
602 
 
339 (56.3) 
 
Rome I criteria 
Faecal calprotectin 
(<10mg/L) and 
intestinal permeability 
ratio (<0.05) 
Faecal calprotectin, 
intestinal permeability 
ratio, and Rome I 
criteria 
Normal 
colonoscopy or 
barium enema 
Low 
Crade 2006 
 
USA 
 
Cross-
sectional 
 
Secondary care 
(1) 
 
175 
 
27 (15.4) 
 
Sigmoid muscularis 
propria thickness: cut-
off >3mm used to 
diagnose IBS 
Physician’s 
diagnosis 
 
High 
Hammer 2008 
 
Australia 
 
Cross-
sectional 
 
Secondary care 
(1) 
 
538 
 
233 (43.3) 
 
>3 Manning criteria 
>4 Manning criteria 
Rome I criteria 
Rome II criteria 
Normal 
colonoscopy or 
barium enema 
High 
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Lembo 2009 
 
USA 
 
Cross-
sectional 
 
Secondary care 
(6) 
 
516 
 
256 (49.6) 
 
10 serum-based 
biomarker panel 
Rome II and 
Rome III criteria 
High 
Kim 2010 
 
South 
Korea 
 
Cross-
sectional 
 
Secondary care 
(1) 
 
217 
 
101 (46.5) 
 
Visceral 
hypersensitivity: VAS 
to record pain 
perception during 
colonoscopy 
Rome III 
criteria 
Low 
Spiller 2010 
 
England 
 
Case-control 
 
Secondary care 
(2) 
 
470 
 
319 (67.9) 
 
Psychological markers: 
optimum performance 
determined using a cut-
off >6 for PHQ-12 and 
>7 when assessing 
individual components 
of  HADS 
Rome II criteria 
 
High 
 
 
117 
 
Öhman 2012 
 
Sweden 
 
Case-control 
 
Secondary care 
(1) 
111 
 
82 (73.9) 
 
Faecal chromogranins 
and secretogranins: 
optimum performance 
determined using a cut-
off of >0.16 nmol/g of 
SgII, >0.53 nmol/g of 
SgIII and <0.48 nmol/g 
of CgB 
Rome II criteria 
 
High 
Ahmed 2013 
 
England 
 
Case-control 
 
Secondary care 
(1) 
140 
 
30 (21.4) VOMs: optimum 
performance 
determined using a 
ROC curve 
Manning criteria 
 
High 
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Ford  2013 
 
 
 
 
 
 
 
 
 
 
 
Canada 
 
Cross-
sectional 
 
 
 
 
 
 
 
Secondary care 
(2) 
 
 
 
 
 
1878 
 
 
 
 
379 (20.2) 
 
 
 
 
 
 
 
>2 Manning criteria 
>3 Manning criteria 
>4 Manning criteria 
Rome I criteria 
Rome II criteria 
Rome III criteria 
Normal 
colonoscopy 
 
 
 
Low 
Camilleri 2014 
 
USA 
 
Case-control 
 
Secondary care 
(1) 
124 
 
94 (75.8) 
 
Bile acid secretion and 
colonic transit: optimum 
performance 
determined using an  
ROC  curve 
Rome III criteria 
 
High 
 
 
119 
 
Jones 2014 
 
USA 
 
Case-control 
 
Secondary care 
(35) 
 
244 
 
168 (68.9) 
 
10 serum-based 
biomarker panel 
34 serum-based 
biomarker panel 
Psychological markers 
alone 
34 serum-based 
biomarker panel and 
psychological markers 
Rome III criteria 
 
High 
El-Salhy 2014 
 
Norway Case-control 
 
Secondary care 
(3) 
289 
 
203 (70.2) 
 
Mucosal intestinal 
endocrine cells: 
optimum performance 
determined 
using a cut-off of <200 
cells/mm2 of duodenal 
CgA 
Rome III criteria 
 
High 
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El-Salhy 2014 
 
 
 
 
 
Norway Case-control 
 
Secondary care 
(1) 
77 
 
50 
( 64.9) 
Mucosal intestinal 
endocrine cells:-
optimum performance 
determined using an 
ROC curve 
Rome III criteria 
 
 
 
 
 
 
High 
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     Table 6. Pooled Positive and Negative Likelihood Ratios (LRs) of Diagnostic Tests for Irritable Bowel Syndrome. 
 
 
 
Diagnostic test applied No. of 
studies 
No. of 
patients 
Positive 
LR 
95% CI Negative 
LR 
95% CI 
Symptom-based 
diagnostic 
criteria 
Manning ≥2 criteria 5 2452 2.20 1.54-3.14 0.18 0.10-0.32 
Manning ≥3 criteria 6 2966 2.85 1.95-4.15 0.36 0.24-0.53 
Manning ≥4 criteria 6 2986 3.43 2.49-4.71 0.66 0.60-0.73 
Rome I 3 3006 3.20 2.29-4.47 0.22 0.10-0.49 
Rome II 2 2402 2.56 1.64-4.00 0.25 0.08-0.85 
Rome III 1 1848 3.35 2.97-3.79 0.39 0.34-0.46 
Biomarkers Visceral hypersensitivity 2 328 3.71 2.74-5.02 0.16 0.10-0.24 
Pain perception 1 138 0.98 0.80-1.60 1.09 0.40-3.98 
Serum-based 10 biomarker panel 2 760 3.03 1.49-6.17 0.52 0.43-0.64 
Serum-based 34 biomarker panel 1 244 2.28 1.71-3.17 0.30 0.21-0.42 
VOMs in faeces 1 140 4.83 3.36-7.14 0.04 0.01-0.21 
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Chromogranins and secretogranins in 
faeces: 
Secretogranin II (SgII) 
Secretogranin III (SgIII) 
Chromogranin B (CgB) 
 
 
1 
1 
1 
 
 
111 
111 
111 
 
 
3.89 
2.59 
2.51 
 
 
2.07-8.23 
1.61-4.70 
1.56-4.56 
 
 
0.25 
0.28 
0.32 
 
 
0.15-0.39 
0.17-0.47 
0.20-0.51 
Duodenal chromogranin A (CgA) 1 289 18.5 7.58-47.3 0.14 0.10-0.20 
Rectal endocrine cells: 
Peptide YY 
Oxyntomodulin 
Somatostatin 
 
1 
1 
1 
 
77 
77 
77 
 
7.56 
4.32 
7.20 
 
2.96-21.9 
2.14-9.87 
2.81-20.9 
 
0.18 
0.25 
0.23 
 
0.09-0.33 
0.14-0.43 
0.12-0.38 
Sigmoid muscularis propria thickness 1 175 14.9 7.07-31.5 0.31 0.17-0.51 
Faecal calprotectin and small intestinal 
permeability ratio 
1 602 8.64 5.76-13.1 0.34 0.28-0.39 
Bile acid secretion and colonic transit 1 124 2.78 1.55-5.58 0.46 0.33-0.65 
Psychological 
markers 
PHQ-12 score 1 470 12.5 6.55-24.6 0.35 0.30-0.41 
Anxiety component of the HADS 1 470 2.88 2.20-3.86 0.37 0.30-0.45 
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Depression component of the HADS 1 470 5.44 3.01-10.1 0.68 0.62-0.75 
Combination of HADS, PHQ-15, and the 
perceived stress scale 
1 244 2.95 2.04-4.48 0.35 0.26-0.46 
Combinations of 
symptoms, 
biomarkers, 
and/or  
psychological 
markers 
Kruis et al. statistical model 4 1171 8.63 2.89-25.8 0.26 0.17-0.41 
Modified Kruis statistical model 1 253 7.73 4.83-12.4 0.34 0.22-0.49 
Bellentani et al. statistical  model 1 254 4.29 2.86-6.66 0.30 0.22-0.39 
Faecal calprotectin, small intestinal 
permeability ratio, and Rome criteria 
1 602 26.4 11.4-61.9 0.51 0.45-0.56 
Serum-based 34 biomarker panel and 
psychological markers 
1 244 7.14 4.01-13.3 0.18 0.12-0.25 
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     Table 7. QUADAS-2 Risk of Bias and Applicability for All Eligible Studies. 
 
 Risk of bias Applicability concerns 
Study Patient 
selection 
Index 
test 
Reference 
standard 
Flow and 
timing 
Patient 
selection 
 
Index 
test 
Reference 
standard 
Manning 1979 Low Low Low Low High Low Low 
Kruis 1984 Low Low Low Low Low Low Low 
Bellentani 1990 Low Low Low Low Low Low Low 
Frigerio 1992 Low Low Low Low Low Low Low 
Jeong 1993 Low Low Low Low Low Low Low 
Rao 1993 Low Low Low Low Low Low Low 
Kang 1994 High Low Low High Low Low Low 
Dogan 1996 Low Low Low Low High Low Low 
Bouin 2002 High Low Low Low Low Low Low 
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Tibble 2002 Low Low Low Low Low Low Low 
Crade 2006 Low Low Unclear Unclear High Low Low 
Hammer 2008 Low Low Low Low High Low Low 
Lembo 2009 High Low Low High Low Low Low 
Kim 2010 Low Low Low Low Low Low Low 
Spiller 2010 High High Low Low Low Low Low 
Öhman 2012 High Low Unclear Unclear Low Low Low 
Ahmed 2013 High Low Low Low Low Low Low 
Ford 2013 Low Low Low Low Low Low Low 
Camilleri 2014 High Low Low Low Low Low Low 
Jones 2014 High Low Low Low Low Low Low 
El-Salhy 2014 High High Low Low Low Low Low 
El-Salhy 2014 High High Low Low Low Low Low 
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3.3.1 Symptom-based Diagnostic Criteria 
 Five studies evaluated ≥2 of the Manning criteria (Dogan and Unal, 1996; Ford 
et al., 2013; Jeong et al., 1993; Manning et al., 1978; Rao et al., 1993), six studies ≥3 
(Dogan and Unal, 1996; Ford et al., 2013; Hammer and Talley, 2008; Jeong et al., 
1993; Manning et al., 1978; Rao et al., 1993), and six studies ≥4 (Manning et al., 
1978; Jeong et al., 1993; Rao et al., 1993; Dogan and Unal, 1996; Hammer and 
Talley, 2008; Ford et al., 2013). The Rome I criteria were evaluated in three studies 
(Ford et al., 2013; Hammer and Talley, 2008; Tibble et al., 2002), the Rome II 
criteria in two studies (Ford et al., 2013; Hammer and Talley, 2008) and the Rome 
III criteria in only one study (Ford et al., 2013). All studies were cross-sectional in 
design, collected symptom data using a questionnaire completed by the patient, and 
utilised a reference standard of a normal colonoscopy or barium enema to confirm 
the diagnosis of IBS.  
 
3.3.1.1 The Manning Criteria 
 Pooled positive and negative LRs when using ≥2 of the Manning criteria in a 
total of 2452 patients were 2.20 (95% CI 1.54 to 3.14; I2 = 90.5%; P <  0.001) and 
0.18 (95% CI 0.10 to 0.32; I2 = 72%; P = 0.006) respectively (Dogan and Unal, 
1996; Ford et al., 2013; Jeong et al., 1993; Manning et al., 1978; Rao et al., 1993).  
In studies assessing ≥3 of the Manning criteria (Dogan and Unal, 1996; Ford et al., 
2013; Hammer and Talley, 2008; Jeong et al., 1993; Manning et al., 1978; Rao et al., 
1993), accuracy was best in the study conducted by Dogan et al. (Dogan and Unal, 
1996), with a positive LR of 7.15 (95% CI 4.93 to 10.57) and a negative LR of 0.11 
(95% CI 0.07 to 0.17). However, this was not replicated in the five other studies, 
including in the original validation study (Manning et al., 1978). The pooled positive 
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and negative LRs, in a total of 2966 patients, were 2.85 (95% CI 1.95 to 4.15; I2 = 
89%; P < 0.001) and 0.36 (95% CI 0.24 to 0.53; I2 = 89%; P < 0.001) respectively 
(Figure 3 and 4). Finally, when data were pooled from the six studies assessing the 
accuracy of ≥4 of the Manning criteria (Dogan and Unal, 1996; Ford et al., 2013; 
Hammer and Talley, 2008; Jeong et al., 1993; Manning et al., 1978; Rao et al., 
1993), positive and negative LRs, in a total of 2986 patients, were 3.43 (95% CI 
2.49-4.71; I2 = 59%; P = 0.03) and 0.66 (95% CI 0.60-0.73; I2 = 47%; P = 0.09) 
respectively (Figure 5 and 6). 
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Figure 3. Pooled Positive Likelihood Ratios of ≥3 Manning Criteria. 
 
 
 
Figure 4. Pooled Negative Likelihood Ratios of ≥3 Manning Criteria. 
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Figure 5. Pooled Positive Likelihood Ratios of ≥4 Manning Criteria. 
 
 
 
Figure 6. Pooled Negative Likelihood Ratios of ≥4 Manning Criteria. 
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3.3.1.2 The Rome Criteria  
 Pooled positive and negative LRs in the three studies (Ford et al., 2013; 
Hammer and Talley, 2008; Tibble et al., 2002), containing 3006 patients, that 
reported on the Rome I criteria were 3.20 (95% CI 2.29 to 4.47; I2 = 90.5%; P < 
0.001) and 0.22 (95% CI 0.10 to 0.49; I2 = 97%; P < 0.001) respectively.  Pooled 
positive and negative LRs of the two studies (Ford et al., 2013; Hammer and Talley, 
2008), containing 2402 patients, that evaluated the Rome II criteria were 2.56 (95% 
CI 1.64 to 4.00) and 0.25 (95% CI 0.08 to 0.85) respectively. The positive and 
negative LRs in the one study (Ford et al., 2013), containing 1848 patients, that 
reported on the Rome III criteria were 3.35 (95% CI 2.97 to 3.79) and 0.39 (95% CI 
0.34 to 0.46). 
 
3.3.2 Biomarkers 
 
    3.3.2.1 Visceral Hypersensitivity and Pain Perception as a Biomarker 
 One case-control study and one cross-sectional study evaluated the role of 
visceral hypersensitivity using rectal barostat testing (Bouin et al., 2002) and pain 
perception (Kim et al., 2010) during colonoscopy, in differentiating IBS from HCs 
and miscellaneous GI and medical conditions, in a total of 328 patients. Pooled 
positive and negative LRs in the two studies were 3.71 (95% CI 2.74 to 5.02) and 
0.16 (95% CI 0.10 to 0.24) respectively. One case-control study, containing 138 
patients, reported on colonic air insufflation to reproduce typical abdominal pain 
experienced in IBS as a biomarker in differentiating the disorder from colonic 
structural disease (Kang et al., 1994). This test performed poorly, with positive and 
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negative LRs of 0.98 (95% CI 0.80 to 1.60) and 1.09 (95% CI 0.40 to 3.98) 
respectively.  
 
3.3.2.2 Serum-based Biomarkers 
 The diagnostic accuracy of a serum-based 10 biomarker panel, which were 
selected by examining differences in biomarker expression between IBS patients and 
HCs (among them IL-1ß, anti-TTG and ANCA), was reported in one cross-sectional 
study (Lembo et al., 2009) and one case-control study (Jones et al., 2014) containing 
a total of 760 patients, with a pooled positive LR of 3.03 (95% CI 1.49 to 6.17) and 
pooled negative LR of 0.52 (95% CI 0.43 to 0.64). In the study conducted by Jones 
et al. (Jones et al., 2014), an additional 24 serum biomarkers, selected through a 
combination of gene chip human array, gene array data analysis and real-time 
quantitative PCR, were added to the original 10 biomarker panel. Positive and 
negative LRs of the 34 biomarker panel were 2.28 (95% CI 1.71 to 3.17) and 0.30 
(95% CI 0.21-0.42) respectively.  
 
3.3.3 Faecal Biomarkers 
 
3.3.3.1 Volatile Organic Metabolites 
 The diagnostic accuracy of VOMs were assessed in one case-control study 
containing 30 IBS-D patients, 62 patients with active Crohn’s disease and 48 
patients with active UC (Ahmed et al., 2013). Using a ROC curve to determine 
optimum performance, the positive and negative LRs in differentiating IBS from 
active IBD were 4.83 (95% CI 3.36 to 7.14) and 0.04 (95% CI 0.01 to 0.21) 
respectively.  
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3.3.3.2 Chromogranins and Secretogranins 
 In one case-control study, CgB and SgII and SgIII levels were measured in 
faecal samples from 82 IBS patients and 29 HCs (Ohman et al., 2012). SgII and 
SGIII levels were higher in the IBS patients, and CgB levels were lower. SgII 
performed the most accurately using a cut-off of >0.16 nmol/g, with a positive LR of 
3.89 (95% CI 2.07 to 8.23) and negative LR of 0.25 (95% CI 0.15 to 0.39).   
 
3.3.4 Mucosal Intestinal Endocrine Cells as a Biomarker 
 Quantification of CgA cells was performed on biopsy samples taken from the 
duodenum during gastroscopy in one case-control study (El-Salhy al., 2014). Using 
a cut-off of <200 cells/mm2, the positive and negative LRs in differentiating 203 IBS 
patients from 86 HCs, were 18.5 (95% CI 7.58 to 47.3) and 0.14 (95% CI 0.10 to 
0.20). In a similarly designed study (El-Salhy et al., 2014), rectal biopsies were 
taken from 50 patients with IBS and 27 HCs. Endocrine cell content was quantified 
and three endocrine cells, (peptide YY, oxyntomodulin and somatostatin) were 
validated as diagnostic tests. Using optimum performance determined on an ROC 
curve, peptide YY performed the best, with a positive LR of 7.56 (95% CI 2.96 to 
21.9) and a negative LR of 0.18 (95% CI 0.09 to 0.33) at a cut-off of <30 cells/mm2. 
 
3.3.5 Sigmoid Muscularis Propria Thickness as a Biomarker 
 In a cross-sectional study of 175 female patients who were undergoing trans-
vaginal ultrasound for investigation of gynaecological symptoms, sigmoid 
muscularis propria thickness was measured (Crade and Pham, 2006).  A diagnosis of 
IBS was made using a cut-off for abnormal muscularis propria thickness of ≥3 mm.  
A clinical diagnosis of IBS was confirmed with the primary physician and/or 
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Gastroenterologist following ultrasound. Positive and negative LRs were 14.9 (95% 
CI 7.07 to 31.5) and 0.31 (95% CI 0.17 to 0.51) respectively. 
 
3.3.6 Combinations of Biomarkers 
 
3.3.6.1 Faecal Calprotectin and Intestinal Permeability Ratio as a Biomarker 
In the previously discussed study from Tibble et al. (Tibble et al., 2002), all 
patients provided a stool sample for measurement of faecal calprotectin levels, in 
addition to undergoing a lactulose/L-rhamnose small intestinal permeability test. 
Using a faecal calprotectin level of <10 mg/L and a permeability ratio of <0.05, this 
biomarker combination was able to identify IBS patients with a positive LR of 8.64 
(95% CI 5.76 to 13.1) and a negative LR of 0.34 (95% CI 0.28 to 0.39). 
 
3.3.6.2 Bile Acid Secretion and Colonic Transit as a Biomarker  
 One case-control study used a 2-item model consisting of total faecal bile acid 
excretion and colonic transit to differentiate between 64 IBS-D patients, 30 IBS-C 
patients, and 30 HCs (Camilleri et al., 2014). Using the optimum cut-off on an ROC 
curve, the 2-item model was able to differentiate IBS from HCs with a positive LR 
of 2.78 (95% CI 1.55 to 5.58) and a negative LR of 0.46 (95% CI 0.33 to 0.65). 
 
3.3.7 Psychological Markers 
 The use of psychological markers in differentiating IBS from health was 
evaluated in two case-control studies containing 714 patients (Jones et al., 2014; 
Spiller et al., 2010). In the study conducted by Spiller et al. 319 IBS patients and 
151 HCs completed the patient health questionnaire 12 (PHQ-12). 
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 The PHQ-12 differs from the PHQ-15 in that the three specific GI-related 
questions are removed. Using a cut-off score of >6, the positive LR for the PHQ-12 
in differentiating IBS from health was 12.5 (95% CI 6.55 to 24.6), and the negative 
LR was 0.35 (95% CI 0.30 to 0.41). Using a cut-off score of >7, the anxiety 
component of the HADS score was reported to have positive and negative LRs of 
2.88 (95% CI 2.20 to 3.86) and 0.37 (95% CI 0.30 to 0.45) respectively. At a cut-off 
of >7, the depression component of the HADS demonstrated positive and negative 
LRs of 5.44 (95% CI 3.01 to 10.1) and 0.68 (95% CI 0.62-0.75), respectively. 
 In the previously described study conducted by Jones et al.(Jones et al., 2014), 
participants were asked to complete the HADS, PHQ-15, and the perceived stress 
scale. Positive and negative LRs of these measures of psychological well-being 
combined in differentiating between IBS and HCs were 2.95 (95% CI 2.04 to 4.48) 
and 0.35 (95% CI 0.26 to 0.46) respectively.  
 
3.3.8 Combinations of Symptoms, Biomarkers and Psychological Markers 
 
3.3.8.1 Kruis Statistical Model 
 The accuracy of the Kruis statistical model was assessed in four cross-sectional 
studies, including a total of 1171 patients (Bellentani et al., 1990; Dogan and Unal, 
1996; Frigerio et al., 1992; Kruis et al., 1984). A score of ≥44 was used as the 
optimal cut-off to diagnose IBS, as validated in the original study. The pooled 
positive LR of these studies as assessed in a previous meta-analysis (Ford et al., 
2008), as there have been no studies published in the interim, was 8.63 (95% CI 2.89 
to 25.8; I2 = 95%; P < 0.001) and the pooled negative LR was 0.26 (95% CI 0.17 to 
0.41; I2 = 84.5%; P < 0.001).  
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3.3.8.2 Other Statistical Models 
 Frigerio et al. (Frigerio et al., 1992), in a cross-sectional study, lowered the 
predetermined cut-off point of haemoglobin level in the Kruis statistical model from 
14g/100ml to 13g/100ml in males and from 12g/100ml to 11g/100ml in females. 
Positive and negative LRs for this modified model, containing 253 patients, were 
7.73 (95% CI 4.83 to 12.4) and 0.34 (95% CI 0.22 to 0.49) respectively.  
 Although differing from the Kruis model in the items included, the model 
validated in the cross-sectional study by Bellentani et al. (Bellentani et al., 1990), 
also incorporated the clinical history, physical examination, and an ESR and 
leucocyte count. Positive and negative LRs for this statistical model, containing 254 
patients, were 4.29 (95% CI 2.86 to 6.66) and 0.30 (95% CI 0.22 to 0.39) 
respectively. 
 
3.3.8.3 A Combination of Faecal Calprotectin, Intestinal Permeability Ratio, 
and the Rome I Criteria   
In the previously described study by Tibble et al. (Tibble et al., 2002), if a 
positive result for the Rome I criteria was incorporated with faecal calprotectin 
levels of <10mg/L and permeability ratio of <0.05, the positive and negative LRs 
were 26.4 (95% CI 11.4 to 61.9) and 0.51 (95% CI 0.45 to 0.56) respectively. 
 
3.3.8.4 A Combination of Serum-based Biomarkers and Psychological Markers 
 Finally, in the study conducted by Jones et al. (Jones et al., 2014), the serum-
based 34 biomarker panel and psychological measures were combined to ascertain 
whether this improved accuracy in diagnosing IBS. Positive and negative LRs for 
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this combined approach in differentiating IBS from health were 7.14 (95% CI 4.01 
to 13.3) and 0.18 (95% CI 0.12 to 0.25) respectively.  
 
3.3.9 Pooled Positive and Negative LRs for Each Approach Used to Diagnose 
IBS 
When individual study results were combined to obtain pooled positive and 
negative LRs for each of the approaches to diagnose IBS, there were significant 
differences in the pooled positive LR between studies using symptom-based criteria 
alone (positive LR 2.85; 95% CI 2.53 to 3.20), and studies that used a combination 
of symptoms, biomarkers, and psychological markers (positive LR = 8.48; 95% CI 
4.64 to 15.5), but not between any of the other methods (Figure 7). Negative LRs 
were not significantly different for any of the four approaches (Figure 8). The 
sensitivities, specificities, PPVs, and NPVs for all the studies are shown in Table 8. 
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Figure 7. Pooled Positive Likelihood Ratios for All Approaches to the Diagnosis 
of IBS. 
 
 
 
Figure 8. Pooled Negative Likelihood Ratios for All Approaches to the 
Diagnosis of IBS. 
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     Table 8. Pooled Sensitivity, Specificity, and Predictive Values of Diagnostic Tests for Irritable Bowel Syndrome. 
 
 Diagnostic test 
applied 
No. of 
studies 
No. of 
patients 
Sensitivity  
(95% CI) 
Specificity 
(95% CI) 
Positive 
predictive value 
(95% CI) 
Negative 
predictive value 
(95% CI) 
Symptom-
based 
diagnostic 
criteria 
Manning ≥2 criteria 5 2452 0.90 (0.84-0.96) 0.66 (0.57-0.76) 0.68 (0.53-0.88) 0.93 (0.88-0.99) 
Manning ≥3 criteria 6 2966 0.72 (0.61-0.86) 0.77 (0.70-0.84) 0.71 (0.57-0.90) 0.79 (0.71-0.88) 
Manning ≥4 criteria 6 2986 0.42 (0.38-0.47) 0.89 (0.87-0.92) 0.74 (0.59-0.92) 0.60 (0.50-0.73) 
Rome I 3 3006 0.77 (0.60-0.99) 0.75 (0.66-0.85) 0.63 (0.42-0.94) 0.80 (0.61-1.00) 
Rome II 2 2402 0.79 (0.61-1.00) 0.69 (0.64-0.75) 0.52 (0.39-0.70) 0.85 (0.65-1.00) 
Rome III 1 1848 0.69 (0.64-0.73) 0.80 (0.77-0.82) 0.45 (0.41-0.49) 0.91 (0.90-0.93) 
Biomarkers Visceral 
hypersensitivity 
2 328 0.88 (0.84-0.94) 0.77 (0.70-0.84) 0.85 (0.68-1.00) 0.82 (0.70-0.97) 
Pain perception 1 138 0.78 (0.70-0.85) 0.20 (0.02-0.56) 0.93 (0.87-0.96) 0.07 (0.008-0.22) 
Serum-based 10 
biomarker panel 
2 760 0.59 (0.43-0.82) 0.78 (0.60-1.00) 0.82 (0.77-0.87) 0.58 (0.45-0.74) 
Serum-based 34 1 244 0.81 (0.74-0.87) 0.64 (0.53-0.75) 0.83 (0.77-0.89) 0.60 (0.49-0.71) 
 
 
139 
 
biomarker panel 
Volatile organic 
metabolites in faeces 
1 140 0.97 (0.83-1.00) 0.80 (0.71-0.87) 0.57 (0.42-0.71) 0.99 (0.94-1.00) 
Chromogranins and 
secretogranins in 
faeces: 
Secretogranin II 
Secretogranin III 
Chromogranin B 
 
 
 
1 
1 
1 
 
 
 
111 
111 
111 
 
 
 
0.80 (0.70-0.88) 
0.80 (0.70-0.88) 
0.78 (0.68-0.86) 
 
 
 
0.79 (0.60-0.92) 
0.69 (0.49-0.85) 
0.69 (0.49-0.85) 
 
 
 
0.92 (0.83-0.97) 
0.88 (0.78-0.94) 
0.88 (0.78-0.94) 
 
 
 
0.59 (0.42-0.74) 
0.56 (0.38-0.72) 
0.53 (0.36-0.69) 
Duodenal 
chromogranin A 
 
1 
 
289 
 
0.86 (0.81-0.91) 
 
0.95 (0.89-0.99) 
 
0.98 (0.94-0.99) 
 
0.75 (0.65-0.82) 
Rectal endocrine 
cells: 
Peptide YY 
Oxyntomodulin 
Somatostatin 
 
 
1 
1 
1 
 
 
77 
77 
77 
 
 
0.84 (0.71-0.93) 
0.80 (0.66-0.90) 
0.80 (0.66-0.90) 
 
 
0.89 (0.71-0.98) 
0.81 (0.62-0.94) 
0.89 (0.71-0.98) 
 
 
 
0.93 (0.82-0.99) 
0.89 (0.76-0.96) 
0.93 (0.82-0.99) 
 
 
0.75 (0.57-0.89) 
0.69 (0.50-0.84) 
0.71 (0.53-0.85) 
Sigmoid muscularis 1 175 0.70 (0.50-0.86) 0.95 (0.90-0.98) 0.73 (0.52-0.88) 0.95 (0.90-0.98) 
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propria thickness 
Faecal calprotectin 
and small intestinal 
permeability ratio 
1 602 0.69 (0.64-0.74) 0.92 (0.88-0.95) 0.92 (0.88-0.95) 0.70 (0.65-0.75) 
Bile acid secretion 
and colonic transit 
1 124 0.65 (0.54-0.74) 0.77 (0.58-0.90) 0.90 (0.80-0.96) 0.41 (0.28-0.55) 
Psychologica
l markers 
PHQ-12 score 1 470 0.66 (0.61-0.72) 0.95 (0.90-0.98) 0.96 (0.93-0.98) 0.57 (0.51-0.63) 
Anxiety component 
of the HADS 
1 470 0.72 (0.67-0.77) 0.75 (0.67-0.82) 0.86 (0.81-0.90) 0.56 (0.49-0.63) 
Depression 
component of the 
HADS 
1 470 0.36 (0.31-0.42) 0.93 (0.88-0.97) 0.92 (0.86-0.96) 0.41 (0.36-0.46) 
Combination of 
HADS, PHQ-15, and 
the perceived stress 
scale 
1 244 0.74 (0.66-0.80) 0.75 (0.64-0.84) 0.87 (0.80-0.92) 0.56 (0.46-0.66) 
Combinatio
ns of 
Kruis et al. statistical 
model 
4 1171 0.80 (0.73-0.87) 0.91 (0.86-0.96) 0.85 (0.77-0.94) 0.86 (0.80-0.92) 
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symptoms, 
biomarkers, 
and/or  
psychologica
l markers 
Modified Kruis 
statistical model 
1 253 0.69 (0.55-0.81) 0.91 (0.86-0.95) 0.67 (0.53-0.79) 0.92 (0.87-0.95) 
Bellentani et al. 
statistical  model 
1 254 0.76 (0.68-0.82) 0.82 (0.74-0.89) 0.86 (0.79-0.92) 0.69 (0.60-0.77) 
Faecal calprotectin, 
small intestinal 
permeability ratio, 
and Rome criteria 
1 602 0.50 (0.45-0.56) 0.98 (0.96-0.99) 0.97 (0.93-0.99) 0.60 (0.56-0.65) 
Serum-based 34 
biomarker panel and 
psychological 
markers 
1 244 0.85 (0.78-0.90) 0.88 (0.79-0.94) 0.94 (0.90-0.97) 0.72 (0.62-0.81) 
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3.4 Discussion 
 This study has examined the accuracy of symptom-based diagnostic criteria, 
biomarkers, psychological markers, or combinations thereof, in making a diagnosis of 
IBS. The Rome IV criteria have yet to be externally validated, and the Rome III criteria, 
the previous gold standard for the diagnosis of IBS, have only been validated in one study 
to date, and performed modestly and similarly to the other symptom-based diagnostic 
criteria that have been described previously, with a positive LR >3 and a negative LR of 
approximately 0.4. Proposed biomarkers, with the exception of abnormal sigmoid 
muscularis propria thickness in female patients, intestinal mucosal endocrine cells, and 
faecal VOMs, and a combination of faecal calprotectin and intestinal permeability, all 
examined in single or small cohort studies, appeared to perform no better than available 
symptom-based diagnostic criteria. The accuracy of psychological markers was also 
similar. Combining symptoms, biomarkers, and/or psychological markers in various 
permutations seemed to perform better generally in diagnosing IBS, and with a 
significantly greater pooled positive LR compared with symptom-based criteria alone. 
 Strengths of this study include a comprehensive search strategy, including a 
recursive search of the bibliographies of all eligible studies, and searching of conference 
proceedings to identify any potential studies published that may not have been included in 
the original search of the medical literature. This resulted in the identification of a wide 
range of potential methods for diagnosing IBS; specifically four different symptom-based 
diagnostic criteria evaluated in seven studies, eleven biomarkers evaluated in twelve 
studies, four psychological markers evaluated in two studies, and five different 
combinations of symptoms, biomarkers, and/or psychological markers evaluated in six 
studies. Pooling the data in some of our analyses resulted in a study population of 1800 
patients or more for each of the symptom-based diagnostic criteria, and >1000 patients for 
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the Kruis statistical model. Furthermore, this is the first study that has attempted to 
summarise data from all available methods, including novel approaches, to diagnose IBS.  
 There are some limitations to this study. When data were pooled, there was 
significant heterogeneity between studies that evaluated the same diagnostic method in 
some analyses, which may be partly explained by differences in study design, recruitment, 
setting, and country, and differences in the reference standard used for diagnosing IBS. 
However, a random effects model was used when pooling study data in all these analyses, 
in order to provide a more conservative estimate of diagnostic accuracy. The cut-offs that 
were used to define presence of IBS for each of the diagnostic tests assessed in this meta-
analysis were imposed by the reporting of the authors of the original studies. This is less 
relevant for studies employing diagnostic criteria, such as the Manning criteria, because 
data were obtained for several thresholds, but is an issue for studies using laboratory tests, 
such as faecal chromogranins or VOMs, or the measures of psychological affect, which 
were not always used at the threshold recommended by the original authors. Additionally, 
the pooled IBS prevalence of all studies was high at >50%, as the majority of studies were 
conducted in referral populations in secondary care, meaning that some of the findings 
may not be applicable to a primary care setting, where the majority of patients with IBS 
are diagnosed and managed, as the prevalence may well be lower. The inclusion of case-
control studies may lead to an overestimation of the diagnostic performance of the test 
being examined, compared with studies using a clinical cohort, because these are subject 
to spectrum bias as the study design often omits mild cases that are difficult to diagnose 
(Lijmer et al., 1999). Finally, 14 of the 22 eligible studies were judged as high risk of 
bias, or had other applicability concerns, when assessing quality using the QUADAS-2 
tool, highlighting the limitations of data from some of the studies. 
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 Guidelines for the management of IBS recommend making a positive diagnosis of 
IBS based on symptoms, and discouraging a “diagnosis of exclusion” approach (Ford et 
al., 2014; National Institute for Health and Care Excellence, 2008). Symptom-based 
diagnostic criteria were developed to aid in this, and therefore avoid unnecessary and 
potentially invasive investigations. However, one of the most consistent findings of this 
study is the modest performance of all the available symptom-based criteria in identifying 
IBS. As stated previously, this comparable performance between the symptom-based 
criteria is perhaps not surprising, considering they are derivatives of each other, and 
therefore share the same strengths and weaknesses.  
 In general, the performance of biomarkers in the studies that were identified was 
similar to symptom-based diagnostic criteria, which is disappointing considering their 
potentially expensive nature. In some cases, the biomarkers would not be considered 
useful as a test outside of a tertiary referral centre, due to the invasive nature or 
complexity of the test applied. Furthermore, a number of the studies that assessed the 
accuracy of biomarkers used healthy volunteers as controls whereas, as highlighted 
previously, a biomarker that differentiates IBS from other organic disorders in which the 
symptoms are likely to overlap with those of IBS, would be more clinically useful. 
Sigmoid muscularis propria measurement using trans-vaginal ultrasound, appeared to 
perform well with a positive LR of 15. However, this study had a number of limitations, 
including the failure to exclude other causes of abnormal muscularis propria thickness, 
such as colorectal cancer, IBD, or diverticular disease, only 27 patients in the study 
population having a confirmed diagnosis of IBS, and the generalisability of the results, 
given that the test was applied in female patients only. Additionally, the results have yet 
to be validated by other investigators, despite the study being published 8 years ago. 
Duodenal mucosal CgA cell quantification also performed well in differentiating IBS 
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from health, but only in a single study, and the test is invasive.  In addition, the effect of 
coeliac disease, duodenitis, duodenal ulcers or IBD on numbers of CgA cells in the 
duodenum has not been studied, and therefore further work in this area is required before 
any definitive conclusion can be drawn.  Faecal VOMs showed some promise in 
differentiating IBS from active IBD in one small study, but again results of this study will 
require validating by others. 
 Given the degree of psychological co-morbidity in many IBS patients, it is perhaps 
surprising that the performance of psychological markers were, in general, no better than 
that of symptom-based criteria. Additionally, the two studies that have reported on the 
accuracy of psychological markers differentiated IBS from health, and therefore whether 
psychological markers can accurately discriminate between IBS and organic GI disorders 
is unclear. This would seem less likely, as there is evidence to suggest that many organic 
GI disorders are also associated with psychological impairment (Devlen et al., 2014; 
Iglesias-Rey et al., 2014; Sainsbury et al., 2013).  
 Combinations of symptoms, biomarkers, and/or psychological markers seemed to 
perform better, generally, in the six studies that assessed the accuracy of these 
approaches, and were superior to symptom-based criteria in terms of the pooled positive 
LR. This may be because IBS is a complex, heterogeneous disorder, for which there is no 
single unifying explanation, and for which numerous mechanisms have been proposed. 
Combining symptoms or examination findings, biomarkers and/or psychological markers 
may therefore be a more useful approach to diagnosing IBS, and perhaps points the way 
forward for future iterations of the Rome process.  
 In conclusion, this meta-analysis has shown that symptom-based diagnostic criteria, 
biomarkers, and psychological markers perform only moderately well in diagnosing IBS, 
and in the case of biomarkers many of these are potentially expensive or invasive, and are 
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not yet practical for clinical application. Combining symptoms with markers of organic 
disease or psychological affect, may represent the best way forward in improving the 
accuracy of diagnosing IBS.  
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CHAPTER 4 
Enhancing Diagnostic Performance of Symptom-
based Criteria for Irritable Bowel Syndrome by 
Additional History and Limited Diagnostic 
Evaluation. 
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4.1 Introduction 
 One of the limitations of current diagnostic test studies for IBS is the lack of an 
accepted reference standard. As previously stated, most investigators have used a normal 
colonoscopy as confirmation of a diagnosis of IBS (Ford et al., 2008), that is, physicians 
still regard IBS as a diagnosis of exclusion, which is perhaps justified by the modest 
performance of the different symptom-based criteria for IBS proposed over the last four 
decades (Manning et al., 1978; Ford et al., 2013). Indeed, the current level of diagnostic 
confidence, based exclusively on these criteria, has not reduced the performance of testing 
such as colonoscopy and biopsies in some settings (Spiegel et al., 2010), despite the 
desirability to enhance high-value care. 
 The systematic review and meta-analysis undertaken in the previous chapter 
evaluated approaches to diagnosing IBS, and this study showed that biomarkers alone 
performed similarly to symptom-based criteria, while probably adding to the cost of care. 
Interestingly, studies using combinations of symptoms with biomarkers and/or measures 
of psychological wellbeing reported improved diagnostic accuracy (Jones et al., 2014; 
Tibble et al., 2002). Other investigators have reported that the absence of ”red flag” 
features, such as nocturnal symptoms of abdominal pain or diarrhoea (Vanner et al., 1999; 
Macaigne et al., 2014), or, as previously discussed, incorporating the results of simple 
laboratory tests, including haemoglobin and ESR (Kruis et al., 1984), may increase the 
ability to distinguish between IBS and organic lower GI diseases.  
The aim of this study, based on these observations, was therefore to conduct a 
diagnostic accuracy study to examine whether the performance of the Rome III criteria 
could be improved if combined with additional items from the history, results of simple 
blood tests, markers of anxiety, depression, or somatoform-type behaviour, or 
combinations thereof. Proof of enhancement in the diagnostic performance of symptom-
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based criteria could result in a reliable, inexpensive, and easily administrable clinical test, 
and represent a considerable advancement in assisting clinicians to make a positive 
diagnosis of IBS.  
 
4.2 Methods 
 
4.2.1 Participants and Setting 
 
 Unselected, consecutive patients aged ≥16 years newly referred from primary care to 
secondary care for consideration of investigation of GI symptoms were considered as 
eligible for the study. All patients were approached in six of the medical gastroenterology 
outpatient clinics of Leeds Teaching Hospitals Trust, West Yorkshire, United Kingdom 
(UK). The hospitals provide secondary care services to a local population of almost 
800,000 people in the North of England. The only exclusion criteria were an inability to 
understand written English, as the questionnaires utilised were self-administered. 
Potentially eligible subjects were given a study information sheet at their initial clinic 
visit, before consultation with a gastroenterologist. Those agreeing to participate provided 
written informed consent at that visit. The local ethics committee approved the study 
(reference 13/YH/0216), with recruitment commencing in January 2014, and continuing 
through to December 2015. During the 2-year recruitment period the six involved clinics 
saw approximately 2200 new outpatient referrals. As the study was conducted in routine 
clinical practice, the diagnostic evaluation of the recruited patients was not standardised, 
and was left at the discretion of the responsible physician. A minimum panel of blood 
tests, or collection of colonic biopsy specimens in all patients was not mandated. 
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 Potential participants were provided with an information sheet. They were then 
given the opportunity to ask any questions they may have had about the study. If they 
agreed to take part, they were asked to provide written, informed consent.  
  
4.2.2 Data Collection and Synthesis 
 
4.2.2.1 Demographic and Symptom data 
 All demographic and symptom data were collected prospectively at the initial clinic 
visit. Demographic data of interest in this study included age, height (in metres), and 
weight (in kilograms), from which body mass index (BMI) was calculated, gender, 
tobacco and alcohol use, marital status, educational level, and ethnicity. The Rome III 
diagnostic questionnaire for adult FGIDs was used to collect data on GI symptoms 
(Whitehead WE, 2006).  Patients were also asked as to whether they experienced 
nocturnal passage of stools, which was recorded as occurring never, rarely, sometimes, 
often, most of the time, or always, with a symptom frequency of sometimes or greater 
used to define its presence.  
 
4.2.2.2 Mood and Somatisation Data 
The HADS was used to collect information about mood (Zigmond and Snaith, 
1983). This 14-item instrument contains seven questions concerning anxiety, and another 
seven depression. Each of these questions is scored from 0 to 3, giving a total possible 
score of 21 for anxiety or depression separately. A score of ≥8 was used to define possible 
anxiety or depression (see the appendix for individual items of the HADS).  
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The validated PHQ-15 was used to assess for evidence of somatisation-type 
behaviour (Kroenke et al., 2002). Each of these questions is scored on a scale from 0 to 2, 
giving a total possible score of 30. A score of ≥15 is the validated threshold used to define 
high levels of somatisation (see the appendix for individual items of the PHQ-15).  
 
4.2.2.3 Baseline Tests in Diagnostic Evaluation 
Information was also collected from patients’ case notes and computerised 
records. Haemoglobin level (normal for males ≥13.5g/dL, normal for females ≥11.5g/dL) 
and CRP levels (normal <5mg/L) were recorded at the initial clinic visit. The initial 
diagnosis made by the physician who consulted with the patient at their first outpatient 
clinic appointment, as well as the final diagnosis made after investigation to the level 
deemed appropriate by each individual consulting physician, were also recorded.   
 
4.2.2.4 Definition of IBS 
The presence or absence of Rome III-defined IBS among individual patients was 
assigned according to the scoring algorithm proposed for use with the Rome III 
questionnaire (see the Rome III questionnaire in the appendix).  
 
4.2.2.5 Colonoscopic and Histopathological Data  
All included patients underwent complete colonoscopy to the caecum or terminal 
ileum. The endoscopy units in Leeds Teaching Hospitals Trust employ colonoscopes from 
both Olympus and Fujinon. Bowel preparation was either a combination of polyethylene 
glycol and sodium picosulfate, or polyethylene glycol alone, depending on renal function. 
All endoscopists performing colonoscopic examinations remained blinded to the 
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questionnaire data of the patient. Findings were recorded using the ADAM reporting 
system (Fujifilm, Europe), with reports accessed by study investigators in order to record 
the final colonoscopic diagnosis for each included patient. Findings classified as 
consistent with organic disease at colonoscopy are provided in Table 9. The presence of 
diverticular disease was not considered an organic disease finding at colonoscopy as there 
is a lack of evidence to associate the presence of uncomplicated diverticular disease with 
chronic GI symptoms. In a recent prospective study, no association was found between 
diverticulosis and symptoms of irritable bowel syndrome (OR 0.53; 95% CI 0.26 to 
1.05) or chronic abdominal pain (OR 0.68; 95% CI 0.38 to 1.23) (Peery et al., 2017).  
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 Table 9. Findings Consistent with Organic Disease at Colonoscopy, or After    
  Histopathological Interpretation of Colonic Biopsies. 
 
At Colonoscopy After Histopathological Interpretation of 
Colonic Biopsies 
Evidence of colitis  
Evidence of terminal ileitis (inflammation or 
ulceration) 
Colorectal carcinoma 
Colonic stricture 
Evidence of radiation-induced colorectal disease 
Colonic adenocarcinoma  
Rectal adenocarcinoma 
UC 
Crohn’s disease 
IBD-unclassifiable 
Microscopic colitis 
Ischaemic colitis 
Radiation enteropathy  
Ulceration seen macroscopically at colonoscopy 
with non-specific inflammation on histological 
examination 
Neuroendocrine tumour 
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Biopsy specimens were obtained at the discretion of the endoscopist performing 
the colonoscopy. Standard policy during these colonoscopies in any patient with chronic 
diarrhoea and a macroscopically normal colon is to take two biopsies from the right colon, 
two from the left colon, and two from the rectum. All biopsies were interpreted by 
experienced GI histopathologists, who remained blinded to the questionnaire data of the 
patient. Histopathological findings were accessed using computerised records to obtain 
the final histopathological diagnosis. Findings classified as being consistent with organic 
disease after histopathological examination of biopsy specimens are also provided in 
Table 9.  
Using these data, patients were classified according to the presence or absence of 
organic lower GI disease. Individuals had to have no evidence of an organic explanation 
for their symptoms at both colonoscopy and histopathological examination of biopsy 
specimens in order to be classified as exhibiting no organic lower GI disease. 
 
4.2.2.6 Reference Standard to Define the Presence of IBS 
 The reference standard used to define the presence of IBS was lower abdominal pain 
or discomfort occurring at least 3 days per month over the last 3 months, in association 
with a change in bowel habit, and in the absence of organic lower GI disease after 
colonoscopy and histopathological examination of colonic biopsies, if obtained, which 
would explain these symptoms. Exclusion of coeliac disease with distal duodenal biopsy 
was also undertaken, if coeliac serology was positive.  
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4.2.2.7 Statistical Analysis 
In order to assess whether those who underwent colonoscopy and provided 
complete symptom data were representative of all patients recruited, demographic data 
were compared between those undergoing colonoscopy who completed the symptom 
questionnaire, and those who completed the symptom questionnaire but did not undergo 
colonoscopy, using a χ2 test for categorical data, and an independent samples t-test for 
continuous data, with a mean and standard deviation (SD). Due to multiple comparisons a 
2-tailed P value of < 0.01 was considered statistically significant for these analyses. 
Organic findings in those meeting the Rome III criteria for IBS were compared with those 
who did not, using Fisher’s exact test, as numbers in each cell were relatively small. 
These statistical analyses were performed using SPSS for Windows version 21.0 (SPSS 
Inc, Chicago, IL, USA). 
The first aim of the study was to ascertain the performance of the Rome III criteria 
for IBS in determining the presence of IBS versus the reference standard of symptoms 
suggestive of IBS and a negative colonoscopy, as described above. Sensitivity analyses 
were also performed, within which the reference standard was varied. We assessed how 
the Rome III criteria performed versus: 
a. A physician’s final diagnosis that this was IBS, after investigation to the level 
deemed appropriate, which may or may not have included complete 
colonoscopy depending on whether that individual physician used a positive 
diagnostic strategy for IBS (physician’s final diagnosis of IBS), or; 
 
b. A combination of symptoms suggestive of IBS and a negative colonoscopy 
described above, and a physician’s final diagnosis of IBS as described in a.  
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To that end, sensitivity, specificity, PPVs and NPVs, and their 95% CIs, were 
calculated for the Rome III criteria versus the reference standard using StatsDirect version 
2.8.0 (StatsDirect Ltd, Sale, Cheshire, England). The positive LR and negative LR, and 
their 95% CIs, were also calculated. These analyses were performed for all individuals 
recruited who underwent colonoscopy for investigation of their lower GI symptoms, and 
provided complete Rome III symptom data. However, in clinical practice there may be 
less uncertainty in the diagnosis of IBS-C as the degree of overlap of symptoms with 
those of an organic GI disease is probably smaller, so the challenge is often in 
distinguishing between IBS-D and other potential organic GI causes of diarrhoea. With 
this in mind, post hoc analyses were performed, including only those participants 
reporting either ≥4 stools per day, or loose, mushy, or watery stools.  
As stated previously, the advantage of using LRs over predictive values is that 
LRs do not vary to the same degree as predictive values with a change in disease 
prevalence. As a rule of thumb, a positive LR of more than 10 is useful for ruling in a 
disease, and a negative LR of less than 0.1 is useful for ruling out a disease. However, in 
diseases of higher prevalence, the positive LR threshold required to cause a useful 
increase in probability that will result in a change of management may be lower. In a 
recently published systematic review, the authors assumed “medical certainty” for a novel 
biomarker in diagnosing IBS as a post-test probability (derived from the pre-test 
probability and positive LR) of >80% (Shah et al., 2015). At this threshold, in a secondary 
or tertiary care population with a prevalence of IBS of around 50%, a test with a positive 
LR of ≥5 would identify IBS with a post-test probability of 86.5%.  
The second aim was to compare the performance of proposed modifications to the 
Rome III criteria, by including information on nocturnal passage of stools, a physician’s 
working diagnosis that this was IBS at the initial consultation, laboratory results of 
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haemoglobin and CRP, and measures of anxiety, depression, or somatisation, against the 
best performing of the three reference standards described above. Again, sensitivities, 
specificities, PPVs and NPVs, and positive and negative LRs were calculated for each of 
these modifications both individually, and as combinations.  
 
4.3 Results 
 There were 1002 consecutive patients (mean age 54.4 years (range 16 to 92 years), 
638 (63.7%) female) who gave informed consent and were recruited into the study 
between January 2014 and December 2015. Of these, 318 (31.7%) patients (mean age 
54.0 years (range 18 to 92 years), 216 (67.9%) female) underwent colonoscopy for 
investigation of their lower GI symptoms, and provided complete Rome III symptom data 
(Figure 9).  
 Comparison of the demographic data of this group with those who did not undergo 
colonoscopy is provided in Table 10. Patients providing complete symptom data and 
undergoing colonoscopy had a higher BMI and were more likely to meet the Rome III 
criteria for IBS, but there were no other significant differences between the two groups. 
Patients with IBS-D were more likely to undergo colonoscopy, but not patients with IBS-
C or those with IBS-M.  
 Among the 318 individuals providing complete symptom and colonoscopy data, 98 
(30.8%) met the Rome III criteria for IBS. The mean age of these 98 patients was 46.7 
years, and 73 (74.5%) were female. There were 286 (89.9%) patients who had a 
haemoglobin check, 178 (56.0%) with a CRP measurement, 212 (66.7%) with coeliac 
serology, and 215 (67.6%) who had colonic biopsy specimens obtained. Relevant organic 
findings after colonoscopy and histopathological interpretation of biopsy specimens, plus 
duodenal biopsy in those with positive coeliac serology, in those that met the Rome III 
 
 
158 
 
criteria compared with the 220 patients that did not are detailed in Table 11. There were 
no significant differences in the prevalence of any of these organic findings between the 
two groups. 
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Figure 9. Flow of Study Participants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
  
1002 consecutive 
patients with GI 
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underwent complete 
colonoscopy 
642 patients did not 
undergo colonoscopy 
318 patients 
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Rome III symptom 
and colonoscopy 
data 
42 patients did not 
provide complete 
symptom or 
colonoscopy data 
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    Table 10. Demographics and Baseline Characteristics of Patients Who Underwent     
    Colonoscopy and Provided Complete Symptom Data Compared with Those That Did 
    Not Undergo Colonoscopy. 
 
 Underwent 
colonoscopy and 
provided 
complete Rome 
III symptom data 
(n = 318) 
Did not undergo 
colonoscopy 
(n = 642) 
P 
value* 
Mean age in years (SD) 54.0 (16.3) 54.6 (18.1) 0.57 
Mean BMI (SD) 27.2 (6.0) 26.2 (5.3) 0.02 
Female gender (%) 216 (67.9) 402 (62.6) 0.11 
Tobacco use (%) 74 (23.3) 149 (23.2) 0.99 
Alcohol use (%) 171 (53.8) 351 (54.7) 0.87 
Marital status (%) 
Married or cohabiting 
Divorced or separated 
Never Married 
Widowed 
 
177 (55.7) 
44 (13.8) 
59 (18.6) 
26 (8.2) 
 
354 (55.1) 
74 (11.5) 
116 (18.1) 
73 (11.4) 
 
 
 
 
0.38 
Educational level (%) 
Primary school 
Secondary school 
College or technical school 
University 
Postgraduate 
 
2 (0.6) 
144 (45.3) 
77 (24.2) 
47 (14.8) 
29 (9.1) 
 
3 (0.5) 
277 (43.1) 
137 (21.3) 
91 (14.2) 
55 (8.6) 
 
 
 
 
 
0.98 
White Caucasian ethnicity (%) 292 (91.8) 573 (89.3) 0.25 
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Met Rome III criteria for IBS (%) 
IBS-D 
IBS-C 
IBS-M 
98 (30.8) 
46 (14.6) 
5 (1.6) 
45 (14.2) 
126 (19.6) 
32 (5.0) 
25 (3.9) 
60 (9.3) 
< 0.001 
< 0.001 
0.08 
0.03 
HADS score ≥8  
(n = 829) 
144/292 (49.3) 278/537 (51.8) 0.50 
High level of somatisation  
(n = 725) 
57/258 (22.1) 99/467 (21.2) 0.78 
*P value for independent samples t-test for continuous data and Pearson χ2 for comparison 
of categorical data. 
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Table 11. Prevalence of Organic Disease in Patients Meeting the Rome III Criteria 
Compared With Those Who Did Not. 
 
 Met Rome III 
criteria for 
IBS 
(n = 98) 
Did not meet 
Rome III 
criteria for 
IBS 
(n = 220) 
P value* 
UC (%) 2 (2.0) 2 (0.9) 0.59 
Crohn’s disease (%) 4 (4.1) 2 (0.9) 0.08 
IBD-unclassifiable (%) 0 (0) 2 (0.9) 0.52 
Non-specific GI ulceration (%) 1 (1.0) 4 (1.8) 1.0 
Collagenous colitis (%) 4 (4.1) 12 (5.5) 0.78 
Lymphocytic colitis (%) 2 (2.0) 9 (4.1) 0.51 
Colorectal cancer (%) 0 (0) 2 (0.9) 1.0 
Coeliac disease (%) 2 (2.0) 5 (2.3) 1.0 
     *P value for Fisher’s exact test for comparison of categorical data. 
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4.3.1 Performance of the Rome III Criteria for IBS Against All Reference Standards 
Of 79 (24.8%) individuals meeting the reference standard of symptoms suggestive 
of IBS and a negative colonoscopy, 55 met the Rome III criteria, giving a sensitivity of 
69.6% (Table 12). Among the 239 patients without IBS according to this reference 
standard, 196 did not meet the Rome III criteria, giving a specificity of 82.0%. Positive 
and negative LRs of the Rome III criteria were therefore 3.87 (95% CI 2.85 to 5.26) and 
0.37 (95% CI 0.26 to 0.51) respectively. Altering the reference standard to one that used a 
physician’s final diagnosis of IBS, or one that included a composite of symptoms 
suggestive of IBS, a negative colonoscopy, negative coeliac serology, and a physician’s 
final diagnosis of IBS did not improve the performance of the Rome III criteria (Table 
12), with lower positive LRs and higher negative LRs. A reference standard of symptoms 
suggestive of IBS and a negative colonoscopy was therefore used in all subsequent 
analyses.  
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Table 12. Diagnostic Accuracy of the Rome III Criteria for Irritable Bowel Syndrome versus Various Reference Standards. 
 
Reference 
standard used 
Number of 
patients 
included  
(% with IBS) 
Sensitivity  
(95% CI) 
Specificity  
(95% CI ) 
Positive 
predictive value  
(95% CI)  
Negative 
predictive value  
(95% CI) 
Positive 
likelihood 
ratio  
(95% CI) 
Negative 
likelihood 
ratio  
(95% CI) 
Symptoms 
suggestive of 
IBS and a 
negative 
colonoscopy 
318 (24.8) 69.6%  
(58.3% – 79.5%) 
82.0%  
(76.5% – 86.7%) 
56.1%  
(46.3% – 65.5%) 
89.1%  
(84.3% – 92.6%) 
3.87  
(2.85 – 5.26) 
0.37 
(0.26 – 0.51) 
Physician’s 
final 
diagnosis of 
IBS 
545 (29.4) 58.8%  
(50.7% – 66.5%) 
77.4%  
(72.9% – 81.5%) 
51.9%  
(44.7% – 59.1%) 
81.9%  
(77.6% – 85.5%) 
2.60 
(2.07 – 3.26) 
0.53  
(0.44 – 0.64) 
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Symptoms 
suggestive of 
IBS, a 
negative 
colonoscopy, 
and a 
physician’s 
final 
diagnosis of 
IBS 
215 (16.3) 71.4%  
(53.7% – 85.4%) 
70.0%  
(62.7% – 76.6%) 
31.6%  
(22.5% – 42.6%) 
92.7%  
(87.0% – 96.0%) 
2.38  
(1.71 – 3.19) 
0.41  
(0.23 – 0.65) 
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4.3.2 Rome III Criteria and No Nocturnal Passage of Stools  
  The effect on the Rome III criteria by combining it with no nocturnal passage of 
stools was studied. When this was compared against the original reference standard, there 
were 311 patients with full data for analysis, of whom 78 had IBS according to the 
original reference standard. Of these, 26 met the combination of positive Rome III criteria 
and absence of nocturnal stools, resulting in a sensitivity of 33.3% (95% CI 23.1% to 
44.9%) in detecting IBS. Of the 233 individuals that did not meet the original reference 
standard, 212 did not meet this combination, giving a specificity of 91.0% (95% CI 86.6% 
to 94.3%). Positive and negative LRs were therefore 3.70 (95% CI 2.21 to 6.14) and 0.73 
(95% CI 0.61 to 0.84) (Table 13). 
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Table 13. Diagnostic Accuracy of the Rome III Criteria, and Modifications to the Rome III Criteria with the Inclusion of No Nocturnal 
Passage of Stools, Physician’s Initial Impression that this was IBS, Biomarkers or Markers of Affective Disorders, or a Combination 
Thereof, versus the Reference Standard. 
 Number of 
patients 
providing 
data in the 
analysis 
Sensitivity 
(95% CI) 
Specificity 
(95% CI ) 
Positive 
predictive value 
(95% CI) 
Negative 
predictive value 
(95% CI) 
Positive 
likelihood 
ratio (95% 
CI) 
Negative 
likelihood 
ratio (95% 
CI) 
Rome III 
criteria alone 
318 69.6% 
(58.3% – 79.5%) 
82.0% 
(76.5% – 86.7%) 
56.1% 
(46.3% – 65.5%) 
89.1% 
(84.3% – 92.6%) 
3.87 
(2.85 – 5.26) 
0.37 
(0.26 – 0.51) 
Rome III 
criteria and 
no nocturnal 
passage of 
stools 
311 33.3% 
(23.1% – 44.9%) 
91.0% 
(86.6% – 94.3%) 
55.3% 
(41.3% – 68.6%) 
80.3% 
(75.1% – 84.7%) 
3.70 
(2.21 – 6.14) 
0.73 
(0.61 – 0.84) 
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Rome III 
criteria and 
physician’s 
initial 
impression 
that this was 
IBS 
112 50.0% 
(33.4% – 66.6%) 
79.7% 
(68.8% – 88.2%) 
55.9% 
(39.5% – 71.1%) 
75.6% 
(65.1% – 83.8%) 
2.47 
(1.42 – 4.27) 
0.63 
(0.43 – 0.84) 
Rome III 
criteria and 
normal 
haemoglobin  
and CRP 
208 49.0% 
(34.8% – 63.4%) 
89.2% 
(83.2% – 93.6%) 
59.5% 
(44.5% – 73.0%) 
84.3% 
(78.0% – 89.1%) 
4.53 
(2.67 – 7.64) 
0.57 
(0.42 – 0.73) 
Rome III 
criteria and a 
HADS score 
≥8 
292 47.2% 
(35.3% – 59.4%) 
89.1% 
(84.2% – 92.9%) 
58.6% 
(45.8% – 70.4%) 
83.8% 
(78.5% – 87.9%) 
4.33 
(2.76 – 6.76) 
0.59 
(0.46 – 0.72) 
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Rome III 
criteria and a 
high level of 
somatisation 
258 37.9% 
(26.2% – 50.7%) 
94.8% 
(90.6% – 97.5%) 
71.4% 
(55.0% – 83.7%) 
81.6% 
(76.0% – 86.1%) 
7.27 
(3.74 – 14.2) 
0.66 
(0.53 – 0.77) 
Rome III 
criteria, 
normal 
haemoglobin 
and CRP, and 
a HADS score 
≥8 
195 34.0% 
(20.9% – 49.3%) 
93.2% 
(87.9% – 96.7%) 
61.5% 
(42.5% – 77.6%) 
81.7% 
(75.1% – 86.8%) 
5.04 
(2.48 – 10.2) 
0.71 
(0.55 – 0.84) 
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Rome III 
criteria, 
normal 
haemoglobin 
and CRP, and 
a high level of 
somatisation 
165 24.4% 
(12.4% – 40.3%) 
96.8% 
(92.0% – 99.1%) 
71.4% 
(45.4% – 88.3%) 
79.5% 
(72.3% – 85.1%) 
7.56 
(2.63 – 21.7) 
0.78 
(0.63 – 0.90) 
Rome III 
criteria, no 
nocturnal 
passage of 
stools, and a 
HADS score 
≥8 
290 22.2% 
(13.3% – 33.6%) 
95.4% 
(91.7% – 97.8%) 
61.5% 
(42.5% – 77.6%) 
 
 
 
78.8% 
(73.5% – 83.3%) 
4.84 
(2.33 – 10.0) 
0.82 
(0.70 – 0.91) 
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Rome III 
criteria, no 
nocturnal 
passage of 
stools, and a 
high level of 
somatisation 
256 18.2% 
(9.8% – 29.6%) 
99.0% 
(96.3% – 99.9%) 
85.7% 
(60.1% – 96.0%) 
77.7% 
(72.0% – 82.5%) 
17.3 
(4.45 – 67.6) 
0.83 
(0.72 – 0.90) 
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4.3.3 Rome III Criteria and a Physician’s Initial Impression That This Was IBS 
 The Rome III criteria were then combined with a physician’s initial impression that 
this was IBS at the first outpatient clinic visit (i.e. prior to any investigation being 
undertaken). Of 112 patients, 38 had IBS according to the original reference standard, of 
whom 19 met the combination of the Rome III criteria and a physician’s initial impression 
that this was IBS, resulting in a sensitivity of 50.0% (95% CI 33.4% to 66.6%) in 
detecting IBS. Of the 78 that did not meet the original reference standard for IBS, 59 
patients did not meet this combination, resulting in a specificity of 79.7% (95% CI 68.8% 
to 88.2%). Positive and negative LRs were 2.47 (95% CI 1.42 to 4.27) and 0.63 (95% CI 
0.43 to 0.84) (Table 13). 
 
4.3.4 Rome III Criteria and Normal Haemoglobin and CRP 
 When the Rome III criteria were combined with a normal haemoglobin and CRP, 
and compared with the original reference standard, 51 of 208 patients met the reference 
standard for IBS. Of these 51 patients, 25 met the combination of the Rome III criteria 
and a normal haemoglobin and CRP, resulting in a sensitivity of 49.0% (95% CI 34.8 to 
63.4%). Of the 157 individuals that did not meet the original reference standard, 140 did 
not meet this combination, resulting in a specificity of 89.2% (95% CI 83.2% to 93.6%). 
Positive and negative LRs were 4.53 (95% CI 2.67 to 7.64) and 0.57 (95% CI 0.42 to 
0.73) (Table 13). 
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4.3.5 Rome III Criteria and Psychological Markers 
 
4.3.5.1 Rome III Criteria and a High Level of Somatisation 
 The Rome III criteria were combined with high somatisation levels, considered as a 
PHQ-15 score >15. Of 258 individuals, 66 met the original reference standard for IBS, of 
whom 25 met a combination of both the Rome III criteria and a high level of 
somatisation, giving a sensitivity of 37.9% (95% CI, 26.2% to 50.7%). Of the 192 
individuals who did not meet the reference standard, 182 did not meet the combination of 
Rome III and somatisation, resulting in a specificity of 94.8% (95% CI 90.6% to 97.5%). 
Positive and negative LRs were 7.27 (95% CI 3.74 to 14.2) and 0.66 (95% CI 0.53 to 
0.77) (Table 13). 
 
4.3.5.2 Rome III Criteria and a HADS score >8 
 The Rome III criteria were then combined with markers for anxiety and depression, 
using a HADS anxiety or depression score of ≥8 to define possible anxiety or depression, 
and were compared against the original reference standard. Of 292 patients, 72 met the 
original reference standard for IBS, of whom 34 met the combination of Rome III criteria 
and a HADS anxiety or depression score ≥8, resulting in a sensitivity of 46.4% (95% CI 
34.3% to 58.8%). Of the 220 patients that did not meet the original reference standard, 
196 did not meet this combination, resulting in a specificity of 85.7% (95% CI 79.5% to 
90.6%). Positive and negative LRs were 3.25 (95% CI 2.07 to 5.07) and 0.63 (95% CI 
0.49 to 0.77) respectively (Table 13). 
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4.3.6 Combinations of the Rome III Criteria, Passage of Nocturnal Stools, 
Biomarkers, and Psychological Markers 
 
4.3.6.1 Rome III Criteria, Normal Haemoglobin and CRP, and a HADS score >8  
 Of 195 individuals, 47 were considered to have met the original reference standard 
for IBS, and 16 met the combination of positive Rome III criteria, normal haemoglobin 
and CRP levels, and a HADS anxiety or depression score >8, giving a sensitivity of 
34.0% (95% CI 20.9% to 49.3%). Of the 148 patients that did not meet the original 
reference standard, 138 did not meet this combination, giving a specificity of 93.2% (95% 
CI 87.9% to 96.7%). The positive and negative LRs were 5.04 (95% CI 2.48 to 10.2) and 
0.71 (95% CI 0.55 to 0.84) respectively (Table 13). 
 
4.3.6.2 Rome III Criteria, Normal Haemoglobin and CRP, and a High Level of 
Somatisation 
 Of 165 patients, 41 met the original reference standard for IBS, of whom 10 had a 
combination of positive Rome III criteria, normal biomarkers, and a high level of 
somatisation, resulting in a sensitivity of 24.4% (95% CI 12.4% to 40.3%). Of the 124 
patients that did not meet the original reference standard, 120 did not meet this 
combination, giving a specificity of 96.8% (95% CI 92.0% to 99.1%). Positive and 
negative LRs were 7.56 (95% CI 2.63 to 21.7) and 0.78 (95% CI 0.63 to 0.90) (Table 13). 
 
4.3.6.3 Rome III Criteria, No Nocturnal Passage of Stools, and a HADS >8 
 When combining the Rome III criteria with no nocturnal passage of stools and a 
HADS anxiety or depression score >8, 72 of 290 patients met the original reference 
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standard for IBS, of whom 16 met this combination of Rome III and markers, resulting in 
a sensitivity of 22.2% (95% 13.3% to 33.6%). Of the 218 patients that did not meet the 
original reference standard, 208 did not meet the combination, giving a specificity of 
95.4% (95% CI 91.7% to 97.8%). Positive and negative LRs were 4.84 (95% CI 2.33 to 
10.0) and 0.82 (95% CI 0.70 to 0.91) respectively (Table 13). 
 
4.3.6.4 Rome III Criteria, No Nocturnal Passage of Stools, and a High Level of 
Somatisation 
 Finally, the Rome III criteria were combined with no nocturnal passage of stools and 
a high level of somatisation. Of 256 patients, 66 met the original reference standard for 
IBS, of whom 12 met the combination of the Rome III criteria, no nocturnal passage of 
stool, and a high level of somatisation, resulting in a sensitivity of 18.2% (95% CI 9.8% 
to 29.6%). Of the 190 patients that did not meet the original reference standard, 188 did 
not meet this combination, resulting in a specificity of 99.0% (95% CI 96.3% to 99.9%). 
Positive and negative LRs were 17.3 (95% CI 4.45 to 67.6) and 0.83 (95% CI 0.72 to 
0.90) respectively. (Table 13) 
 
4.3.6.5 Accuracy of the Rome III Criteria and Modifications in Patients Presenting with 
Diarrhoea 
When the analyses were restricted to participants who reported either ≥4 stools per 
day, or loose, mushy, or watery stools, there were similar enhancements of positive LRs 
(in some instances, almost two-fold those for the Rome III criteria alone) with the 
incorporation of additional factors from the clinical history and simple laboratory tests 
into the Rome III criteria (Table 14). 
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  Table 14. Diagnostic Accuracy of the Rome III Criteria, and Modifications to the Rome III Criteria with the Inclusion of No Nocturnal 
  Passage of Stools, Physician’s Initial Impression that this was IBS, Biomarkers or Markers of Affective Disorders, or a Combination   
  Thereof, versus the Reference Standard Among Patients Presenting with Diarrhoea 
 
 Number of 
patients 
providing 
data in the 
analysis 
Sensitivity 
(95% CI) 
Specificity 
(95% CI ) 
Positive 
predictive value 
(95% CI) 
Negative 
predictive value 
(95% CI) 
Positive 
likelihood 
ratio (95% 
CI) 
Negative 
likelihood 
ratio (95% 
CI) 
Rome III criteria 
alone 
252 68.0% 
(56.2% – 78.3%) 
76.8% 
(69.9% – 82.4%) 
55.4% 
(44.7% – 65.8%) 
85.0% 
(78.5% – 90.2%) 
2.94 
(2.16 – 4.01) 
0.42 
(0.29 – 0.57) 
Rome III criteria 
and no nocturnal 
passage of stools 
251 30.7% 
(20.5% – 42.4%) 
89.2% 
(83.7% – 93.4%) 
54.8% 
(38.7% – 70.2%) 
75.1% 
(68.7% – 80.8%) 
2.84 
(1.65 – 4.85) 
0.77 
(0.65 – 0.89) 
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Rome III criteria 
and physician’s 
initial impression 
that this was IBS 
100 54.3% 
(36.7% – 71.2%) 
76.9% 
(64.8% – 86.5%) 
55.9% 
(37.9% – 72.8%) 
75.8% 
(63.6% – 85.5%) 
2.35 
(1.38 – 4.03) 
0.59 
(0.39 – 0.84) 
Rome III criteria 
and normal 
haemoglobin and 
CRP 
163 51.0% 
(36.3% – 65.6%) 
85.1% 
(77.2% – 91.1%) 
59.5% 
(43.3% – 74.4%) 
80.2% 
(71.9% – 86.9%) 
3.42 
(2.05 – 5.72) 
0.58 
(0.41 – 0.75) 
Rome III criteria 
and a HADS 
score ≥8 
237 46.4% 
(34.3% – 58.8%) 
85.7% 
(79.5% – 90.6%) 
57.1% 
(43.2% – 70.3%) 
79.6% 
(72.9% – 85.2%) 
3.25 
(2.07 – 5.07) 
0.63 
(0.49 – 0.77) 
Rome III criteria 
and a high level of 
somatisation 
207 38.1% 
(26.2% – 51.2%) 
93.1% 
(87.6% – 96.6%) 
70.6% 
(52.5% – 84.9%) 
77.5% 
(70.5% – 83.5%) 
5.49 
(2.83 – 10.7) 
0.67 
(0.53 – 0.79) 
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Rome III criteria, 
normal 
haemoglobin and 
CRP, and a 
HADS score ≥8 
158 34.8% 
(21.4% – 50.3%) 
91.1% 
(84.2% – 95.6%) 
61.5% 
(40.6% – 79.8%) 
77.3% 
(69.2% – 84.1%) 
3.90 
(1.93 – 7.83) 
0.72 
(0.55 – 0.86) 
Rome III criteria, 
normal 
haemoglobin and 
CRP, and a high 
level of 
somatisation 
131 25.0% 
(12.7% – 41.2%) 
95.6% 
(89.1% – 98.8%) 
71.4% 
(41.9% – 91.6%) 
74.4% 
(65.5% – 82.0%) 
5.69 
(2.00 – 16.3) 
0.78 
(0.62 – 0.91) 
Rome III criteria, 
no nocturnal 
passage of stools, 
and a HADS 
score ≥8 
237 20.3% 
(11.6% – 31.7%) 
94.1% 
(89.3% – 97.1%) 
58.3% 
(36.6% – 77.9%) 
74.2% 
(67.8% – 79.9%) 
3.41 
(1.61 – 7.16) 
0.85 
(0.73 – 0.94) 
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Rome III criteria, 
no nocturnal 
passage of stools, 
and a high level of 
somatisation 
207 17.5% 
(9.1% – 29.1%) 
98.6% 
(95.1% – 99.8%) 
84.6% 
(54.6% – 98.1%) 
73.2% 
(66.4% – 79.3%) 
12.6 
(3.23 – 49.5) 
0.84 
0.72 – 0.92) 
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4.4 Discussion 
 This study has validated the symptom-based Rome III criteria for IBS against an 
accepted clinical reference standard. These criteria performed only modestly, with a 
positive and negative LR of 3.87 and 0.37 respectively. In addition, the effect of addition 
of nocturnal symptoms, factors related to somatisation, affective disorders, and 
haemoglobin and CRP measurements on the accuracy of the symptom-based Rome III 
criteria were examined. Sensitivities in diagnosing IBS ranged from 18.2% for presence 
of the Rome III criteria, no nocturnal passage of stools, and a high level of somatisation to 
50.0% for presence of the Rome III criteria and a physician’s initial impression that the 
diagnosis was IBS. Specificities ranged from 79.7% for presence of the Rome III criteria 
and a physician’s initial impression that the diagnosis was IBS, to 99.0% for presence of 
the Rome III criteria, no nocturnal passage of stools, and a high level of somatisation. 
Furthermore, specificity approached 95% or more with a number of these modifications; 
thus the risk of a missed diagnosis of organic GI disease would be small, as the false 
positive rate was extremely low. 
 A combination of the Rome III criteria with any of a high level of somatisation, a 
normal haemoglobin and CRP with a HADS score of ≥8, a normal haemoglobin and CRP 
with a high level of somatisation, or no nocturnal passage of stools with a high level of 
somatisation all provided positive LRs of ≥5. Improved positive LRs were obtained by 
combining the Rome III criteria with a high level of somatisation alone (positive LR 7.27; 
95% CI 3.74 to 14.2); a normal haemoglobin and CRP with a HADS score of ≥8 (positive 
LR 5.04; 95% CI 2.48 to 10.2); a normal haemoglobin and CRP with a high level of 
somatisation (positive LR 7.56; 95% CI 2.63 to 21.7); and no nocturnal passage of stools 
with a high level of somatisation (positive LR 17.3; 95% CI 4.45 to 67.6). In a secondary 
or tertiary referral population in a university hospital practice with a prevalence of IBS of 
 
 
181 
 
50% or more, a positive LR of this magnitude would be clinically useful for the diagnosis 
of IBS, identifying IBS with a post-test probability of >85% (Shah et al., 2015).  
 The performance of the Rome III criteria in this study is remarkably similar to that 
observed in the only other previous validation study, which also used a reference standard 
of the combination of symptoms suggestive of IBS and a negative colonoscopy (Ford et 
al., 2013). In that prior study from Canada, which included more than 1800 patients, the 
positive and negative LRs of the Rome III criteria were 3.35 (95% CI 2.97 to 3.79) and 
0.39 (95% CI 0.39 to 0.46) respectively. Unlike the current study, the previous study did 
not incorporate other features of the clinical history or simple laboratory tests with the 
Rome III criteria. Sensitivity analyses were conducted in the Canadian study (Ford et al., 
2013), where individuals reporting lower GI alarm symptoms, including rectal bleeding, 
anaemia, weight loss, or a family history of colorectal cancer were excluded. However, 
the addition of lower GI alarm symptoms resulted in only a small improvement in the 
positive LR. There have been few other studies that have attempted to modify the 
symptom-based Rome criteria. Vanner et al. examined the effect on the Rome I criteria of 
excluding patients with “red flag” features, including nocturnal GI symptoms  (Vanner et 
al., 1999). An improvement was shown in the accuracy of the Rome I criteria in 
differentiating IBS from organic disease, with a sensitivity of 65% and a specificity of 
100%.However, this was a small retrospective study, and the investigators did not attempt 
to separate nocturnal GI symptoms from other alarm symptoms, which are reported 
frequently by patients with functional bowel disorders (Whitehead et al., 2006).  
 As discussed previously, psychological or affective disorders have been shown to be 
strongly associated with IBS (Camilleri et al., 2008). There was an improvement in 
diagnostic test accuracy when other investigators added these to a biomarker panel, as 
shown in the recent study from Jones et al. (Jones et al., 2014). Rates of somatoform-type 
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behaviour, in particular, have been shown to be significantly higher in patients with IBS 
(Patel et al., 2015), and to differentiate IBS from health with greater accuracy, compared 
with markers of anxiety and depression, as shown in one of the studies discussed in the 
previous chapter (Spiller et al., 2010). The results of the current study support these 
findings, with a greater accuracy when a combination of the Rome III criteria and high 
level of somatisation was used, as compared with a combination of the Rome III criteria 
and HADS scores. Incorporating the presence of co-existent FGIDs into the modifications 
to the Rome III criteria may also have improved their performance. However, unlike in 
IBS, some other FGIDs are diagnoses of exclusion. For instance, a diagnosis of functional 
heartburn would not be made on symptoms alone, but only after a negative upper 
endoscopy and normal pH and impedance studies. As this study did not mandate the 
relevant investigations to confirm that, when the appropriate symptoms were reported, the 
cause was indeed another FGID this issue was therefore not examined.   
 The performance of the modifications to the Rome III criteria used in the current 
study can be best appreciated by comparing them with the accuracy of biomarkers. In 
general, biomarkers have been shown to perform no better than symptom-based 
diagnostic criteria in IBS, as shown in the preceding chapter and, in some cases, are 
probably not clinically useful outside of a research or tertiary care setting, due to their 
complex or invasive nature e.g. brain imaging, or endoscopy and biopsy with specialised 
histopathology.(Bouin et al., 2002; Kim et al., 2010; El-Salhy et al., 2014; El-Salhy et al., 
2014).  Furthermore, as previously discussed, many of the studies that have validated 
biomarkers have been limited by the fact that their utility in IBS was compared with HCs, 
when it would be more useful to assess the performance of the biomarker in 
distinguishing between IBS and organic disease. Alternatively, other appraisals of 
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biomarkers have used IBS-enriched populations, reducing their generalisability to a 
clinical setting, where the prevalence of IBS is likely to be lower.   
 One biomarker that is available for use in clinical practice currently was examined 
for its ability to differentiate IBS-D from IBD, coeliac disease, or health (Pimentel et al., 
2015). The methodology of this study has previously been described, but to recap, 
antibodies to cytolethal toxin B and to vinculin performed best when differentiating IBS-
D from IBD, with positive LRs of 5.2 and 2.0 respectively. However, as discussed, the 
authors used an enriched sample of cases, that consisted of a cohort of patients enrolled in 
a large randomised clinical trial of rifaximin, with >80% of participants having IBS-D. 
Thus, the LRs may not be reproducible in other populations, or in those with IBS-C or 
IBS-M. This underlines the importance of this study’s findings in a consecutive, 
unselected secondary care population, where various combinations of the Rome III 
criteria, two routine blood tests, and a symptom-item checklist, appeared accurate and 
would be inexpensive to administer as a diagnostic test in the outpatient clinic.  
The improved performance of the Rome III criteria when combined with relevant 
blood tests and markers of anxiety, depression, or somatisation is perhaps not surprising 
given the findings of other investigators, summarised in the meta-analysis in the previous 
chapter, which showed that studies that have used symptoms with clinical laboratory tests, 
biomarkers, and markers of psychological disorders, seem to lead to an increased ability 
to differentiate between IBS and organic GI disease.  
There are methodological strengths to this study. First, it was conducted in a large, 
unselected population referred to secondary care, so the results are likely to be 
generalisable to patients with suspected IBS seen in usual clinical care by 
gastroenterologists. The sample size, although smaller than the previous validation study 
of the Rome III criteria (Ford et al., 2013) is larger than most other studies that have 
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assessed the accuracy of diagnostic tests for IBS.  Second, it was designed to adhere to the 
STARD guidelines for the reporting of studies of diagnostic accuracy, with consecutive 
patients recruited, assessors blinded, and accepted references standard used. Third, it used 
inexpensive factors to modify the symptom-based criteria, and these lend themselves to 
application in either primary or secondary care. 
 There are some limitations to the study. Although the modifications made to the Rome III 
criteria result in an appreciable improvement in specificity and positive LR, this comes at the 
expense of worsening sensitivity and negative LR. This is likely to result in some patients 
who have IBS undergoing unnecessary investigation. However, clinicians need to have 
confidence that a test for IBS has a low probability of missing organic GI pathology. The 
modifications made to the Rome III criteria in this study succeed in this respect. Not all 
patients that underwent colonoscopy provided complete symptom data, and therefore these 
individuals were not included in the analyses. However, this number was relatively small, 
with almost 90% of patients providing full data. Most of the patients included in the study 
were White Caucasian, meaning that these results may not be applicable to other ethnicities. 
The mean age of included individuals was relatively high at 54 years, which probably reflects 
the use of a negative colonoscopy as a reference standard, meaning that there is some 
selection bias and that the results may therefore not be generalisable to a younger population. 
The study was conducted in secondary care as the reference standard used to define IBS 
mandated a negative colonoscopy. As a result, one possible criticism is that the study findings 
may not be reproducible in primary care where the majority of patients are diagnosed. 
However, the patient cohort referred to secondary care is more likely to contain mild cases 
that are difficult to diagnose. The expected result of this would be enhanced performance of 
the Rome III modifications in differentiating IBS from organic disease in a primary care 
setting. In addition, the reference standard used in the analyses included symptom data from 
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the questionnaire, which may have resulted in an overestimation of the accuracy of the Rome 
III criteria and its modifications, and a negative colonoscopy. Approximately one-third of 
patients included in the study did not have coeliac serology tested. In a recent systematic 
review and meta-analysis, the prevalence of positive coeliac serology in individuals 
presenting with symptoms suggestive of IBS was significantly higher when compared with 
HCs (OR 3.21; 95% CI 1.55 to 6.65) (Irvine et al., 2017). It is therefore possible that some 
patients who did not have a coeliac serology test were erroneously given a diagnosis of IBS. 
There are also other conditions that may mimic IBS, such as BAM, small intestinal bacterial 
overgrowth, or fructose and lactose intolerance (Aziz et al., 2015; Ford et al., 2009; Wilder-
Smith et al., 2013), which are not excluded by a negative colonoscopy. These were not 
screened for routinely in this study, which was conducted within usual clinical practice. 
However, the prevalence of unequivocal small intestinal bacterial overgrowth in patients 
presenting with symptoms suggestive of IBS is probably less than 5% (Posserud et al., 2007). 
The modifications to symptom-based criteria in the current study enhance the diagnosis of 
IBS, but do not necessarily identify actionable features of the disorder. Thus, the recently 
validated additional measurements of colonic transit or of bile acid metabolism may still 
provide the best biomarkers to individualise therapy in subsets of IBS patients (Camilleri et 
al., 2014; Camilleri, 2015). Finally, the approaches suggested by these findings may not 
completely change physician behaviour, due to uncertainty or fear of a missed organic 
diagnosis, which is reflected by the fact that significantly more patients who met the Rome III 
criteria for IBS were referred for colonoscopy in this study. However, further proof of the 
validity of this approach in prospective cohorts will enhance the confidence with which 
physicians can make a positive diagnosis of IBS, which was the intent of the original 
symptom-based criteria proposed by Manning et al. (Manning et al., 1978).  
 
 
186 
 
 In summary, the performance of the Rome III criteria in diagnosing IBS was similar 
to that observed in a previous validation study from a Canadian cohort (Ford et al., 2013). 
Important novel findings from this study were that modifying these criteria, with 
questionnaires concerning nocturnal symptoms, anxiety, depression, or somatisation, in 
addition to simple blood tests, improved their diagnostic performance. An inexpensive 
clinical test that combines symptoms with clinical markers, which is easily administered 
in a routine care setting, and accurate enough to allow the physician to confidently make a 
positive diagnosis of IBS would be highly desirable, and may have important implications 
for enhanced value care.  
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CHAPTER 5 
Derivation and Validation of a Diagnostic Test for 
Irritable Bowel Syndrome Using Latent Class 
Analysis 
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5.1 Introduction  
 Although modifications to the Rome III criteria described in the previous chapter, in 
some instances, resulted in acceptable positive LRs for a diagnostic test for IBS, one 
criticism that can be made is that these modifications could result in a test similar to the 
Kruis statistical model (Kruis et al., 1984), which although shown to be accurate, was not 
widely used, probably as a result of its complexity. 
 As previously discussed, LCA is a statistical method that hypothesises the existence 
of one or more unobserved groups (latent classes) among a set of observed categorical 
variables, such as patient-reported symptoms. For example, symptoms that are reported 
by patients with IBS, or are known to be associated with IBS, could be incorporated into a 
latent class model, and it can then be observed how individuals cluster into IBS or non-
IBS groups naturally, based on these variables. Individuals are classified according to 
their most likely latent class membership probabilities, that is the probability for a 
randomly selected member of a given latent class, a given response pattern will be 
observed. Although this method may initially appear overly complex for a diagnostic test, 
in the modern era of smartphones, an easy to use app could be developed, in which 
symptoms are inputted by the patient in the outpatient waiting room whilst waiting to see 
a physician, and then the relevant physical findings and blood test results are incorporated 
into the app during the clinician’s assessment, which would then provide an overall 
probability of the patient having IBS.  
 Although there are only a few examples of LCA being used in gastroenterology 
(Christensen et al., 1992; Koloski et al., 2015), this statistical technique has been used 
successfully in other medical conditions where, as is the case in IBS, a gold standard 
diagnostic test is lacking (Rindskopf and Rindskopf, 1986; Ferraz et al., 1995; LaJoie et 
al., 2005; Kato et al., 2010). LCA was therefore applied to two unselected patient cohorts, 
 
 
189 
 
recruited prospectively, who were referred to secondary care gastroenterology services for 
investigation of their GI symptoms in Canada and the UK, and who answered identical 
questionnaires. The aims of this study were to develop a latent class model that could 
detect previously unobserved IBS and non-IBS latent classes using intestinal and extra-
intestinal symptom data, and then to assess the ability of the model to correctly identify 
IBS, if used as a diagnostic test.  
 
5.2. Methods 
 
5.2.1 Participants and Settings 
 In both studies, unselected patients >16 years of age referred from primary care to 
secondary care for investigation of lower GI symptoms were considered eligible. There 
were no exclusion criteria, other than an inability to understand written English, as the 
questionnaires were self-administered. Potentially eligible participants were approached at 
their first clinic visit, and those agreeing to participate provided written informed consent 
at that visit. All questionnaires were completed prior to the patient’s consultation with a 
gastroenterologist. The questionnaires used in both studies collected the same 
demographic data, and in both studies we used the validated Rome III questionnaire to 
collect data concerning individual GI symptom items, using Likert scales (Whitehead 
WE, 2006). The PHQ-15 was used to assess for evidence of somatisation-type behaviour 
(Kroenke et al., 2002). 
 In Canada, patients were recruited at the outpatient clinics of McMaster University 
Medical Centre and St Joseph’s Healthcare, two hospitals in Hamilton, Ontario, serving a 
local population of more than 500,000. The Hamilton Health Sciences and McMaster 
University research ethics board approved the study in January 2008 and recruitment 
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continued until December 2012. The data from these patients were used to derive a latent 
class model to predict the presence of IBS. 
 The UK patients were recruited at the outpatient clinics of Leeds Teaching Hospitals 
NHS Trust, West Yorkshire as previously described. We used these patients to validate 
the latent class model derived from the patients contained within the Canadian dataset.  
 
5.2.2. Data Collection and Synthesis 
 
5.2.2.1 Demographic and Symptom Data 
 All demographic and symptom data were collected prospectively from the 
questionnaire at the initial clinic visit. Questionnaire data were entered into a database by 
trained researchers who were not involved in the clinical care of the patients; therefore 
ensuring assessors were blinded to symptom status. Demographic data of interest included 
age, height (in metres), and weight (in kilograms), from which BMI was calculated, 
gender, tobacco and alcohol use, marital status, educational level, and ethnicity.  
 
5.2.2.2 Colonoscopic and Histopathological Data 
 In both studies, all patients underwent colonoscopy to the caecum or terminal ileum, 
using Pentax colonoscopes in the Canadian study, and Olympus or Fujinon colonoscopes 
in the UK study. All endoscopists performing colonoscopic examinations were blinded to 
the questionnaire data of the patient. Biopsy specimens were obtained at the discretion of 
the endoscopist performing the colonoscopy, and were interpreted by experienced GI 
histopathologists, who were again blinded to the questionnaire data of the patient. 
Findings classified as being consistent with organic disease at colonoscopy, or after 
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histopathological examination of biopsy specimens, in both studies are the same as those 
described in Table 9. 
 
5.2.2.3 Data Incorporated into the Latent Class Model 
 Individual symptoms were used to identify naturally occurring clusters within the 
data. All intestinal symptoms that have been reported to be associated with IBS were 
considered, such as upper and lower abdominal pain or discomfort, abdominal bloating 
(Ryu et al., 2016), dyspepsia (Rasmussen et al., 2015; Ford et al., 2010), gastro-
oesophageal reflux-type symptoms (Lovell and Ford, 2012) and nausea (Van Oudenhove 
et al., 2016). The absence of alarm signs or symptoms, such as weight loss or rectal 
bleeding, were not considered in the model, as it has been shown previously that these do 
not differentiate between IBS and organic disease with any great accuracy (Whitehead et 
al., 2006; Ford et al., 2013). Nor were demographic data, such as age or gender, included 
as the aim of the model was to identify naturally occurring clusters in patient-reported 
symptoms that could be used to distinguish between IBS and non-IBS latent classes. LCA 
assumes that there is no dependent association between variables entered into the model 
(Moayyedi et al., 2004). An example of this would be when the presence of one symptom 
is dependent on the presence or absence of another symptom, such as a change in stool 
frequency or form, in association with abdominal pain, as seen in the Rome IV criteria for 
IBS (Mearin et al., 2016). The full criteria would therefore be unsuitable to incorporate 
into such a model. However, if an individual reported abdominal pain, or an increased 
stool frequency, as symptoms independent of each other, then these symptoms would be 
suitable to incorporate into the model.  
 Individual items from the PHQ-15 questionnaire were also considered, as a recent 
study showed that both mean somatisation scores and mean number of somatic symptom 
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items were higher in patients with IBS, when compared with other patients with GI 
symptoms that did not meet criteria for IBS (Patel et al., 2015). In particular, the 
prevalence of nine of the 12 extra-intestinal symptoms that are included in the PHQ-15 
was found to be statistically significantly higher in IBS patients. These nine items were 
therefore included in the latent class model. The variables incorporated into the model are 
shown in Table 15. 
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     Table 15. Individual Symptom Items Included in the Latent Class Model. 
 
     
 
Presence of the following symptoms in the preceding 3 months  
Heartburn 
Fullness after a regular-sized meal 
Early satiety 
Upper abdominal discomfort 
Nausea 
Belching 
Lower abdominal discomfort 
Abdominal bloating 
<3 bowel movements per week 
Hard or lumpy stools 
>4 bowel movements per day 
Loose, mushy, or watery stool 
Mucus per rectum 
PHQ-9 somatic symptom items  
Back pain 
Arm, leg, or joint pain 
Menstrual cramps or other period problems 
Headaches  
Dizziness  
Heart pounding or racing 
Pain or problems during sexual intercourse 
Tired or low in energy 
Trouble sleeping 
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5.2.2.4 Reference Standard to Define the Presence of IBS 
 The reference standard used to define the presence of IBS in both study populations 
was lower abdominal pain or discomfort occurring at least once a week, in association 
with a change in bowel habit, and in the absence of organic lower GI disease after 
colonoscopy and histopathological examination of colonic biopsies, if obtained, which 
would explain these symptoms. Exclusion of coeliac disease with distal duodenal biopsy 
was also undertaken in both studies, if coeliac serology was positive.  
 
5.2.3 Statistical Analysis 
 The statistical program LatentGOLD version 4.5 (Vermunt and Magidson, 2005, 
Statistical Innovations, Inc., Belmont, MA, USA) was used to perform LCA. The modal 
assignment, which places individuals in the latent class in which they have the highest 
probability of membership was used. The latent class model was derived using the 
Canadian dataset, and an identical model was then applied to the UK dataset as a means 
of validating it. In order to determine the optimum number of classes that best fit the data, 
up to six latent class models were used, and the number of classes that best fit the data 
was determined using the likelihood ratio chi-squared (LR2) statistic, and parsimony 
indices, which help in maintaining a balance between goodness-of-fit and model 
complexity. The parsimony indices used were: the number of parameters, the Akaike 
information criterion (AIC), and the Bayesian information criterion (BIC). In general, 
smaller values correspond to more parsimonious models.  
 The Wald statistical test was used to determine the significance of the responses 
given by the participants in the Canadian study, when deriving the latent class model. A P 
value < 0.05 means that the knowledge of the response for a particular symptom in the 
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model contributes in a significant way to discriminating between the clusters (Vermunt 
and Magidson, 2005).  
 Once individual membership to a latent class was derived, and the IBS and non-IBS 
latent classes determined based on their characteristics, correct latent class membership 
for each individual was calculated by comparing against the reference standard for IBS. 
From this we calculated the sensitivity, specificity, PPVs, NPVs, and positive and 
negative LRs of the latent class model, when compared with the reference standard, using 
a Microsoft Excel spreadsheet (2013 Edition; Microsoft Corp, Redmond, WA).  
 As LCA was used to calculate the probability of having IBS, this means it was 
possible to vary the discrimination threshold utilised in the model. In a diagnostic test for 
IBS, it is important that the false positive rate of the test is minimised, and therefore the 
risk of missing organic GI disease is low. ROC curves were constructed, and were used to 
maximise specificity over sensitivity, in order to calculate the maximum positive LR 
available for the latent class model. The AUC was calculated to assess the accuracy of the 
model in differentiating IBS from organic disease. These analyses were performed using 
SPSS for Windows version 21.0 (SPSS Inc, Chicago, IL, USA). 
 
5.3 Results 
 
5.3.1 Demographics 
 There were 4224 consecutive patients recruited into the Canadian study between 
January 2008 and December 2012. Of these, 1981 (46.9%) underwent colonoscopy for 
investigation of their symptoms and therefore provided data for the derivation of the latent 
class model. Mean age of those undergoing colonoscopy was 49.3 years (SD 17.1 years), 
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1251 (63.1%) were female and 1787 (90.2%) were White Caucasian. The prevalence of 
IBS in the study population as defined by the reference standard was 19.9% (n = 394). 
 Of the 1002 consecutive patients recruited to the UK study between January 2014 
and December 2015, 360 (35.9%) underwent colonoscopic investigation for their 
symptoms, and therefore provided data to validate the latent class model. The mean age of 
those who underwent colonoscopy was 53.9 years (SD 16.5 years), 236 (65.6%) were 
female and 329 (91.4%) were White Caucasian. The prevalence of IBS was higher in the 
UK study at 27.5% (n = 99; P = 0.001 vs. the Canadian dataset).  
 Demographics of those undergoing colonoscopic examination in the Canadian and 
UK studies are shown in Table 16. Those in the UK study were older, but there were no 
other significant differences between individuals in the two studies. The prevalence of 
organic GI disease in the Canadian study was 20.6% compared with 16.7% in the UK 
study (P = 0.10). The breakdown of organic GI diseases in the two patient cohorts is 
detailed in Table 17. The prevalence of all types of idiopathic IBD was significantly 
higher in the Canadian study, and the prevalence of microscopic colitis was significantly 
higher in the UK study. 
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Table 16. Demographics and Baseline Characteristics of Those Undergoing   
Colonoscopy in the Canadian and UK studies. 
 
 Canadian 
study 
(n = 1981) 
UK study 
(n = 360) 
P 
Value* 
Mean age in years (SD) 
 
49.3 (17.1) 53.9 (16.5) 0.006 
Mean BMI (SD) 
 
27.3 (6.0) 27.1 (5.9) 0.61 
Female gender (%) 
 
1251 (63.1) 236 (65.6) 0.42 
Tobacco use (%) 409 (20.6) 86 (23.9) 
 
0.19 
Alcohol use (%) 1165 (58.8) 195 (54.2) 
 
0.11 
Married or co-habiting (%) 1212 (61.2) 203 (56.4) 0.10 
University graduate or Postgraduate 
level of education (%)  
467 (23.6) 68 (18.9) 0.06 
White Caucasian ethnicity (%) 1787 (90.2) 329 (91.4) 0.55 
*P value for independent samples t-test for continuous data and Pearson χ2    
for comparison of categorical data. 
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Table 17. Prevalence of Organic Disease in the Canadian Study In Comparison     
With the UK Study. 
 
 Canadian study 
(n = 1981) 
 
UK study 
(n = 360) 
P value* 
UC (%) 95 4 
 
0.0005 
Crohn’s disease (%) 136 7 
 
0.0001 
IBD-unclassifiable (%) 66 4 0.02 
Non-specific GI ulceration (%) 7 5 0.03 
Collagenous colitis (%) 8 17 0.0001 
Lymphocytic colitis (%) 25 12 0.009 
Colorectal cancer (%) 47 4 
 
0.17 
Coeliac disease (%) 24 7 
 
0.31 
*P value for Fisher’s exact test for comparison of categorical data. 
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5.3.2 Assessment of Model Fit 
 In order to determine the optimum number of classes that best fit the data, up to six 
latent class models were used. Using trends in the LR2 statistic, BIC, and AIC it was 
determined that a four-class solution best fitted the Canadian dataset, and maintained the 
optimum balance between goodness-of-fit and model complexity. The P value for the 
Wald statistical test was < 0.05 for all the symptoms entered into the latent class model 
derived from the Canadian dataset (Table 18).  
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Table 18. LR2 Statistic and Parsimony Indices Values for Six Latent Classes Derived 
from the Canadian Dataset. 
 
Number of 
classes 
 
Likelihood 
ratio chi-
squared 
statistic 
Bayesian 
information 
criterion 
 
Akaike 
information 
criterion 
Number of 
parameters 
2 66328.69 
 
88393.42 
 
87912.57 
 
86 
 
3 65089.70 87329.03 
 
86719.57 
 
109 
 
4 64445.44 
 
86859.37 
 
86121.31 
 
132 
 
5 63995.82 86584.35 
 
85717.69 
 
155 
 
6 63656.78 
 
86419.91 85424.65 178 
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5.3.3 Description of the Latent Class Model Clusters 
 The clinical characteristics of each class in the model in the Canadian and UK 
studies are shown in Table 19 and Table 20 respectively. In the Canadian study, the latent 
class that was predominantly IBS represented 20.8% of the population (n = 412), and in 
the UK study, 26.1% of the study population (n = 94). In the Canadian study, in the 
preceding 3 months, the IBS class were more likely to experience the following 
symptoms: heartburn, feeling uncomfortably full after a meal, inability to finish a regular 
sized meal, pain or burning in the upper abdomen, bothersome nausea, and bothersome 
belching, all at a frequency of every day, as well as bloating or distension occurring most 
of the time, than when compared with the non-IBS classes, as well as experiencing many 
of the extra-intestinal somatisation symptoms at a greater severity. However, although the 
IBS class was more likely to experience discomfort or pain in the lower abdominal pain 
once a week or more, non-IBS class 3 was more likely to experience the symptom of 
frequent loose, mushy, or watery stools at a frequency of ≥75%, and to report always 
having ≥4 bowel movements per day, than when compared with the IBS class. 
 In the UK study, in the previous 3 months, the IBS class were more likely to 
experience the following: feeling uncomfortably full after a meal, inability to finish a 
regular sized meal, bothersome nausea, and discomfort or pain in the lower abdomen 
every day, loose, mushy, or watery stools, ≥4 bowel movements per day, and bloating and 
distension occurring always, or 100% of the time. The majority of somatisation symptoms 
were also more severe. The IBS class experienced similar levels of heartburn, pain or 
burning in the upper abdomen, and bothersome belching to that reported by non-IBS class 
2, who also experienced frequent somatisation symptoms, although to a lesser severity 
than the IBS class. 
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     Table 19. Clinical Characteristics of the IBS and non-IBS Latent Classes in the Canadian Model. 
 
       Proportion of patients in each latent class  
 IBS class 
(n = 412) 
Non-IBS class 1  
(n = 648) 
Non-IBS class 2 
(n = 562) 
Non-IBS class 3 
(n = 359) 
Female gender 
 
0.8141 0.4426 0.7188 0.6201 
Age <40 years 
 
0.4122 0.1665 0.2204 0.4372 
Symptoms occurring within 
the last 3 months 
    
Heartburn 
Never 
Less than once a week 
Once a week or more 
Every day 
 
0.1867 
0.2901 
0.3549 
0.1682 
 
0.6845 
0.2413 
0.0670 
0.0072 
 
0.4041 
0.3303 
0.2126 
0.0530 
 
0.4768 
0.3198 
0.1689 
0.0345 
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Uncomfortably full after a 
meal 
Never 
Less than once a week 
Once a week or more 
Every day 
 
 
0.0292 
0.0815 
0.3408 
0.5484 
 
 
0.8096 
0.1465 
0.0397 
0.0041 
 
 
0.3397 
0.2537 
0.2841 
0.1224 
 
 
0.3757 
0.2569 
0.2634 
0.1040 
Unable to finish a regular 
sized meal 
Never 
Less than once a week 
Once a week or more 
Every day 
 
 
0.1801 
0.1809 
0.3365 
0.3025 
 
 
0.8682 
0.1055 
0.0237 
0.0026 
 
 
0.4557 
0.2306 
0.2160 
0.0978 
 
 
0.5038 
0.2280 
0.1910 
0.0773 
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Pain or burning in the 
upper abdomen 
Never 
Less than once a week 
Once a week or more 
Every day 
 
 
0.1568 
0.1389 
0.3718 
0.3325 
 
 
0.8467 
0.1071 
0.0409 
0.0052 
 
 
0.4794 
0.1925 
0.2334 
0.0946 
 
 
0.4503 
0.1928 
0.2492 
0.1077 
Bothersome nausea 
Never 
Less than once a week 
Once a week or more 
Every day 
 
0.0650 
0.1740 
0.4411 
0.3199 
 
0.8230 
0.1499 
0.0259 
0.0013 
 
0.3736 
0.3157 
0.2528 
0.0579 
 
0.4128 
0.3141 
0.2264 
0.0467 
Bothersome belching 
Never 
Less than once a week 
Once a week or more 
Every day 
 
0.2962 
0.1752 
0.2141 
0.3145 
 
0.7834 
0.1409 
0.0524 
0.0234 
 
0.4896 
0.1942 
0.1593 
0.1570 
 
0.5646 
0.1907 
0.1331 
0.1117 
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Discomfort or pain in the 
lower abdomen 
Never 
Less than once a week 
Once a week or more 
Every day 
 
 
0.0372 
0.1105 
0.3932 
0.4591 
 
 
0.5798 
0.2583 
0.1378 
0.0241 
 
 
0.3027 
0.2787 
0.3073 
0.1112 
 
 
0.1159 
0.1989 
0.4091 
0.2762 
<3 bowel movements per 
week 
Never / rarely 
Sometimes 
Often 
Most of the time 
Always 
 
 
0.5942 
0.1706 
0.0890 
0.0762 
0.0699 
 
 
0.8520 
0.1090 
0.0253 
0.0097 
0.0040 
 
 
0.6056 
0.1700 
0.0867 
0.0726 
0.0651 
 
 
0.8681 
0.1006 
0.0212 
0.0073 
0.0027 
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Hard or lumpy stools 
Never / rarely 
About 25% of the time 
About 50% of the time 
About 75% of the time 
Always, 100% of the time 
 
0.3712 
0.3119 
0.1596 
0.1178 
0.0395 
 
0.6083 
0.2778 
0.0772 
0.0310 
0.0056 
 
0.3025 
0.2991 
0.1801 
0.1565 
0.0617 
 
0.6514 
0.2598 
0.0631 
0.0221 
0.0035 
≥4 bowel movements per 
day 
Never / rarely 
Sometimes 
Often 
Most of the time 
Always 
 
 
0.2879 
0.2738 
0.1852 
0.1223 
0.1307 
 
 
0.6404 
0.2568 
0.0732 
0.0204 
0.0092 
 
 
0.7211 
0.2185 
0.0471 
0.0099 
0.0034 
 
 
0.1432 
0.1968 
0.1924 
0.1837 
0.2838 
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Mushy, watery, or loose 
stools 
Never / rarely 
About 25% of the time 
About 50% of the time 
About 75% of the time 
Always, 100% of the time 
 
 
0.0964 
0.2017 
0.2149 
0.3147 
0.1723 
 
 
0.4479 
0.3389 
0.1305 
0.0691 
0.0137 
 
 
0.4717 
0.3354 
0.1214 
0.0604 
0.0112 
 
 
0.0320 
0.1030 
0.1684 
0.3785 
0.3181 
Mucus in the bowel 
movement 
Never / rarely 
Sometimes 
Often 
Most of the time 
Always 
 
 
0.2473 
0.2978 
0.2301 
0.1418 
0.0831 
 
 
0.7592 
0.2013 
0.0343 
0.0046 
0.0006 
 
 
0.6902 
0.2432 
0.0550 
0.0099 
0.0017 
 
 
0.2785 
0.3090 
0.2201 
0.1249 
0.0674 
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Bloating or distension 
Never / rarely 
Sometimes 
Often 
Most of the time 
Always 
 
0.0173 
0.0799 
0.3397 
0.5572 
0.0059 
 
0.6514 
0.2489 
0.0878 
0.0119 
0.0000 
 
0.2150 
0.2823 
0.3422 
0.1600 
0.0005 
 
0.1282 
0.2322 
0.3882 
0.2503 
0.0010 
PHQ symptoms 
experienced during the past 
4 weeks 
    
Back pain 
No 
A little 
A lot 
 
0.0487 
0.3183 
0.6331 
 
0.5580 
0.3681 
0.0739 
 
0.2445 
0.4749 
0.2806 
 
0.2775 
0.4750 
0.2475 
Arm, leg, or joint pain 
No 
A little 
A lot 
 
0.1373 
0.3414 
0.5212 
 
0.4995 
0.3499 
0.1506 
 
0.2744 
0.3882 
0.3373 
 
0.3550 
0.3865 
0.2585 
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Period pain 
No 
A little 
A lot 
 
0.5491 
0.2383 
0.2125 
 
0.8793 
0.0981 
0.0225 
 
0.7275 
0.1805 
0.0920 
 
0.6788 
0.2001 
0.1212 
Headache 
No 
A little 
A lot 
 
0.0925 
0.4318 
0.4757 
 
0.6478 
0.3158 
0.0363 
 
0.3674 
0.4829 
0.1498 
 
 
0.3676 
0.4828 
0.1496 
Dizziness 
No 
A little 
A lot 
 
0.1457 
0.5175 
0.3368 
 
0.8378 
0.1568 
0.0054 
 
0.4801 
0.4445 
0.0754 
 
0.5062 
0.4276 
0.0662 
Palpitations 
No 
A little 
A lot 
 
0.3059 
0.4519 
0.2421 
 
0.8754 
0.1188 
0.0058 
 
0.5658 
0.3539 
0.0803 
 
0.6901 
0.2712 
0.0387 
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Dyspareunia 
No 
A little 
A lot 
 
0.5091 
0.2607 
0.2302 
 
0.9127 
0.0763 
0.0110 
 
0.8073 
0.1467 
0.0460 
 
0.8502 
0.1204 
0.0294 
Feeling tired or low in 
energy 
No 
A little 
A lot 
 
 
0.0018 
0.0888 
0.9094 
 
 
0.4128 
0.4739 
0.1133 
 
 
0.0478 
0.3665 
0.5857 
 
 
0.0369 
0.3340 
0.6291 
Insomnia 
No 
A little 
A lot 
 
0.0345 
0.2349 
0.7306 
 
0.5517 
0.3480 
0.1003 
 
0.1918 
0.4093 
0.3990 
 
0.2237 
0.4186 
0.3577 
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     Table 20. Clinical Characteristics of the IBS and non-IBS Latent Classes in the UK Model. 
 
                                                                                Proportion of patients in each latent class 
 IBS class 
(n = 94) 
Non-IBS class 1 
(n = 106) 
Non-IBS class 2 
(n = 86) 
Non-IBS class 3 
(n = 74) 
Female gender 
 
0.7849 0.5779 0.7345 0.5080 
Age <40 years 
 
0.3427 0.2332 0.2241 0.0008 
Symptom occurring within 
the last 3 months 
    
Heartburn  
Never 
Less than once a week 
Once a week or more 
Every day 
 
0.2366 
0.2861 
0.2988 
0.1786 
 
0.7052 
0.2238 
0.0614 
0.0096 
 
0.2635 
0.2946 
0.2846 
0.1573 
 
0.6704 
0.2413 
0.0750 
0.0133 
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Uncomfortably full after a 
meal  
Never 
Less than once a week 
Once a week or more 
Every day 
 
 
0.1224 
0.1613 
0.3179 
0.3983 
 
 
0.7621 
0.1695 
0.0564 
0.0119 
 
 
0.3158 
0.2354 
0.2626 
0.1862 
 
 
0.7959 
0.1525 
0.0437 
0.0080 
Unable to finish a regular 
sized meal  
Never 
Less than once a week 
Once a week or more 
Every day 
 
 
0.2976 
0.1760 
0.3000 
0.2264 
 
 
0.7994 
0.1287 
0.0597 
0.0123 
 
 
0.4529 
0.1908 
0.2317 
0.1246 
 
 
0.7663 
0.1411 
0.0749 
0.0176 
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Pain or burning in the 
upper abdomen  
Never 
Less than once a week 
Once a week or more 
Every day 
 
 
0.2918 
0.1801 
0.3021 
0.2260 
 
 
0.7845 
0.1369 
0.0649 
0.0137 
 
 
0.2852 
0.1788 
0.3046 
0.2314 
 
 
0.8659 
0.0991 
0.0308 
0.0043 
Bothersome nausea 
Never 
Less than once a week 
Once a week or more 
Every day 
 
0.1920 
0.2195 
0.4126 
0.1759 
 
0.7259 
0.1871 
0.0793 
0.0076 
 
0.3290 
0.2543 
0.3234 
0.0933 
 
0.8951 
0.0896 
0.0147 
0.0006 
Bothersome belching 
Never 
Less than once a week 
Once a week or more 
Every day 
 
0.4103 
0.1422 
0.1932 
0.2544 
 
0.7075 
0.1309 
0.0949 
0.0667 
 
0.3600 
0.1373 
0.2053 
0.2974 
 
0.7720 
0.1175 
0.0701 
0.0405 
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Discomfort or pain in the 
lower abdomen 
Never 
Less than once a week 
Once a week or more 
Every day 
 
 
0.0401 
0.0712 
0.3741 
0.5146 
 
 
0.3249 
0.1911 
0.3325 
0.1515 
 
 
0.3259 
0.1912 
0.3319 
0.1510 
 
 
0.7766 
0.1393 
0.0739 
0.0103 
<3 bowel movements per 
week 
Never / rarely 
Sometimes 
Often 
Most of the time 
Always 
 
 
0.7608 
0.1403 
0.0386 
0.0333 
0.0270 
 
 
 
0.8306 
0.1178 
0.0249 
0.0165 
0.0103 
 
 
 
0.6299 
0.1595 
0.0601 
0.0713 
0.0792 
 
 
0.8283 
0.1187 
0.0253 
0.0170 
0.0107 
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Hard or lumpy stools 
Never / rarely 
About 25% of the time 
About 50% of the time 
About 75% of the time 
Always, 100% of the time 
 
0.6030 
0.2403 
0.1067 
0.0437 
0.0063 
 
 
0.6052 
0.2398 
0.1058 
0.0431 
0.0062 
 
0.3924 
0.2586 
0.1897 
0.1286 
0.0307 
 
0.6935 
0.2106 
0.0712 
0.0222 
0.0024 
≥4 bowel movements per 
day 
Never / rarely 
Sometimes 
Often 
Most of the time 
Always 
 
 
0.0627 
0.1927 
0.2252 
0.2328 
0.2866 
 
 
0.1740 
0.3281 
0.2354 
0.1494 
0.1130 
 
 
0.5592 
0.3413 
0.0792 
0.0163 
0.0040 
 
 
0.8671 
0.1256 
0.0069 
0.0003 
0.0000 
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Mushy, watery, or loose 
stools 
Never / rarely 
About 25% of the time 
About 50% of the time 
About 75% of the time 
Always, 100% of the time 
 
 
0.0113 
0.1010 
0.1651 
0.4040 
0.3185 
 
 
0.0545 
0.2639 
0.2348 
0.3126 
0.1341 
 
 
0.2339 
0.4739 
0.1764 
0.0982 
0.0176 
 
 
0.7259 
0.2559 
0.0166 
0.0016 
0.0001 
Mucus in the bowel 
movement 
Never / rarely 
Sometimes 
Often 
Most of the time 
Always 
 
 
0.2925 
0.3352 
0.2029 
0.1122 
0.0572 
 
 
0.5501 
0.3184 
0.0973 
0.0272 
0.0070 
 
 
0.6072 
0.2953 
0.0758 
0.0178 
0.0038 
 
 
0.9193 
0.0772 
0.0034 
0.0001 
0.0000 
 
 
217 
 
Bloating or distension 
Never / rarely 
Sometimes 
Often 
Most of the time 
Always 
 
0.0504 
0.0785 
0.0026 
0.4511 
0.4174 
 
0.3775 
0.2513 
0.0036 
0.2635 
0.1042 
 
0.1839 
0.1790 
0.0037 
0.4014 
0.2321 
 
0.7181 
0.2214 
0.0015 
0.0498 
0.0091 
PHQ symptoms 
experienced during the past 
4 weeks 
    
Back pain 
No 
A little 
A lot 
 
0.1184 
0.3956 
0.4860 
 
0.5704 
0.3504 
0.0791 
 
0.2157 
0.4457 
0.3386 
 
0.6349 
0.3096 
0.0555 
Arm, leg, or joint pain 
No 
A little 
A lot 
 
0.1891 
0.2998 
0.5112 
 
0.5314 
0.2939 
0.1747 
 
0.2952 
0.3235 
0.3812 
 
0.5482 
0.2885 
0.1633 
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Period pain 
No 
A little 
A lot 
 
0.7846 
0.1433 
0.0721 
 
0.8719 
0.0978 
0.0303 
 
0.7678 
0.1507 
0.0815 
 
0.9495 
0.0447 
0.0058 
Headache 
No 
A little 
A lot 
 
0.2925 
0.4326 
0.2749 
 
0.6792 
0.2735 
0.0473 
 
0.2633 
0.4320 
0.3046 
 
0.8891 
0.1055 
0.0054 
Dizziness 
No 
A little 
A lot 
 
0.2852 
0.5066 
0.2082 
 
0.7748 
0.2118 
0.0134 
 
0.3990 
0.4719 
0.1292 
 
0.7797 
0.2076 
0.0128 
Palpitations 
No 
A little 
A lot 
 
0.3239 
0.4404 
0.2357 
 
0.8167 
0.1695 
0.0138 
 
0.6383 
0.3045 
0.0572 
 
0.8838 
0.1108 
0.0055 
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Dyspareunia 
No 
A little 
A lot 
 
0.6543 
0.2063 
0.1395 
 
0.9143 
0.0731 
0.0125 
 
0.9236 
0.0662 
0.0102 
 
0.9981 
0.0019 
0.0000 
Feeling tired or low in 
energy 
No 
A little 
A lot 
 
 
0.0087 
0.1442 
0.8472 
 
 
0.1771 
0.4386 
0.3843 
 
 
0.0442 
0.2886 
0.6672 
 
 
0.2995 
0.4555 
0.2450 
Insomnia 
No 
A little 
A lot 
 
0.1015 
0.2765 
0.6220 
 
0.4616 
0.3362 
0.2023 
 
0.2161 
0.3405 
0.4434 
 
0.5852 
0.2933 
0.1215 
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5.3.4 Accuracy of the Latent Class Model 
 In the Canadian dataset, the latent class model was able to predict a diagnosis of IBS 
with a sensitivity of 44.7% and specificity of 85.3%. Positive and negative LRs were 3.03 
and 0.65 respectively (Table 21). Following construction of a ROC curve (Figure 10), 
specificity was maximised at 92.7%, with a sensitivity of 28.7%, resulting in a maximum 
positive LR of 3.93 and a negative LR of 0.77. The AUC was 0.77. Performance of the 
latent class model using data from the UK study was similar, with a sensitivity of 52.5% 
and specificity of 84.3%. Positive and negative LRs were 3.35 and 0.56 respectively 
(Table 21). Following construction of a ROC curve (Figure 11), specificity was 
maximised at 93.0%, with a sensitivity of 29.3%, resulting in a maximum positive LR of 
4.15 and a negative LR of 0.76, with an AUC of 0.79. 
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    Table 21. Sensitivity, Specificity, Likelihood Ratios, and Predictive Values of the   
    Canadian and UK Latent Class Models. 
 
 Sensitivity 
(%) 
Specificity 
(%) 
Positive 
LR 
Negative 
LR 
PPV 
(%) 
NPV 
(%) 
Canadian 
study 
44.7 85.3 3.03 0.65 43.6 85.8 
UK  
Study 
52.5 84.3 3.35 0.56 56.5 82.1 
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Figure 10. Receiver Operating Characteristic Curve for the Canadian Latent Class 
Model. 
 
 
 
Figure 11. Receiver Operating Characteristic Curve for the UK Latent Class Model. 
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5.4. Discussion 
 This study has derived a latent class model for IBS in unselected patients referred to 
a secondary care hospital in Canada. The same model was then validated in unselected 
patients referred to a secondary care hospital in the UK. LCA was used to identify 
naturally occurring clusters in the data incorporated into the model, and it was then 
determined if correct latent class membership was obtained by comparing against the 
reference standard for IBS used in this study. In both cohorts of patients, the IBS class 
was more likely to experience post-prandial symptoms, nausea, lower abdominal pain or 
discomfort, and somatisation symptoms, compared with the non-IBS classes. In the 
Canadian study, following construction of an ROC curve, the model had a positive LR 
approaching 4 when used as a diagnostic test for IBS, and when specificity was 
maximised, whilst in the UK study the positive LR was 4.15. The discriminatory accuracy 
of the two models, as measured by the AUC, were good at 0.77 and 0.79 for the Canadian 
and UK models respectively. 
 The study has a number of strengths. The test performed similarly in two large 
cohorts of patients referred to secondary care. The patient groups studied were 
demographically distinct, with a significant difference in prevalence of both IBS and 
individual organic GI diseases, suggesting that the performance of the test is reliable. As 
the study was conducted in an unselected patient cohort, it means that the results are 
likely to be generalisable to gastroenterologists consulting with patients who have lower 
GI symptoms, including those suggestive of IBS, in usual clinical care. Furthermore, the 
test developed from this study is inexpensive, and should be considered at least as 
accurate as biomarkers, as demonstrated in the previous meta-analysis chapter, and these 
are potentially more expensive.  
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 However, the study does also have limitations. The reference standard used to 
compare the accuracy of the latent class model included some of the symptoms that were 
also used in the model itself. This may have resulted in an overestimation of its accuracy. 
In both populations, the majority of the participants were White Caucasian and, in the UK 
study, tended to be older, meaning that our findings may not be applicable to different 
ethnicities or to younger individuals. Furthermore, not all patients that were recruited into 
the two studies underwent colonoscopy. These patients were therefore not included in the 
latent class model, and some of these excluded patients may have been given a diagnosis 
of IBS based on a physician’s assessment alone. If the diagnosis of IBS were correct in all 
these patients then the true positive rate of the latent class model assessed would have 
been artificially reduced, leading to an underestimation of its accuracy. There was no 
mandate for serological screening to rule out coeliac disease, and the decision to obtain 
biopsy specimens at colonoscopy was at the discretion of the endoscopist, so it is possible 
that cases of coeliac disease or microscopic colitis may have been missed, meaning that 
these patients were incorrectly classified as having IBS. Lastly, as previously discussed, 
the study only used symptom data to differentiate between IBS and non-IBS. It would be 
interesting to note if the addition of clinical tests, such as normal haemoglobin and CRP, 
negative coeliac serology, or normal faecal calprotectin, resulted in improved accuracy of 
the test. 
 There are no other published studies that have used LCA to derive and then validate 
a diagnostic test for IBS. Only one other study has utilised LCA in the diagnosis of 
FGIDs. In a postal questionnaire conducted by Koloski et al. (Koloski et al., 2015), Rome 
III criteria symptoms for IBS-C and CIC were included in a latent class model, with the 
aim of identifying clinical and lifestyle factors that could be used to differentiate between 
the two. Of 3260 participants, 109 met the Rome III criteria for IBS-C, and 206 met the 
 
 
225 
 
threshold for CIC. A two class solution was yielded in which the first class was 75% CIC 
(n = 164) and 25% IBS-C (n = 54), whilst the other class was approximately half CIC (n = 
42) and half IBS-C (n = 55). The CIC-dominant group had lower levels of abdominal 
symptoms, although the mixed group demonstrated higher levels of constipation 
symptoms. The model was unable to reproduce the Rome III criteria differentiation of 
individuals with IBS-C and CIC. The authors concluded that using these criteria to 
distinguish between the two disorders may be, to some degree, artificial and that 
differentiation between the two based on severity of abdominal symptoms may represent 
the way forward. This is in keeping with this study’s findings, which suggest that IBS 
exists as a latent construct, consisting of a combination of both GI and non-GI symptoms. 
Given the significant associations with other GI symptoms, such as heartburn, post-
prandial distress, and nausea that have been observed in this study, as well as extra-
intestinal symptoms, attempting to define IBS as either a discrete FGID based on specific 
symptoms, or even as a purely GI disorder, may therefore be an overly simplistic 
approach. 
 The LCA model derived and validated in the current study compares favourably with 
currently available approaches to diagnosing IBS. As previously discussed, The Rome IV 
criteria are the preferred method for diagnosing IBS (Mearin et al., 2016), but have yet to 
be validated by an independent group, and the Rome III criteria (Longstreth et al., 2006) 
have been validated in one large study (Ford et al., 2013), and performed modestly in 
differentiating IBS from organic disease, with a sensitivity and specificity of 68.8% and 
specificity of 79.5%. Positive and negative LRs were 3.35 and 0.39 respectively. 
 The LCA model has a positive LR of 3.93 and 4.15 in the Canadian and UK cohorts 
respectively. However, the study was conducted in an unselected population referred to 
secondary care, with an IBS prevalence of 23.7% among the two cohorts combined, lower 
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than that used to calculate the post-test probability threshold of 86.5% recommended, in 
the previously discussed study (Shah et al., 2015), as useful for a diagnostic test in IBS. 
This suggests that the performance of the latent class model should be at least comparable 
to that of the previously aforementioned  only commercial biomarker, which had a 
maximum positive LR of 5.2 when validated in an IBS-enriched population (Pimentel et 
al., 2015). Furthermore, the latent class model has the potential for an improvement in its 
accuracy. The addition of relevant biochemical tests, such as faecal calprotectin, may 
result in a reduction in the number of false positives, and therefore an improvement in the 
ability of the model to differentiate IBS from organic lower GI disease.  
 The used of statistical modelling to diagnose IBS may result in a more complex test, 
which is perhaps the reason why the Kruis model (Kruis et al., 1984) has never been 
widely used in routine clinical care. However, as mentioned previously, in the era of 
smartphone apps, data can be inputted into an online statistical model that uses techniques 
such as LCA, to give an accurate probability of IBS that can then be used to aid the 
physician consulting in routine clinical care. 
 Data from this study also provide some interesting insights into possible directions 
for the development of symptom-based diagnostic criteria in the future. The observation 
that patients in the latent class of IBS in both cohorts were more likely to report upper GI 
symptoms consistent with functional dyspepsia, such as early satiety and postprandial 
fullness suggest that, rather than making FGIDs discrete entities, the presence of these co-
existent symptoms are likely to be supportive of a diagnosis of IBS. In addition, in this 
study bloating or distension seemed to be a key feature of IBS, present in over 80% of 
patients. This was first proposed as part of the diagnostic criteria for IBS by Manning et 
al. in 1978  (Manning et al., 1978), but is no longer required in the Rome criteria, and 
should perhaps be re-incorporated into the list of required symptoms for future iterations.  
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 In conclusion, this study has identified the existence of a latent construct for IBS 
consisting of intestinal and extra-intestinal symptoms. Furthermore, a diagnostic test for 
IBS using LCA has been derived and validated. The study has shown that the resulting 
model performs similarly to the Rome III criteria, and is likely to perform as well as 
available commercial biomarkers. Importantly, the test has the potential for improvement 
in its accuracy, and future studies should consider the addition of biochemical markers to 
the model, in order to assess whether this is indeed achievable. 
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CHAPTER 6 
Conclusions 
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There has been much progress in the methods employed to aid in diagnosing IBS 
since the condition was first recognised as a distinct entity, with the development of non-
invasive approaches, such as the symptom-based diagnostic criteria for IBS, and some 
novel biomarkers, which have aided in our understanding of the pathophysiological 
mechanisms underpinning the disorder. However, despite this many physicians still 
consider IBS to be a diagnosis of exclusion. This may be due to the fear of missing 
organic pathology that can mimic IBS, such as colorectal cancer and IBD, but is also 
likely due to the lack of an accurate, simple, and non-invasive diagnostic test for IBS.  
This thesis has examined the accuracy and practicality of all approaches available to 
diagnose IBS, and used these findings to develop novel and non-invasive tests to aid in 
the diagnosis of IBS, which are potentially easily administrable in a clinical setting. 
 A previous systematic review and meta-analysis that assessed the accuracy of 
symptom-based diagnostic criteria showed that these performed only modestly in 
differentiating IBS from organic disease (Ford et al., 2008). However, at the time when 
the review was conducted, neither the Rome II or Rome III criteria had been externally 
validated. Furthermore, the authors did not assess the accuracy of other available 
diagnostic tests, which were out of the scope of the study. An up to date systematic 
review and meta-analysis that took in to account studies assessing the accuracy of the 
remaining iterations of the Rome criteria, as well as more novel techniques, was therefore 
timely.  
 This systematic review assessed the accuracy of symptom-based diagnostic criteria, 
biomarkers, psychological markers, and combinations thereof in diagnosing IBS against 
an accepted reference standard. The study showed that the symptom-based criteria 
performed comparably in accuracy to each other, whilst biomarkers, including novel 
serum and faecal biomarkers (Jones et al., 2014; Ahmed et al., 2013), on the whole 
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performed no better, or were only used to differentiate IBS from health, rather than from 
organic disease, which is more clinically useful. Interestingly, when combinations of 
symptoms, biomarkers and/or psychological markers were used, then for some of these 
tests, for example combining serum biomarkers with psychological markers (Jones et al., 
2014), combining the Rome I criteria with intestinal permeability and faecal calprotectin 
(Tibble et al., 2002), or combining symptoms with blood test results in the Kruis 
statistical model (Kruis et al., 1984) the positive LRs were approaching what would be 
considered an acceptable accuracy for a diagnostic test for IBS (Shah et al., 2015). 
However, these tests have a number of limitations including only differentiating between 
IBS and health in the study from Jones et al. (Jones et al., 2014), and concerns regarding 
applicability for their use in routine clinical care due to the perceived complex nature of 
the tests in the studies from Tibble et al. (Tibble et al., 2002) and Kruis et al. (Kruis et al., 
1984).  
 The findings from the completed systematic review aided in developing the 
hypothesis underpinning the final two results chapters of this thesis. Could the Rome III 
criteria, the accepted diagnostic test for IBS at the time the study was conducted, be 
improved by combining them with other relevant symptoms from the history, markers of 
psychological effect, and/or blood tests?  
 In the first diagnostic test study, questionnaire data from participants included in the 
Leeds study, along with relevant clinical blood test results, were used to modify the Rome 
III criteria, in an attempt to enhance the diagnostic ability of these criteria. Of 1002 
patients recruited to the Leeds study, 318 provided the relevant questionnaire data and 
underwent colonoscopy. In keeping with the findings of the systematic review, 
combinations of different types of markers outperformed single markers alone (in this 
case the Rome III symptom-based diagnostic criteria). All modifications to the Rome III 
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criteria performed better than the Rome III criteria alone, irrespective of the combination 
used. In particular, when the Rome III criteria were combined with markers of high level 
of somatisation, the positive LR increased from 3.87 to 7.27, and this increase was more 
marked when the Rome III criteria were combined with no nocturnal passage of stools 
and high level of somatisation with a positive LR greater than 17. The impressive 
performance of psychological markers, in particular somatisation, in this study is in 
keeping with findings from other investigators, and highlights the large psychological 
component underpinning IBS, as discussed in the first chapter.  
 A potential weakness of combining multiple markers is the resulting increased 
complexity of the test derived. One way to overcome this complexity is to employ 
statistical models, which are able to give a probability of a diagnosis of IBS. LCA is one 
such method, which hypothesises the existence of one of more unobserved groups, so 
called latent classes, amongst a set of observed variables. In the second diagnostic test 
study, two separate patient cohorts from Canada and the UK were included. The LCA 
model was derived using the Canadian dataset, before being validated in the UK dataset. 
Patients were assigned to latent classes, according to the severity of GI symptoms 
associated with IBS, and individual answers from nine items of the PHQ-15 
questionnaire. Each individual item incorporated in to the model was chosen based on 
evidence of an association with IBS. Correct latent class membership was confirmed by 
comparing against an accepted reference standard. In the Canadian cohort of 1981 
individuals, the model had a sensitivity of 44.7% and a specificity of 85.3%. A maximum 
positive LR of 3.93 was achieved following construction of an ROC curve. The model 
performed similarly in the UK database of 360 individuals, with a sensitivity and 
specificity of 52.5% and 84.3%, with a maximum positive LR of 4.15. Performance of the 
diagnostic test was similar to the Rome III criteria.  
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 The work undertaken in this thesis has also highlighted where future research is 
required. It has clearly been shown that tests consisting of one measurable aspect of the 
complex and multifactorial aetiology of IBS are unlikely to provide an accurate and 
acceptable performance. Therefore, combining more than one of these tests, or markers, 
appears to represent the optimum way forward. LCA could simplify the complex process 
of combining markers by the use of technological advances in computer software and 
applications. Although the LCA test derived performed no better than the current 
symptom-based diagnostic criteria, as previously stated, the test has the potential for 
improvement, and future studies could look at enhancing the derived LCA model through 
the addition of non-invasive tests such as faecal calprotectin, or other novel faecal and 
serum biomarkers.  
 This body of work also highlights how the existing symptom-based diagnostic 
criteria could be improved upon. It has been shown that minor modifications such as the 
addition of markers of somatisation and absence of nocturnal symptoms markedly 
improves the diagnostic accuracy of these criteria, and the results from this work could 
inform future iterations of the Rome criteria. Furthermore, findings from the LCA 
diagnostic study indicate that IBS is more likely to be associated with upper GI 
symptoms, such as early satiety and post-prandial fullness, and other symptoms such as 
abdominal bloating and distension, which suggests that there is likely to be significant 
overlap amongst the different FGIDs, and that attempts to classify them as distinct 
disorders is somewhat arbitrary. The model derived in this study not only shows the 
potential for an accurate diagnostic test for IBS, but also highlights that the presence of 
other FGIDs should be considered as supportive evidence for a diagnosis of IBS. This 
issue should therefore also be considered when developing future iterations of the Rome 
criteria. 
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 In summary, this thesis has examined available methods to diagnose IBS and has 
shown that combining symptoms with clinical markers, markers of psychological affect, 
and/or novel biomarkers leads to greater accuracy in diagnosing IBS. The findings from 
the two diagnostic test studies undertaken confirm that this approach may represent the 
way forward in developing an accurate and non-invasive diagnostic test for IBS. 
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Appendix A: Patient Information Sheet 
 
 
 
PATIENT INFORMATION SHEET 
 
PART 1 
 
Study Title: A Study to Validate and Test the Durability of the Rome III criteria for 
Functional Gastrointestinal Disorders Among Patients Referred to Secondary Care. 
 
We would like you to take part in our research study. Before you decide we would like 
you to understand why the research is being done, and what it would involve for you. 
Please take time to read the following information carefully, and talk to others about the 
study if you wish. Ask us if there is anything that is not clear, or if you would like more 
information. 
 
What is the purpose of the study? 
 
Symptoms that are caused by problems with the gastrointestinal (digestive) tract are very 
common. This research study aims to find out how many of those people who suffer from 
these symptoms will have an obvious explanation for them when they are sent for an 
endoscopic examination (camera test) of either their stomach (upper gastrointestinal (GI) 
endoscopy) or large bowel (colonoscopy) or both, and how many people will have no 
explanation for their symptoms. If an obvious cause for the symptoms is found at upper 
GI endoscopy or colonoscopy this is usually known as “organic disease”, whereas if no 
cause is found doctors often call this “functional” disease. This study also aims to find out 
how good the criteria that Gastroenterologists have for classifying functional GI 
disorders, called the Rome III criteria, are at telling the difference between “organic” and 
“functional” disease. Finally, the study is interested in discovering how many people with 
symptoms that are felt to be due to a functional GI disorder when the person is first seen 
by a Gastroenterologist end up being found to have another, organic, cause for their 
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symptoms in the future. We intend to recruit around 4000 people who have these 
symptoms. 
 
In order to help us perform this study we are asking you to answer questionnaires about 
your symptoms, about anxiety, depression, quality of life, other symptoms not related to 
the bowel, and to give us some other personal information, such as your age, gender, 
ethnicity, occupation, marital status, and tobacco and alcohol consumption. All this 
information will be collected at your outpatient clinic appointment or upper GI endoscopy 
or colonoscopy appointment. We will also ask for your permission to access your medical 
records in the future, so that we can see what happens to you, and whether your diagnosis 
changes in the future, and also your permission to contact you in the future with further 
questionnaires.  
 
Why have I been invited? 
 
You have been invited because you are suffering from symptoms that are caused by 
problems with the gastrointestinal tract, have been referred by your general practitioner 
for further tests because of this, and will be attending our clinic or upper GI endoscopy or 
colonoscopy list here at the Leeds General Infirmary or St. James’s University Hospital.   
 
Do I have to take part? 
 
It is up to you to decide whether to join the study. We will describe the study and go 
through this information sheet. If you agree to take part, we will then ask you to sign a 
consent form. You are free to withdraw at any time, without giving a reason. This would 
not affect the standard of care you receive. If you agree to take part, we will send a letter 
to your general practitioner informing them that you are involved in this research study.  
 
What will happen to me if I take part? 
 
If you agree to take part simply fill out the consent form and questionnaires, following the 
instructions provided on each, at your outpatient clinic appointment or your appointment 
for upper GI endoscopy or colonoscopy. Filling out the questionnaires should only take 
you about 30 minutes.  
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What are the possible disadvantages and risks of taking part? 
 
Filling out the questionnaire may make some people worry about their bowel symptoms. 
If you find this to be the case you can discuss this with us during your visit to clinic. 
Please feel free to ask us any questions about your symptoms.  
 
What are the possible benefits of taking part? 
 
We cannot promise the study will help you, but the information we get from this study 
may help to increase our understanding of gastrointestinal symptoms and the causes of 
these symptoms, and may help us to know better how to investigate them in the future. 
 
What if there is a problem? 
 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this is given in part 
2.  
 
Will my taking part in this study be kept confidential? 
 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The detailed information on this is given in part 2.  
 
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision. 
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PART 2 
 
What will happen if I don’t want to carry on with the study? 
 
You are free to withdraw at any time, without giving a reason. This would not affect the 
standard of care you receive. If you withdraw from the study we will destroy your 
questionnaire data. 
 
What if there is a problem? 
 
If you have a concern about any aspect of this study, you should ask to speak to the study 
doctors who will do their best to answer your questions (contact numbers are given 
below).  
If you remain unhappy and wish to complain formally, you can receive further 
information from NHS Direct by calling 0845 4647. 
 
Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of the research will be 
kept strictly confidential, and any information about you which leaves the hospital will 
have your name and address removed so that you cannot be recognised. It will only be 
used for this study. Only the researchers involved in this study will have access to the 
data, which will be retained in a secure area, to which only researchers associated with 
this study have access for 5 years. Following this, it will be disposed of securely. If you 
do agree to take part, we will send a letter to your general practitioner informing them that 
you are involved in this research study.  
 
What will happen to the results of this research study? 
 
The results of this study may be published in a medical journal, but your identity will not 
be revealed. 
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Who is organising this study? 
 
This study is being organised by Leeds General Infirmary and St. James’s University 
Hospital. 
 
Who has reviewed the study? 
 
In order to protect your interests all research in the NHS is looked at by an independent 
group of people, called a Research Ethics Committee. This study has been reviewed and 
given a favourable opinion by Leeds Central Research Ethics Committee. 
 
Further information and contact details: 
 
Dr. Alex Ford (Investigator – Leeds General Infirmary): 0113 2068536 
 
If you have any questions about your rights as a research volunteer, you may either 
contact your study doctors above, or look for further information on the UK clinical 
research collaboration website: 
http://www.ukcrc.org/publications/informationbooklets.aspx 
This website also provides a list of links to other useful websites. 
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Appendix B: Patient Consent Form 
 
CONSENT FORM 
 
Title of project: A Cross-Sectional Survey to Validate and Test the Durability of the Rome III 
criteria for Functional Gastrointestinal Disorders Among Patients Referred to Secondary Care. 
 
Name of researcher: Dr. Alex Ford.        
 Please initial 
I confirm that I have read and understood the information sheet dated 19th 
April 2013 (version 1.0) for the above study. I have had the opportunity 
to consider the information, ask questions and have had these answered 
satisfactorily. 
 
I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving a reason, without my medical care 
or legal rights being affected. 
 
I understand that relevant sections of my medical notes, and data 
collected during the study, may be looked at by individuals from Leeds 
Teaching Hospitals Trust, regulatory authorities, or the NHS trust, where 
it is relevant to my taking part in this research. I give permission for 
these individuals to access my records. 
 
I understand that I may be contacted in the future to complete further 
questionnaires.   
 
I understand that if I agree to take part in this study you will contact my 
general practitioner to inform them of this.  
 
I agree to take part in the above study. 
 
 
 
_______________________  ___________   ___________________ 
Name of patient   Date    Signature 
 
______________________  ___________   ___________________ 
Name of person taking consent Date    Signature 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical 
notes.  
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Appendix C: Patient Symptom Questionnaire 
 
Name:________________________________         Date of birth: _______________ 
 
1. What is your gender? 
□ Male   □ Female   
 
2. What is your age? ______________________________________________________ 
 
3. What is your current marital status? 
□ Married or co-habiting □ Divorced or separated  
□ Never married   □ Widowed    
□ Civil partnership    
  
4. Do you smoke tobacco? 
□ No    □Yes 
 
If yes, how many cigarettes per day? ____________________________________ 
 
5. Do you drink alcohol? 
□ No    □Yes 
 
If yes, how many units per week? ____________________________________ 
 
6. What is your height (in metres, or feet and inches)? ________________________ 
 
7. What is your weight (in kilograms, or pounds)? 
 ________________________ 
 
8. What is your ethnic group? 
□ White Caucasian  □ African    
□ South Asian   □ South East Asian 
□ Middle-Eastern  □ Latin-American   
□ Other (specify) _________________________ 
 
9. What is your occupation? ________________________________________________ 
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10. What is your educational level? 
□ Some secondary school  □ Some university 
□ Completed secondary school  □ University graduate 
□ Some technical school / college □ Postgraduate / professional 
□ Tech school / college graduate 
  
 
11. Is there any family history of: 
      Yes  No 
a. Oesophageal (gullet) cancer  □  □ 
b. Gastric (stomach) cancer   □  □ 
c. Coeliac disease (gluten intolerance) □  □ 
d. Colorectal (bowel) cancer   □  □ 
e. Crohn’s disease    □  □ 
f. Ulcerative colitis    □  □ 
 
 
12. In the last 3 months how often did you have a feeling of a lump, fullness, or 
something stuck in your throat? 
□ Never       Go to question 15 
□ Less than one day a week    
□ One day a week or more    
□ Every day       
 
13.  Have you had this feeling 6 months or 1onger? 
□ No       
□ Yes       
 
14. Does this feeling occur between meals (when you’re not eating)? 
□ No       
□ Yes       
 
15. When you are eating or drinking does it hurt to swallow? 
□ Never or rarely    
□ Sometimes      
□ Often       
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□ Most of the time     
□ Always 
 
 
16. In the last 3 months how often did you have pain or discomfort in the middle of your 
chest (not related to heart problems)? 
□ Never       Go to question 19 
□ Less than one day a week    
□ One day a week or more    
□ Every day       
 
17. Have you had this chest pain 6 months or longer? 
□ No       
□ Yes       
 
18. When you had your chest pain, how often did it feel like burning? 
□ Never or rarely    
□ Sometimes      
□ Often       
□ Most of the time     
□ Always      
 
19. In the last 3 months how often did you have heartburn (a burning discomfort or 
burning pain in your chest) (see picture)? 
 
 
□ Never        Go to question 21 
□ Less than one day a week    
□ One day a week or more    
□ Every day       
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20. Have you had this heartburn (burning discomfort or pain in the chest) 6 months or 
longer? 
□ No       
□ Yes       
 
21. In the last 3 months how often did food or drinks get stuck after swallowing or go 
down slowly through your chest? 
□ Never       Go to question 24 
□ Less than one day a week    
□ One day a week or more    
□ Every day       
 
22. Has this swallowing problem changed over the last 3 months? 
□ Very much better     
□ Better       
□ Same       
□ Worse       
□ Very much worse     
 
23. Have you had this problem 6 months or 1onger? 
□ No       
□ Yes       
 
24. In the last 3 months how often did you feel uncomfortably full after a regular-sized 
meal? 
□ Never       Go to question 26 
□ Less than one day a week    
□ One day a week or more    
□ Every day       
 
25. Have you had this uncomfortable fullness after meals 6 months or 1onger? 
□ No       
□ Yes       
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26. In the last 3 months how often were you unable to finish a regular sized meal? 
□ Never       Go to question 28 
□ Less than one day a week    
□ One day a week or more    
□ Every day       
 
 
27. Have you had this inability to finish regular-sized meals 6 months or 1onger? 
□ No       
□ Yes       
 
28. In the last 3 months how often did you have pain or burning in the middle of your 
abdomen, above your belly button but not in your chest (see picture)? 
 
□ Never       Go to question 32 
□ Less than one day a week    
□ One day a week or more    
□ Every day       
 
29. Have you had this pain or burning 6 months or longer? 
□ No       
□ Yes       
 
30. Did this pain or burning occur and then completely disappear during the same day? 
□ Never or rarely    
□ Sometimes      
□ Often       
□ Most of the time     
□ Always      
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31. Usually how severe was the pain or burning in the middle of your abdomen above 
your belly button? 
□ Very mild      
□ Mild       
□ Moderate      
□ Severe       
□ Very severe      
 
 
32. In the last 3 months how often did you have bothersome nausea (feeling sick)? 
□ Never       Go to question 34 
□ Less than one day a week    
□ One day a week or more    
□ Every day       
 
33. Did this nausea start more than 6 months ago? 
□ No       
□ Yes       
 
34. In the last 3 months how often did you vomit? 
□ Never       Go to question 40 
□ Less than one day a week    
□ One day a week or more    
□ Every day       
 
35. Have you had this vomiting 6 months or longer? 
□ No      
□ Yes      
 
36. Did you make yourself vomit? 
□ Never or rarely    
□ Sometimes      
□ Often       
□ Most of the time     
□ Always 
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37. Did you have vomiting in the last year that occurred in separate episodes of a few 
days and then stopped? 
□ Never or rarely    
□ Sometimes      
□ Often       
□ Most of the time     
□ Always 
 
38. Did you have at least three episodes during the past year? 
□ No      
□ Yes  
 
39. In the last 3 months how often have you vomited blood? 
□ Never or rarely    
□ Sometimes      
□ Often       
□ Most of the time     
□ Always      
 
40. In the last 3 months how often did you experience bothersome belching? 
□ Never       Go to question 42 
□ Less than one day a week    
□ One day a week or more    
□ Every day       
 
41. Did this bothersome belching start more than 6 months ago? 
□ No       
□ Yes       
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42. In the last 3 months how often did you have discomfort or pain anywhere in your 
lower abdomen below your belly button (see picture)? 
 
 
□ Never       Go to question 50 
□ Less than one day a week    
□ One day a week or more    
□ Every day       
 
 
43. For women only: Did this discomfort or pain occur only during your menstrual 
bleeding and not at other times? 
□ No       
□ Yes       
□ Does not apply because I’ve had the menopause or I am male 
 
44. Have you had this discomfort or pain 6 months or longer? 
□ No       
□ Yes       
 
45. How often did this discomfort or pain get better or stop after you had a bowel 
movement? 
□ Never or rarely    
□ Sometimes      
□ Often       
□ Most of the time     
□ Always      
 
 
46. When this discomfort or pain started did you have more frequent bowel 
movements? 
□ Never or rarely    
□ Sometimes      
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□ Often       
□ Most of the time     
□ Always      
 
 
47. When this discomfort or pain started did you have less frequent bowel movements? 
□ Never or rarely    
□ Sometimes      
□ Often       
□ Most of the time     
□ Always      
 
 
48. When this discomfort or pain started were your stools looser? 
□ Never or rarely    
□ Sometimes      
□ Often       
□ Most of the time     
□ Always      
 
49. When this discomfort or pain started were your stools harder? 
□ Never or rarely    
□ Sometimes      
□ Often       
□ Most of the time     
□ Always      
 
50. In the last 1 year have you had a change in your bowel habit? 
□ No       
□ Yes       
 
51. In the last 3 months how often did you have fewer than 3 bowel movements (0-2) per 
week? 
□ Never or rarely    
□ Sometimes      
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□ Often      
□ Most of the time    
□ Always     
 
 
52. In the last 3 months how often did you have hard or lumpy stools?  
□ Never or rarely    
□ About 25% of the time    
□ About 50% of the time    
□ About 75% of the time    
□ Always, 100% of the time    
 
 
53. In the last 3 months how often did you strain during bowel movements?  
□ Never or rarely    
□ Sometimes      
□ Often       
□ Most of the time     
□ Always      
 
54. In the last 3 months how often did you have a feeling of incomplete emptying after 
bowel movements?  
□ Never or rarely    
□ Sometimes      
□ Often       
□ Most of the time     
□ Always      
 
55. In the last 3 months how often did you have a sensation that the stool could not be 
passed (i.e. was blocked) when having a bowel movement?  
□ Never or rarely    
□ Sometimes      
□ Often       
□ Most of the time     
□ Always      
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56. In the last 3 months how often did you press on or around your bottom or remove 
stool in order to complete a bowel movement? 
□ Never or rarely    
□ Sometimes      
□ Often       
□ Most of the time     
□ Always      
 
57. Did any of the symptoms of constipation listed in questions 51 – 56 above begin more 
than 6 months ago? 
□ No       
□ Yes 
       
58. In the last 3 months how often did you have 4 or more bowel movements per day? 
□ Never or rarely    
□ Sometimes      
□ Often       
□ Most of the time     
□ Always      
 
59. In the last 3 months how often did you have loose, mushy or watery stools? 
□ Never or rarely    Go to question 61 
□ About 25% of the time    
□ About 50% of the time    
□ About 75% of the time    
□ Always, 100% of the time    
 
60. Did you begin having frequent loose, mushy or watery stools more than 6 months 
ago? 
□ No       
□ Yes       
 
61. In the last 3 months how often did you have to get up at night to have a bowel 
movement? 
□ Never or rarely    
□ Sometimes      
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□ Often       
□ Most of the time     
□ Always      
 
62. In the last 3 months how often did you have to rush to the toilet to have a bowel 
movement? 
□ Never or rarely    
□ Sometimes      
□ Often       
□ Most of the time     
□ Always      
 
 
63. In the last 3 months how often was there mucus in your bowel movement? 
□ Never or rarely    
□ Sometimes      
□ Often       
□ Most of the time     
□ Always      
 
64. In the last 3 months how often did you have bloating or distension? 
□ Never       Go to question 66 
□ Less than one day a week    
□ One day a week or more    
□ Every day       
 
65. Did your symptoms of bloating or distension begin more than 6 months ago? 
□ No       
□ Yes     
 
66. In the last 3 months have you noticed blood in your stools? 
□ No       Go to question 68 
□ Yes       
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67. What colour was this blood? 
□ Bright red   
□ Dark red      
□ Maroon      
□ Black       
 
68. In the last 3 months how often have you accidentally leaked liquid or solid stool? 
□ Never        
□ Less than one day a week    
□ One day a week or more    
□ Every day 
 
69. In the last 3 months how often have you had aching, pain, or pressure in or around 
the back passage when you were passing a stool? 
□ Never       Go to question 73 
□ Less than one day a week    
□ One day a week or more    
□ Every day 
 
70. How long did the aching, pain, or pressure last? 
□ Up to 20 minutes and then disappeared completely  
□ More than 20 minutes and up to several days or longer 
 
71. Did the aching, pain, or pressure in your back passage occur and then completely 
disappear during the same day? 
□ No       
□ Yes       
 
72. Did the aching, pain, or pressure in your back passage begin more than 6 months 
ago? 
□ No       
□ Yes       
 
73. In the last 1 year have you noticed any weight loss? 
□ No       
□ Yes       
If yes, how much (in kilograms or pounds)? ______________________________ 
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74. Have you been told by your doctor that you are anaemic (a low blood count or low 
iron) (if female, not due to your menstrual period)? 
□ No       
□ Yes       
 
75. In the last 3 months have you experienced bouts or spasms of coughing? 
□ Never       
□ Less than one day a week    
□ One day a week or more    
□ Every day       
 
 
76. During the past 4 weeks how much have you been bothered by any of the following 
problems?  
       No A little A lot 
a. Stomach pain     □ □  □ 
b. Back pain      □ □  □ 
c. Arm, leg, joint (hip, knee etc) pain  □ □  □  
d. Period pain / period problems   □ □  □ 
e. Headaches      □ □  □ 
f. Chest pain      □ □  □ 
g. Dizziness      □ □  □ 
h. Fainting spells     □ □  □ 
i. Heart pounding / racing    □ □  □ 
j. Shortness of breath    □ □  □ 
k. Pain / problems during intercourse  □ □  □ 
l. Constipation / diarrhoea    □ □  □ 
m. Nausea / gas / indigestion    □ □  □ 
n. Feeling tired or low in energy   □ □  □ 
o. Trouble sleeping     □ □  □ 
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77. I feel tense or “wound up”: 
□ Most of the time     
□ A lot of the time     
□ From time to time, occasionally   
□ Not at all      
 
78. I still enjoy the things I used to enjoy: 
□ Definitely as much     
□ Not quite so much     
□ Only a little      
□ Hardly at all      
 
79. I get a sort of frightened feeling as if something awful is about to happen: 
□ Very definitely and quite badly  
□ Yes, but not too badly    
□ A little, but it doesn’t worry me   
□ Not at all      
 
80. I can laugh and see the funny side of things: 
□ As much as I always could    
□ Not quite so much now    
□ Definitely not so much now    
□ Not at all      
 
81. Worrying thoughts go through my mind: 
□ A great deal of the time   
□ A lot of the time    
□ From time to time, but not too often  
□ Only occasionally     
 
82. I feel cheerful: 
□ Not at all      
□ Not often      
□ Sometimes      
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□ Most of the time     
 
83. I can sit at ease and feel relaxed: 
□ Definitely       
□ Usually      
□ Not often      
□ Not at all      
 
84. I feel as if I am slowed down: 
□ Nearly all the time     
□ Very often      
□ Sometimes      
□ Not at all      
 
85. I get a sort of frightened feeling like “butterflies” in the stomach: 
□ Not at all      
□ Occasionally      
□ Quite often      
□ Very often      
 
86. I have lost interest in my appearance:  
□ Definitely      
□ I don’t take as much care as I should  
□ I may not take quite as much care   
□ I take just as much care as ever   
 
87. I feel restless as if I have to be on the move: 
□ Very much indeed     
□ Quite a lot      
□ Not very much     
□ Not at all      
 
88. I look forward with enjoyment to things: 
□ As much as I ever did    
□ Rather less than I used to   
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□ Definitely less than I used to  
□ Hardly at all     
 
89. I get sudden feelings of panic: 
□ Very often indeed     
□ Quite often      
□ Not very often     
□ Not at all      
 
90.  I can enjoy a good book or radio or TV program: 
□ Often       
□ Sometimes      
□ Not often      
□ Very seldom      
